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Abstract 
 
Somatic cells can be reprogrammed into induced pluripotent stem (iPS) cells 
by overexpression of combinations of transcription factors such as Oct4, Sox2, Klf4 
and c-Myc. However, reprogramming is slow and stochastic, suggesting the 
existence of mechanisms that limit its efficiency. Senescence is an irreversible G1 
cell cycle arrest elicited by replicative exhaustion or in response to stresses such as 
DNA damage, or aberrant expression of oncogenes. The arrest observed during 
senescence is implemented mainly through activation of p53 and the upregulation of 
the cyclin-dependent kinase (CDK) inhibitors, p16INK4a and p21Cip1.  
In this work the relation between the process of reprogramming to iPS cells 
and senescence was investigated. The expression of the 4 reprogramming factors 
from a polycistronic vector in human fibroblasts (IMR90) was shown to induce cell 
cycle arrest and upregulation of p53, p16INK4a and p21Cip1. Reprogramming-induced 
senescence (RIS) results from the activation of a DNA damage response, and 
chromatin remodeling of the INK4a/ARF locus, as shown by a decrease in the levels 
of the H3K27me3 modification following expression of the reprogramming factors. 
RIS resembles a stress response, which parallels oncogene-induced senescence, 
however context-dependent differences may also contribute as shown by the fact 
that ES cells-specific miRNAs can partially bypass RIS.  Additionally when 
expressed individually, each reprogramming factor was shown to have a negative 
effect over the proliferation of somatic cells. 
 Since reprogramming initially triggers a stress response with characteristics 
of senescence it may act as an initial barrier limiting the efficiency of the process. 
Indeed, ablation of different senescence effectors improved the efficiency of 
reprogramming, both in mouse and human cells. Additionally, the polycomb protein 
CBX7 was also shown to increase reprogramming efficiency in a process that may 
partially dependent on repression of the INK4a/ARF locus. The senescence 
response to expression of reprogramming factors uncovers an important barrier to 
induced pluripotency but also highlights the importance of tumour suppressor 
pathways in preventing dedifferentiation during tumorigenesis. Identification of RIS 
mediators may help to understand this connection and provide safer approaches to 
increase reprogramming efficiency.  
 
 
    4 
Acknowledgments  
 
In first place I would like to say thanks to Jesus. Thank you for all you taught 
me, and for giving me the opportunity of participating in the exiting projects running 
in the lab. I hope you are proud of me. 
Everything I’ve learned during this years was possible because of the amazing 
people that are or have been working in the cell proliferation group. Thank you 
Marco and Juan Carlos for helping me from the first day, for all the patience and 
friendship and for setting up almost all the techniques that we use daily.  
Thank you Selina. I would have to write so many pages to explain how much 
you helped me and how much I’ll miss you the day I’ll leave the lab!   
Thank you Nik and Sadaf for sharing with me this amazing experience that is 
“to do a PhD”. The company couldn’t have been better!  
Thank you Marta, Ana O’Loghlen and Ana Munoz for all the help and for being 
good friends. Thank you Nadine, Rita, Mattia, Eddie, Inês, Vineet, Patrick, Aida, 
Nuria, and so many more people for all these years of companionship and for 
making the CSC such a nice place to work in.  
Thank you Tamir, Imbissat and Ludovic Vallier for the all the work with 
reprogramming experiments, and SiDe Li and Martin Walsh for Chip analysis. Jose 
Silva, Filipe, Sandra, Veronique Azuara and Vasso Episkopou for their collaboration 
in this work. Thank you Charlie for the human ES cells and for teaching me how to 
keep them alive… 
Thank you Bram for all the SILAC work and for choosing the nice music :) 
Thank you Fundação para a Ciência e a Tecnologia (FCT) for funding. 
Thank you Patrícia and Margarida for being there for me, always! 
Thank you to all my friends in London, for making it such a good place to live 
in, specially Imanol for the amazing tortilha ;) I miss you grunhon. 
Thank you to all my friends in Lisbon for receiving me back so well, Obrigada, 
 I miss you all a lot, all the time.  
Thank you Juan Carlos (Acostinha), once more…. You are my best friend and 
everything I could ever dream! 
Um beijo muito grande para os meus pais, para os meus avós, para a Mana e 
para o Babo que estao sempre presentes no meu pensamento e em tudo o que eu 
faço. Obrigada. A parte mais difícil do doutoramento foi estar longe de vocês! 
 
  THANK YOU               OBRIGADA 
    5 
Table of Contents 
 
Statement of originality    …………………………………………………………….   2 
Abstract     ……………………………………………………………………………….   3 
Acknowledgments    ………………………………………………………………….    4 
Table of contents     …………………………………………………………….…….    6 
List of Figures and Tables  …………………………………………………………..   9 
Abbreviations   …………………………………………………………………………  12 
 
Chapter 1. Introduction                                                                               16 
 
1.1. The limited lifespan of normal somatic cells   …………………………………... 16 
1.1.1. Main characteristics of cellular senescence  …………………………….   17 
1.1.2. Mechanisms triggering senescence  ………………………………...…..    21 
    1.1.2.1. Replicative senescence    …………………………………………...   21 
 1.1.2.2. Premature senescence and tumour suppression   ………………    22 
1.1.3. Two pathways to senescence    …………………………………...……..    24 
 1.1.3.1. The DNA damage response (DDR)    ………………………………   27 
 1.1.3.2. The INK4b/Arf/INK4a locus   ………………………………………...   29 
1.1.3.3. Epigenetic regulation of INK4b/Arf/INK4a locus   …………………    31 
 
1.2. Developmental potential and cell reprogramming   ………………………...….    34 
1.2.1. The nuclear equivalence and the beginning of cell reprogramming  ….    34 
1.2.2. Pluripotency and self-renewal    ……………………………………………   36 
1.2.3.1. Derivation of pluripotent cells lines    ……………………………….    36 
1.2.3.2. Core transcriptional regulators of pluripotency   ……………………   38 
1.2.3.3. Epigenetic control of pluripotency   …………………………...…….    40 
1.2.3.4. Extrinsic pluripotency regulators in mouse and human ESCs  …....  41 
1.2.4. Somatic cell reprogramming  ……………………………………………….. 43  
1.2.4.1. Reversing Differentiation: Why and how?  ……………………….....  44 
1.2.4.2. Mechanisms underlying reprogramming to iPS cells  …………….... 48 
      1.2.4.2.1. Elite versus stochastic model    …….………………………….  49 
1.2.4.2.2. Sequential events during reprogramming to pluripotency   …. 50 
1.2.4.3. Challenges and advances in the generation of IPS cells   ………… 52 
    6 
1.2.4.3.1. Choice and delivery of reprogramming factors   …………….   52 
 1.2.4.3.2. Increasing reprogramming efficiency: bypassing biological   
  roadblocks    …………………………………………………………………  54 
1.3 The unlimited lifespan of embryonic stem cells    ………………………………..   58 
1.3.1. ES cells do not undergo replicative senescence    ..………...……...……   58 
 1.3.1.1. Embryonic stem cells exhibit telomerase activity   ………………….  58 
1.3.1.2. Cell cycle regulation in embryonic stem cells   ……………………..   59 
 
1.4. Aim of this study    …………………………………………………………………..  62 
 
Chapter 2. Materials and Methods                                                               63 
 
2.1. Cell lines and tissue culture methods   …………………………………………… 63 
2.2. Retrovirus production and transduction of target cells   ………………………… 64 
2.3. Growth assays    …………………………………………………………………….. 65 
2.3.1. Growth curves and colony formation assays   ……………………………  65 
2.3.2. BrdU (5-Bromo-2’-deoxyuridine) incorporation assay   …………………   65 
2.3.3. Senescence-associated β-galactosidade (SA-β-gal) assay ……………   66 
2.3.4. DNA content analysis   ……………………………………………………...  66 
2.4. Plasmid amplification and cloning to generate retroviral vectors   …………….. 67 
2.4.1. Plasmids     …………………………………………………………………… 67 
2.4.2. Transformation of chemically competent E.Coli  …………………………  67 
2.4.3. Plasmid DNA purification    …………………………………………………  68 
2.4.4. Generation of shRNA expressing plasmids   ……………………………..  69 
2.4.5. Agarose gel electrophoresis    ……………………………………………… 69 
2.4.6. TA cloning   …………………………………………………………………… 70 
2.4.7. DNA sequencing  …………………………………………………………….. 70 
2.5. RNA expression analysis    ……………………………………………………….... 71 
2.5.1. Total RNA purification   ……………………………………………………… 71 
2.5.2. Quantitive RT-PCR (q-RT-PCR) Analysis  ……………………………….   71 
2.5.3. Purification and expression analysis of microRNAs   …………………….  72 
2.6. Immunofluorescence and High content analysis (HCA)   ……………………….  73 
2.7. Chromatin immunoprecipitation (ChIP)  …………………………………………..  75 
2.8. Reprogramming to induced pluripotent stem cells (iPS) ………………………..  77 
2.8.1. Transduction of somatic cells   …………………………………………….   77 
    7 
2.8.2. Generation and identification of ES-like colonies   ……………………….  78 
2.8.3. Colony picking and expansion  ……………………………………………..  78 
2.8.4. Reprogramming of mouse embryonic fibroblasts   ……………………….  79 
 
Chapter 3. A senescence response is induced by expression of the four 
reprogramming factors.                                                                                81  
3.1. Early response to reprogramming factors expression in human fibroblasts …   81  
3.1.1.OSKM-transduced cells show characteristics of senescence   ………….  82 
3.1.2 Levels of senescence mediators during OSKM-induced senescence  …  85 
3.3. Epigenetic regulation of the INK4a/ARF locus during RIS …………...…………  93 
3.4 Dissecting the role of p53/p21Cip1 during RIS by individual expression of the  
four reprogramming factors   …………………………………………………………….  95 
3.5. Discussion and conclusions   ………………………………………………………  98 
3.5.1. The senescence response to expression of reprogramming factors  ….. 98  
3.5.2. RIS: Stress or context-dependent response?  ……………………………102 
3.5.3. Different cell fates may limit reprogramming   …………………………… 105 
 
Chapter 4. Modulating senescence to improve reprogramming  
efficiency                                                                                                      108 
 
4.1 Inhibition of senescence mediators improves reprogramming efficiency  ….... 108 
4.2 CBX7 expression improves reprogramming efficiency    ………………………. 115 
4.3. Discussion and conclusions  ……………………………………………………… 123 
4.3.1. Senescence represents a roadblock for successful reprogramming  … 123 
4.3.2. The role of the Polycomb protein CBX7 in reprogramming  …..……….. 127  
4.3.3. Comparing reprogramming efficiencies   ………………………………… 129 
 
Chapter 5. Discussion and future work                                                     131 
 
5.1. The tumour suppressor p53 limits de-differentiation   …………………………. 131 
5.2. Reprogramming the INK4a/ARF locus  ………………………………………….. 133 
5.3. Is cell division required for reprogramming?   …………………………………..  134 
5.4. Pluripotency, reprogramming and transformation   …………………………….. 137 
5.5. Future work: Identification of RIS mediators    ………………………………….. 140 
5.5.1 Genetic screening for bypass of RIS  ………………………………………140 
    8 
5.4.2. SILAC analysis for identification of proteins enriched during RIS  ……..143 
5.6. Concluding remark    ………………………………………………………………..146 
 
References                                                                     147 
Appendix                                                                                                      168 
Publications         176 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    9 
List of Figures and Tables 
 
Figure 1.1. The senescent phenotype       19 
 
Figure 1.2. Senescence is a tumour suppressive mechanism    24
       
Figure 1.3. Two pathways to senescence       26 
 
Figure 1.4. The DNA damage response activates p53     28 
 
Figure 1.5. The INK4b-ARF-INK4a locus       29 
 
Figure 1.6. Epigenetic activation of the INK4b-ARF-INK4a locus due to oncogenic 
stress                      33
           
Figure 1.7. Stem-cell hierarchy        35 
 
Figure 1.8. The core embryonic stem cell transcriptional circuit    40 
 
Figure 1.9. Developmental potential illustrated by the Waddington’s epigenetic 
landscape            44 
 
Figure 1.10. Three strategies for induction of nuclear reprogramming of    46 
somatic cells 
 
Figure 1.11.  Landmark events during reprogramming to pluripotency   51 
 
Figure 1.12. The cell cycle of embryonic stem cells                 61 
 
Figure 2.1. High Content Analysis        76 
 
Figure 2.2. Reprogramming to induced pluripotent stem cells    80 
 
Figure 3.1. Polycistronic vector for expression of the 4 factors in  
IMR90 fibroblasts          83 
 
Figure 3.2. Expression of the 4 reprogramming factors induces growth arrest         84 
 
Figure 3.3. OSKM transduced cells present characteristics of senescence   86 
 
Figure 3.4. OSKM expression induces a DNA damage response    87 
 
Figure 3.5. Molecular analysis of senescence induced by expression of 
reprogramming factors         89 
 
Figure 3.6. Ink4a and Cdkn1a levels during reprogramming of mouse fibroblasts  
and in partially reprogrammed cells                    91
        
Figure 3.7. Expression levels of Ink4a and Cdkn1a are elevated in partially  
reprogrammed iPS cells when compared with fully reprogrammed iPS cells            92 
 
Figure 3.8. The histone demethylase JMJD3 contributes to the regulation of the 
INK4a/ARF locus during reprogramming-induced senescence                                 94 
    10 
 
Figure 3.9. Dissecting the role of p53/p21Cip1 during RIS                        97
  
Figure 3.10. Expression of ES cell-specific miRNAs rescues RIS                          99 
 
Figure 3.11. Alternative cell fates limit reprogramming efficiency            107
  
 
Figure 4.1. Inhibition of senescence improves reprogramming efficiency            109 
of BJ human fibroblasts. 
 
Figure 4.2. Inhibition of senescence improves reprogramming efficiency              110 
 of IMR90 human fibroblasts. 
 
Figure 4.3. hiPS cell lines generated upon knockdown of p53 or p16INK4a              112 
express pluripotency markers 
 
Figure 4.4. hIPS cells generated upon knockdown of p53 or p16INK4a can              113 
differentiate into extra-embryonic tissues and into derivatives of  
the three germ layers. 
 
Figure 4.5. Enhanced efficiency of reprogramming in MEFs knockout or               114 
knockdown for senescence effectors. 
 
Figure 4.6. Cbx7 enhances reprogramming efficiency of human fibroblasts           117 
 
Figure 4.7. Morphology of hiPS cell lines generated in this study              118 
 
Figure 4.8. iPS cell lines generated in 4.6 express pluripotency markers            119 
 
Figure 4.9. hiPS cell lines have silenced expression of exogenous              120 
reprogramming factors 
 
Figure 4.10. Reprogramming of mouse embryonic fibroblasts              122 
 
Figure 4.11. Senescence as an early barrier during reprogramming             125 
 
Figure 5.1. Parallels between reprogramming and oncogenic transformation        139 
 
Figure 5.2. OSKM-inducible system for identification of RIS mediators            142 
 
Figure A1. Cell cycle profiles                  175
  
 
Table A1. List of plasmids used in this study                168 
 
Table A2. Plasmids acquired from addgene                169 
 
Table A3. shRNA target sequences                 169 
 
TableA4. Primers for cloning                  170 
 
Table A5. Sequencing primers                 170 
 
    11 
Table A6. qRT-PCR primers                  171 
 
Table A7. TaqMan gene expression assays                172 
 
Table A8. TaqMan microRNAs assays                172 
 
Table A9. Primary antibodies                  173 
 
Table A10. Secondary antibodies                  173 
                            
Table A11. Antibodies for ChIP                 174 
 
Table A12. Primers for ChIP                  174 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    12 
Abbreviations 
 
 
Ac                   acethylated 
AHR                aryl hydrocarbon receptor 
AID                 activation-induced cytidine deaminase 
AP          alkaline phosphatase 
ARF                alternative reading frame gene 
ATM                ataxia telangiectasia mutated 
ATR                ataxia telangiectasia and Rad3 related 
ATP        adenosine tri-phosphate 
BMP               bone morphogenenic protein 
bp           base pair 
BrdU       5-bromo-2-deoxyuridine 
BSA         bovine serum albumin 
CBX7              chromobox protein homolog 7 
CDK                cyclin dependent kinase 
CDKI               cyclin dependent kinase inhibitor 
CDKN1           cyclin dependent kinase inhibitors, family 1 
CDKN2           cyclin dependent kinase inhibitors, family 2 
cDNA       complementary DNA 
ChIP         chromatin immunoprecipitation 
CSC                cancer stem cell 
C(T)          threshold cycle 
CXCL              CXC chemokine ligand 
DAPI         4,6-diamidino-2-phenylindole    
dNTP              deoxyribonucleotide triphosphate 
DMEM      Dulbecco’s modified Eagle’s medium 
DMSO      dimethyl sulfoxide 
DNA         deoxyribonucleic acid 
DNMT       DNA methyltransferase 
Dox           doycycline 
DTT          dihiothreitol 
E.coli        Escherichia coli 
EDTA   ethylene-dinitrili tetraacetic acid 
EED                embryonic ectoderm development 
EC              embryonic carcinoma 
    13 
EG                embryonic germ 
EpiS                epiblast stem 
ES  embryonic stem 
EZH2              enhancer of zeste homolog 2 
FBS  foetal bovine serum 
FGF  fibroblast growth factors 
g  gram 
GFP  green fluorescent protein 
GLB1              galactosidase, beta 1 
GSK3              glycogen synthase kinase 3 
H  histone 
HAT  histone acetyltransferase 
γH2AX             phosphorylated histone 2, variant X 
HCA                high content analysis 
HDAC  histone deacetylase 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
hES  human embryonic stem  
HMT  histonemethyltransferase 
HP1  heterochromatin protein 1 
HPV16            human papilloma virus 16 
HRAS             Harvey rat sarcoma gene 
HSCs              hematopoietic stem cells 
hTERT            human telomerase reverse transcriptase 
ICM  inner cell mass 
IF  immunofluorescence 
IGF                 insulin growth factor 
IGFBP            insulin growth factor binding protein 
IL  interleukin 
INK4               Inhibitor of CDK4 
iPS  induced pluripotent stem  
JMJD3            jumonji domain containing 3 
K  lysine 
Kb  kilobase 
kDa  kiloDalton 
KLF4               Krüppel-like factor 4 
KSR  knockout serum replacement 
    14 
L  litre 
LB                   lysogeny broth 
LIF  leukaemia inhibitor factor 
m  mili 
M  molar 
MAPK             mitogen-activated protein kinases 
Me3                trimethylated 
Mb  mega base pair 
MEF  mouse embryonic fibroblast 
mES             mouse embryonic stem 
mGS               mouse germ stem  
mRNA  messenger RNA 
miRNA  microRNAs 
MYC                  myelocytomatosis gene 
NEAA              non-essential aminoacids 
NSC                neural stem cell 
OCT4              octamer-binding transcription factor 4 
OIS                 Oncogene induce-senescence 
OSKM             polycistronic cassette containing Oct4, Sox2, Klf4 and c-Myc  
PBS  phosphate buffered saline 
PcG  polycomb group 
PCNA              proliferating cell nuclear antigen 
PCR  polymerase chain reaction 
PEI                  polyethylenimine 
PFA  paraformaldehyde 
PI  propidium iodide 
PRC  polycomb repressive complex 
PRE  polycomb response element 
p(S/T)Q           ATM/ATR phosphorylated serine/threonine  
qPCR  quantitative PCR 
RB                  retinoblastoma 
REX1              RNA exonuclease 1 homolog 
RIS                 reprogramming-induced senescence 
RNA  ribonucleic acid 
ROS               reactive oxygen species 
rpm  rotations per minute 
    15 
SA-β-gal         senescence-associated β-galactosidase 
SAHA  suberoylanilide hydroxamic acid 
SAHF             senescence-associated heterochromatic foci 
SASP             senescence associated secretory phenotype 
SCNT             somatic cell nuclear transfer 
SDS  sodium dodecyl sulphate 
shRNA  small hairpin RNA 
SOX2             SRY (sex determining region Y)-box 2 
SSEA             stage specific embryonic antigen 
SUZ12            suppressor of zeste 12  
SV40 LT         simian vacuolating virus 40 large antigen 
SWI/SNF switch/sucrose non-fermenting family of chromatin remodelling 
ATPases 
TCDD             2,3,7,8-tetrachlorodibenzo-p-dioxin 
TGF                tumour growth factor 
UTR untranslated region  
VPA valproic acid 
WNT               wingless (Wg) and integration site (INT) gene 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
    16 
Chapter 1 – Introduction 
 
1.1. The limited lifespan of normal somatic cells 
 
 In the beginning of the 20th century when tissue culture techniques were 
developing, it was believed that primary cells isolated from tissues and organs could 
be propagated indefinitely if the right culture conditions were used. Alexis Carrel 
proposed that the longevity of a tissue outside of the organism could exceed greatly 
its normal duration within the body (Carrel, 1912). Leonard Hayflick and Paul 
Moorhead, who were working on the isolation of human diploid strains in the 1960s, 
challenged this idea. They proposed that differentiated normal cells, unlike tumour 
cells, could only undergo a limited number of cell divisions after which they would 
enter a state of irreversible growth arrest, which they named cellular senescence 
(Hayflick, 1965). However this idea was not accepted easily. Some thought that the 
failure of normal diploid cells to proliferate indefinitely was due to extrinsic causes, 
including the absence of one or more essential nutrients or growth factors and 
infection with virus or mycoplasma. Subsequent work showed that senescence is not 
specific to human fibroblasts; it was described in cultures established from numerous 
mammalian species and in a variety of cell types other than fibroblasts including 
keratinocytes (Rheinwald and Green, 1975), vascular smooth muscle cells (Bierman, 
1978), lens cells (Tassin et al., 1979) and lymphocytes (Tice et al., 1979). 
The work by Hayflick and Moorhead gave birth to the idea that normal somatic 
cells possessed a “mitotic clock” that dictates their maximum lifespan and highlighted 
the fact that immortality was a key feature of tumour cells. Nowadays cellular 
senescence is known to be a fundamental mechanism, implicated in a number of 
physiological processes and disease states (Campisi et al., 2001).  
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1.1.1. Main characteristics of cellular senescence 
In contrast with quiescence, a state characterized by a growth arrest that can 
be reversed in the presence of proper physiological signals, the hallmark of cellular 
senescence is its irreversible nature. Once they reach senescence, growth arrested 
cells cannot re-enter cell cycle when stimulated, despite remaining metabolically 
active (reviewed in Campisi and d'Adda di Fagagna, 2007). Although cells reach a 
state in which they can no longer initiate replication, this happens asynchronously so 
that at any given moment in active mitotic cultures, the population is a 
heterogeneous mixture of senescent and non-senescent cells, that are at various 
stages in their proliferative life (Cristofalo and Sharf, 1973). Early passage cultures 
consist primarily of cells that exhibit short cell cycle periods. With successive 
subcultivations, the percentage of cells in the population that exhibit longer 
generation times and those unable to proliferate, increases. Successful progression 
through the cell cycle involves the synthesis of new DNA that can be quantified by 5-
bromo-2’-deoxyuridine (BrdU) incorporation assays. Senescent cells fail to 
incorporate BrdU because they are arrested predominantly at the G1 phase of the 
cell cycle and do not progress to S phase for DNA synthesis.  
Together with senescence, apoptosis or programmed cell death protects the 
organism from the propagation of damaged cells. However while senescence 
prevents their growth, apoptosis quickly eliminates them. Interestingly, senescent 
human fibroblasts are resistant to some types of apoptosis such as those caused by 
growth factor deprivation and oxidative stress (Chen et al., 2000; Hampel et al., 
2004). The mechanisms responsible for this resistance are not well understood 
however they are most probably related to their common regulator p53. Upon stress 
the decision between life and death, is dependent on p53 that can in some situations 
preferentially transactivate genes that arrest proliferation, rather than those that 
induce apoptosis (Das et al., 2007; Jackson and Pereira-Smith, 2006). Indeed, 
    18 
although p53 has a key role in inducing apoptosis, some p53 target proteins also 
inhibit apoptosis, including p21Cip1, decoy death receptors such as DcR1 and DcR2, 
the transcription factor SLUG (which represses the expression of PUMA), and 
several activators of the AKT/PKB (protein kinase B) survival pathways (Janicke et 
al., 2008).  This might explain, to some extent, why senescent cells are so stable in 
culture, and why they increase with age in vivo. 
The senescent state is also characterized by a number of morphological, 
structural and functional changes. The most obvious morphological changes that 
accompany the onset of cellular senescence in vitro are an increase in cell size, thin 
cytoplasm and flattened appearance. Related with this change in morphology, there 
is a reorganization of the cytoskeleton that seems to be due to down-regulation of 
actin and upregulation of vimentin (Nishio et al., 2001)(Figure 1.1).  
Senescence-associated β-galactosidase (SA-β-gal) activity detectable at pH 
6.0 produces a blue perinuclear staining and has been widely used as a senescence 
marker (Dimri et al., 1995) (Figure 1.1). SA-β-gal activity is due to an increase in 
GLB1 expression, the gene encoding lysosomal β-D-galactosidase. Fibroblasts from 
patients with autosomal recessive GM1-gangliosidosis, which have defective 
lysosomal β-galactosidase, do not express SA-β-gal at late passages even though 
they undergo replicative senescence (Lee et al., 2006a). These results confirmed 
that (SA-β-gal) activity is a consequence rather than a cause of the senescent state, 
and is instead related with the increased lysosomal biogenesis that is observed in 
these cells (Lee et al., 2006a). Indeed, early reports showed that lysosomes increase 
in number and size in senescent cells (Robbins et al., 1970), therefore it is possible 
that SA-β-gal activity at a suboptimal pH (lysosomal β-D-galactosidase activity is 
typically measured at pH 4.5) becomes detectable as result of increased lysosomal 
content (Kurz et al., 2000). Other results also suggest that an increase in autophagy, 
that is digestion of the cell’s organelles, functions as an effector mechanism during 
    19 
cellular senescence (Young et al., 2009) and may be associated with an increase of 
lysosomal mass and SA β-gal (Gerland et al., 2003). Although widely used as a 
senescence marker, it is important to note that SA-β-gal activity at pH 6, is not 
senescence-specific; therefore it must be used in conjunction with other senescence 
markers (Severino et al., 2000; Yang and Hu, 2005). 
 
 
Figure 1.1. The senescent phenotype. Replicative senescence is described as the growth arrest 
observed after serial passage of normal diploid cells in vitro. Premature senescence can be observed in 
young cells under a number of physiological stresses including expression of oncogenes (oncogene-
induced senescence). Both lead to a senescent phenotype with morphologic and functional 
characteristics, highlighted on the right hand side panel. Panels on the left hand side show bright field 
microphotographs and Dapi stained nuclei, of IMR90 fibroblasts showing the blue perinuclear 
senescence associated β-galactosidase staining and the presence of senescence associated 
heterochromatic foci (SAHF) in late passage cells when compared with early passage cells. Expression 
of oncogenic Ras leads to a similar senescent phenotype. Adapted from (Narita et al., 2003).  
 
 
Concomitant with the morphologic features described, there is a reorganization 
of the heterochromatin. Senescence-associated heterochromatic foci (SAHF) have 
been described in senescent cells undergoing oncogenic stress by expression of an 
oncogenic version of the proto-oncogene HRAS, and in cells undergoing replicative 
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exhaustion. SAHF are enriched for markers of heterochromatin, such as 
heterochromatin protein 1 (HP1) and Lys9 tri-methyl on histone H3 (H3K9me3) and 
exclude euchromatic markers, such as acetylation of histone 3 on lysine 9 (H3K9Ac) 
or tri-methylation on lysine 4 (H3K4me3). The reorganization of heterochromatin that 
gives rise to these foci results in a stable transcriptional repression of E2F target 
genes (Narita et al., 2003). This stable repression is related to another important 
feature of senescent cells, its altered gene expression profile.  
Several studies have identified senescence-associated gene expression 
signatures (Mason et al., 2004; Shelton et al., 1999; Trougakos et al., 2006; Yoon et 
al., 2004). As expected they revealed changes in cell-cycle regulators. Two cell-cycle 
inhibitors that are often expressed by senescent cells are the cyclin-dependent 
kinase inhibitors (CDKIs) CDKN1a (also termed Waf1, encodes p21Cip1) and INK4a 
(also termed CDKN2a, encodes p16INK4a). On the other hand, senescent cells 
repress genes that encode proteins involved in cell-cycle progression; some of them 
are E2F targets (for example, replication-dependent histones, c-FOS, cyclin A, cyclin 
B and PCNA) (Pang and Chen, 1994; Seshadri and Campisi, 1990). Interestingly the 
quest for senescence-specific gene expression signatures also revealed that besides 
changes in cell-cycle regulators, senescent cells exhibited changes in genes that 
appeared to be unrelated with growth arrest (Mason et al., 2004; Shelton et al., 
1999). These included, the upregulation of multiple secreted factors that are known 
to alter the tissue microenvironment, and are thought to contribute to age-related 
pathologies. This senescent-associated secretory phenotype (SASP) can trigger 
different and, sometimes, opposing effects in the microenvironment and surrounding 
cells. Work by Judith Campisi's group suggests that factors secreted by senescent 
fibroblasts promote cancer progression (Krtolica et al., 2001), however, besides its 
implication in tumour clearance by the immune system (Xue et al., 2007), several 
studies suggest that this SASP may also have an important role in establishing and 
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maintaining the senescent state itself. Some of the factors secreted by senescent 
cells were shown to have tumour suppressive roles. The plasminogen activator 
inhibitor (PAI)-1 is necessary and sufficient for the induction of senescence 
(Kortlever et al., 2006). Insulin-like growth factor-binding protein 7 (IGFBP7) was 
shown to mediate senescence induced by oncogenic BRAF (Wajapeyee et al., 
2008). Equally, pro-inflammatory cytokines and chemokines secreted by senescent 
cells, such as IL-8, CXCL1, IL-6, and their receptors have been shown to be up-
regulated during senescence and their depletion to partially bypass replicative and 
oncogene-induced senescence (Acosta et al., 2008; Kuilman et al., 2008).  
 
1.1.2. Mechanisms triggering senescence 
1.1.2.1. Replicative Senescence  
Hayflick and Moorhead observations reveal not only that normal cells had a 
limited number of cell divisions, but also that there was a high reproducibility 
concerning the number of population doublings that fibroblast from different 
embryonic donors underwent (between 40 and 60 population doublings). Additionally 
they observed that cells frozen at any population doubling level could “remember” 
how many populations doublings they have been through before being frozen. This 
implied that cells had some kind of molecular counting mechanism able to register 
rounds of replication, but the nature of this “replicometer” was unknown (reviewed in 
Hayflick, 2000). In the early 1970s when the molecular basis of DNA replication was 
unravelled it became clear that because of the nature of lagging-strand synthesis, 
DNA polymerases could not completely replicate the 3' end of linear duplex DNA. 
Watson described it as the “end-replication problem” (Watson, 1972), however it was 
Alexey Olovnikov who realized that the repeated shortening of the DNA molecule at 
each round of DNA replication could explain why normal cells could divide only a 
limited number of times (Olovnikov, 1973). This idea was later confirmed when the 
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structure of telomeres was determined. Elizabeth Blackburn described that 
telomeres of the ciliated protozoan, Tetrahymena thermophila, consisted of a simple 
sequence of hexameric repeats of the nucleotides TTGGGG (Blackburn and Gall, 
1978). The telomeres in human cells also consist of thousands of repeats, but in 
mammals the sequence is TTAGGG (Moyzis et al., 1988). Once this sequence was 
known, the length of human telomeres could be measured. The mean telomere 
length decreased by 2 to 3 kilobase pairs during the entire in vitro lifetime of several 
strains of cultured normal human diploid fibroblasts (Harley et al., 1990) supporting 
the idea that telomeric shortening is the replicometer that determines the number of 
times that a normal cell is able to divide. 
However one essential question remained: How do immortal cell lines avoid 
telomere shortening? The answer to this critical question originated in studies by 
Greider and Blackburn, who identified telomerase, a ribonucleoprotein enzyme 
terminal transferase that extends the 3′ end of telomeres and thus elongates them 
(Greider and Blackburn, 1985). Telomerase was later found to be present in extracts 
of immortal human cell lines (Counter et al., 1992; Morin, 1989) and in about 90% of 
all human tumours studied (Chiu and Harley, 1997).  
 
1.1.2.2. Premature senescence and tumour suppression 
The replicative exhaustion observed in human cells following extensive 
passage in culture results from progressive shortening of the chromosomes ends 
(Bodnar et al., 1998; Harley et al., 1990). The situation in mouse embryonic 
fibroblasts (MEFs) is different, as they have longer telomeres than human cells (40-
60 Kb versus 10 Kb) and in many cases express telomerase (Itahana et al., 2004; 
Rangarajan and Weinberg, 2003). In MEFs, the main trigger of replicative 
senescence is the generation of reactive oxygen species (ROS). Consequently, 
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senescence of MEFs has been compared with a culture shock. In particular, it has 
been shown that DNA damage caused by oxidative stress is the main cause of 
senescence onset in murine cells (Parrinello et al., 2003). In this study, it was 
demonstrated that when MEFs are propagated in 3% oxygen, rather than the 
commonly used 20% oxygen conditions, they do not suffer senescence.  
Indeed, throughout the years several studies suggested that senescence can 
be initiated in human and mouse cells by various cellular stresses. This has been 
referred to as premature senescence, as opposed to replicative or telomere-
dependent senescence (Ben-Porath and Weinberg, 2005). DNA-damaging agents, 
improper culture conditions and interestingly, activation or overexpression of certain 
oncogenes can trigger this kind of irreversible growth arrest. In 1997, it was 
described that activated RAS elicited a proliferative arrest similar to the replicative 
senescence of human fibroblasts (Serrano et al., 1997). Since this discovery, other 
oncogenes have been shown to induce a similar response, denominated oncogene-
induced senescence (OIS). Importantly, OIS was later proven to take place in vivo 
(Collado et al., 2005) and pre-malignant lesions were shown to be positive for 
markers of cellular senescence (Michaloglou et al., 2005). This is in agreement with 
the fact that cancer is a multistep process that requires both the activation of 
oncogenes and inactivation of tumour suppressor genes (Hanahan and Weinberg, 
2000). As all the evidences are gathered, one idea becomes clear. Regardless of the 
senescence-initiating signals, cellular senescence in both human and mouse cells 
can be triggered by an anomalous activation of the DNA-damage pathways that 
eventually results in p53 activation. This is in agreement with the notion that 
senescence, as apoptosis, is a mechanism that is induced in situations of stress, and 
has a role in preventing proliferation of damaged/altered cells (Figure 1.2).  
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Figure 1.2. Senescence is a tumour suppressive mechanism. (A) Two main mechanisms, 
senescence and apoptosis, act to prevent the proliferation of altered cells.  Senescence can be 
triggered by several different stimuli, including telomere erosion, oxidative stress and others forms of 
DNA damage. Activation of oncogenes can also trigger senescence, highlighting the importance of 
senescence as a tumour suppressor mechanism. (B) Premalignant lesions usually comprise of a 
heterogeneous population of tumour cells, some undergoing apoptosis (purple) others senescence 
(blue). These lesions may remain restricted in growth or if cells are able to override tumour suppressive 
mechanisms, tumour progression to a malignant state will be favoured. (Adapted from (Collado and 
Serrano, 2006; Gil and Peters, 2006). 
 
 
1.1.3. Two pathways to senescence 
During cell cycle progression, checkpoints assure that cells are “ready” to 
progress to the next phase and that no defects during DNA replication or 
chromosome segregation are accumulated. Additionally, two DNA damage 
checkpoints, during G1/S and G2/M assure that cells that acquired DNA breaks or 
other forms of DNA damage, do not progress through the cell cycle. Arresting the 
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cell cycle allows them to repair these defects. If the damage is irreparable due to 
excessive or continuous DNA damage, cells may enter senescence or undergo 
apoptosis (reviewed in Malumbres and Barbacid, 2009). 
Misregulation of cyclin-dependent kinases (CDKs) whose activity requires 
binding of regulatory subunits known as cyclins, is at the heart of the cell cycle 
defects that can lead to unscheduled proliferation. In unstressed cells at G1, the 
phase preceding the DNA replication phase, mitogenic signals are sensed by D-type 
cyclins that preferentially bind CDKs 4 and 6. Activation of the CDK4/6-Cyclin D 
complexes results in partial inactivation of the retinoblastoma protein (RB) and 
retinoblastoma-like proteins (RBL) 1 and 2 (p107 and p130). This allows expression 
of E-type cyclins that bind to and activate CDK2, which will further phosphorylate RB 
proteins thereby inactivating them. Inactivated RB releases E2F transcription factors 
that will induce transcription of genes necessary for DNA replication and cell cycle 
progression (reviewed in Weinberg, 1995)(Figure 1.3). 
If cells encounter various stresses, such as telomere uncapping or expression 
of oncogenes, two main pathways are triggered that converge on modulation of CDK 
activity and are responsible for senescence onset.  The p53-p21Cip1 pathway is 
activated by the DNA damage response mediated by ATM/ATR, and by the ARF 
protein. ATM/ATR are protein kinases that activate p53 mainly by phosphorylation 
while ARF activates p53 by inhibiting HMD2 an ubiquitin E3 ligase that targets p53 
for degradation. Active p53 induces transcription of genes, such as CDKN1a 
(p21Cip1) (El-Deiry, et al 1993).  The other main pathway is frequently referred as the 
p16/RB pathway. Both p21Cip1 and p16INK4a are CDK inhibitors that belong to two 
different families: Cip/Kip or CDKN1 family (p21Cip1, p27Kip1 and p57Kip2) (Gu et al., 
1993; Harper et al., 1993; Lee et al., 1995; Matsuoka et al., 1995; Polyak et al., 
1994; Toyoshima and Hunter, 1994) and the INK4 or CDKN2 family (p16INK4a, 
p15INK4b, p18INK4c and p19INK4d) (Hannon and Beach, 1994; Hirai et al., 1995; Serrano 
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et al., 1993).  p16INK4a interacts strongly with CDK4 and 6 and inhibits their ability to 
interact with D-type cyclins that are therefore targeted for degradation. p21Cip1 
inhibits cell cycle progression mainly through the inhibition of CDK2. However, it is 
known to interact with both CDK4/6-Cyclin D complexes and CDK2-Cyclin E 
complexes. Inactive CDKs result in unphosphorylated RB proteins that sequester 
E2F transcription factors, avoiding cell cycle progression (Figure 1.3) (reviewed in 
Sherr and Roberts, 1999). 
 
 
Figure 1.3. Two pathways to senescence. In unstressed cells and in the presence of mitogenic 
signals activation of the CDK4/6-Cyclin D complexes results in partial inactivation of RB family proteins. 
This allows expression of E-type cyclins that bind to and activate CDK2, which will further 
phosphorylate RB proteins, thus inactivating them. Inactive RB releases E2F transcription factors that 
activate transcription of genes necessary for entry into S-phase. Senescence-inducing signals usually 
engage either the p53 or the p16INK4a–retinoblastoma protein (RB) tumour suppressor pathways. p53 is 
negatively regulated by HDM2 (Mdm2 in mice), which facilitates its degradation. HDM2 is negatively 
regulated by ARF (alternative-reading-frame protein). Active p53 establishes senescence in part by 
inducing the expression of p21Cip1, a cyclin-dependent kinase (CDK) inhibitor that suppresses the 
phosphorylation and, hence, the inactivation of RB. Engagement of p16-Rb pathway, that is 
upregulation of p16INK4a, also results in inhibition of RB phosphorylation and inactivation, by inhibition 
CDK4/6. RB halts cell proliferation by inhibiting the activity of E2F, and thereby suppressing expression 
of genes required for cell-cycle progression. 
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1.1.3.1. The DNA damage response (DDR) 
Several stresses that can lead to senescence converge on a DNA damage 
response (DDR). Telomeres consist of nucleoprotein complexes at the 
chromosomes ends, which terminate in a duplex loop that protects the single 
stranded 3’ DNA overhang. The progressive telomere shortening eventually triggers 
an alteration in telomere structure, referred to as telomere uncapping, revealing the 
chromosome end that is recognized as a DNA break (reviewed in Verdun and 
Karlseder, 2007). This idea is supported by studies that demonstrate that telomere 
structure, rather than telomere length, is the main determinant of functional 
telomeres (Karlseder et al., 2002). A DNA damage response also contributes to the 
onset of oncogene-induced senescence. It has been shown that constitutively active 
HRAS leads to DNA replication stress that might result from impaired or 
inappropriately activated origins of replication, a phenomenon known as hyper-
replication (Bartkova et al., 2006; Di Micco et al., 2006; Malletle et al., 2007).  
Induction of p53 in response to DNA damage is coordinated by the 
serine/threonine protein kinases ataxia telangiectasia mutated (ATM) and the ataxia 
telangiectasia and Rad3-related (ATR). ATM plays a crucial part in the response to 
double strand breaks by activating and executing checkpoint and repair pathways. 
Other forms of DNA damage, such as replication stress, are mainly regulated by 
ATR, however these two regulatory kinases share downstream targets such as 
H2AX (histone 2A variant X) at sites flanking DNA breaks, several DNA damage 
mediators and p53 itself (Figure 1.4). Accordingly DNA damage markers such as 
γH2AX (phosphorylated histone 2A variant X), are detected at the chromosomes 
ends of cells reaching replicative exhaustion and in stalk replication forks in cells 
suffering from oncogenic stress (Di Micco et al., 2006; Takai et al., 2003). 
 The mechanisms regulating p53 activity are complex. Amongst them, p53 can 
be subjected to a range of post-transcriptional changes that include phosphorylation 
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(Atadja et al., 1995; Webley et al., 2000) and acetylation (Tang et al., 2008). In 
addition, its levels are tightly controlled by HMD2, (Mdm2 in mice) which targets p53 
for degradation. Therefore in unstressed cells p53 has a half-life of a few minutes 
and remains at low levels and in an inactive form, until some form of stress results in 
p53 modification and accumulation (reviewed in Vousden and Prives, 2009). 
Activated p53 can effectively block cell cycle progression by activating the 
transcription of the cyclin-dependent kinase inhibitor p21Cip1, although several other 
p53-target genes such as 14-3-3 sigma and GADD45 also contribute to this 
response (el-Deiry et al., 1993; Vousden and Prives, 2009). 
 
 
 
 
Figure 1.4. The DNA damage response activates p53. Double strand breaks are recognized by the 
MRN complex (composed by MRE11, RAD50 and NBS1) and lead to the activation of the kinase 
ataxia-telangiectasia mutated (ATM) and subsequent amplification of the response by recruitment of 
other DNA damage signalling proteins. ATM phosphorylates several proteins including MDM2, MDM4, 
p53 and checkpoint-2 (CHK2), which phosphorylates p53 and other proteins.  Single strand breaks 
become coated with replication protein A (RPA) that attracts the ataxia-telangiectasia and Rad3-related 
(ATR)- interacting protein (ATRIP) complex which phosphorylates the 9-1-1 complex (constituted by 
RAD9, RAD1 and HUS1) further activating ATR. Active ATR phosphorylates p53, MDM2, checkpoint-1 
(CHK1) and other substrates. The DNA damage response ultimately results in activation of effector 
molecules such as p53, CDC25 or structural maintenance of chromosomes (SMC1). Activated p53 will 
induce expression of several genes involved either in cell cycle arrest or apoptosis (Adapted from 
(Campisi and d'Adda di Fagagna, 2007). 
 
    29 
1.1.3.2. The INK4b-ARF-INK4a locus  
The p53 and RB pathways are regulated by, among other proteins, the 
products of the INK4b-ARF-INK4a locus. This locus encodes for two CDK inhibitors 
from the same family, p15INK4b and p16INK4a. Surprisingly, the INK4b-ARF-INK4a 
locus also encodes for ARF (p19ARF in mice and p14ARF in humans), a tumour 
suppressor that induces p53. The INK4a and ARF genes each have their own 
promoters, which produce different transcripts. INK4a consists of exons 1α, 2 and 3, 
while ARF is formed by exons 1β, 2 and 3. Although exons 2 and 3 are common to 
both transcripts, they are read in different reading frames, therefore there is no 
homology at their protein sequence (Mao et al., 1995; Quelle et al., 1995) (Figure 
1.5). 
 
 
Figure 1.5. The INK4b-ARF-INK4a locus. This locus in chromosome 9 includes three tumour 
suppressors genes in close proximity. Both INK4b (green) and INK4a (orange/blue) encode inhibitors of 
cyclin dependent kinases (p16INK4a and p15INK4b). The two INK4 genes flank the ARF exon 1β, which is 
spliced together with the exons 2 an 3 to generate the ARF mRNA (white/red). Exons 2 and 3 are 
shared between ARF and INK4a (red and blue rectangles) however; ARF is read in a different reading 
frame originating unrelated proteins. Exons (ex.) are represented by coloured rectangles and arrows 
designate the gene promoters. 
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The INK4b/ARF/INK4a locus is one of the most commonly altered regions in 
human cancers. This region can be subjected to loss of heterozygosity, point 
mutations or epigenetic alterations, such as promoter hypermethylation, that results 
in loss of expression (reviewed in Ortega et al., 2002). 
Since inactivation of the locus results in the abrogation of three tumour 
suppressor genes, significant debate has focused on which member of the locus 
represents the principal tumour suppressor at chromosome 9p21. The individual 
knockout of each of the three genes in mouse revealed that the three mouse strains 
are more tumour prone than wild-type mice, however each of them is less tumour 
prone when comparing with mice that lack both Arf and p16Ink4a (Latres et al., 2000; 
Sharpless et al., 2004). This implies that there is a synergy between p16Ink4a and Arf 
in tumour suppression. To further complicate matters, several studies revealed that 
these proteins have different relevance in senescence control when comparing 
mouse and human cells. Unlike human cells, which require the inactivation of both 
the p53 and RB pathways to prevent the onset of senescence, MEFs derived from 
p53 or Arf null animals maintain their high proliferative potential, do not senesce, and 
can be propagated indefinitely (Kamijo et al., 1997). On the other hand MEFs 
derived from Rb or p16Ink4a null mice undergo senescence like wild type MEFs 
(DePinho, 2000; Krimpenfort et al., 2001; Sharpless et al., 2001; Sherr and DePinho, 
2000). In mouse cells, the Arf-p53 pathway seems to be the main pathway 
controlling senescence. In addition, MEFs from transgenic mice generated by 
disruption of all Rb family proteins (Rb, p107 and p130) do not senesce 
(Dannenberg et al., 2000; Sage et al., 2000), suggesting that, in mice, Rb function 
can be compensated by Rb related proteins. Furthermore, p19Arf has functions that 
are independent of p53 because when Arf is overexpressed in cells lacking p53, it is 
still able to induce cell cycle arrest (Weber et al., 2000). In contrast, p14ARF seems to 
have a less relevant role in human cells. For example while Ink4a and Arf are largely 
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co-regulated in mouse (Krishnamurthy et al., 2004; Zindy et al., 1997), co-regulation 
of the two genes in human cells is not well established. In cultured human cells, 
senescence onset is usually associated with p16INK4a up-regulation, but not p14ARF 
(Huot et al., 2002; Michaloglou et al., 2005; Munro et al., 1999). 
 
1.1.3.3. Epigenetic regulation of the INK4b-ARF-INK4a locus 
Despite of species-specific differences, activation of the INK4b-ARF-INK4a 
locus is one of the first events that follow oncogenic activation. Understanding the 
molecular mechanisms that regulate this locus should help to identify the properties 
recognized by a cell as malignant as well as the way off recognizing them.  
Epigenetic mechanisms, such as the ones establishing chromatin marks 
present in either the DNA or the associated histones, do not alter the primary DNA 
sequence but are responsible for changes in gene expression that are heritable 
through cell division. Methylation of INK4b-ARF-INK4a promoters has been reported 
to occur in a variety of tumours. On the other hand methylation of histones proteins 
at specific residues, which plays a major role in the maintenance of active and silent 
states of gene expression during development, are also implicated in the regulation 
of the INK4b-ARF-INK4a locus.  
Polycomb group (PcG) proteins regulate chromatin by directly methylating 
histones. There are two core PcG protein complexes: polycomb repressive complex 
2 (PRC2) and polycomb repressive complex 1 (PRC1). PRC2 establishes the 
histone code that is subsequently interpreted by PRC1. The core components of the 
mammalian PRC2 complex are enhancer of zeste homologue 2 (EZH2), embryonic 
ectoderm development (EED), suppressor of zeste homologue 12 (SUZ12) 
(Sparmann and van Lohuizen, 2006) (Figure 1.6A). EZH2 is a histone 
methyltransferase that trimethylates histone H3 at lysine 27 (H3K27me3), an 
epigenetic mark associated with inactive chromatin. EED and SUZ12 are required for 
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EZH2 methytransferase activity. Specific DNA sequences firstly identified in D. 
melanogaster and named polycomb repressive elements (PREs), are recognized 
and bound by PRC2. Repressive histones marks, such as H3K27me3 established by 
PRC2, are than recognized by the PRC1 (reviewed in Mills, 2010). The latter 
stabilizes the inactive state by inhibiting transcription initiation (Cao et al., 2002), 
ATP-dependent chromatin remodelling (Francis et al., 2001) as well as by 
compacting nucleosome arrays (Francis et al., 2004). There is significant diversity 
among complexes of the PRC1 family, in part due to the existence of multiple 
paralogues of each PcG gene. PRC1 homologs of D. melanogaster in mammals are 
expressed differently in distinct tissues or developmental stages. The core of 
mammalian PRC1 is constituted by: a polycomb component containing a chromo 
domain (PC)(CBX2, 4, 6, 7 or 8), a polyhomeotic component (PH) (PH 1, 2, or 3) a 
posterior sex combs element (PSC) (such as BMI or MEL18) and a RING protein 
(RING1A or B) (Simon and Kingston, 2009)(Figure 1.6A).  
PcG proteins such as BMI1 and EZH2 are deregulated during tumorigenesis. 
BMI1 has been shown to regulate cellular senescence in murine and human cells 
(Itahana et al., 2003; Jacobs et al., 1999) and is also thought to prevent premature 
senescence of adult stem cells by repressing the INK4b-ARF-INK4a locus 
(Bruggeman et al., 2005; Molofsky et al., 2005). Other PRC1 member, the polycomb 
homolog CBX7 was identified in a cDNA screen designed for identification of genes 
able to bypass senescence in human epithelial cells. Knockdown of CBX7 in MEFs 
induces senescence whereas its expression extends life span, suggesting that CBX7 
has a role in suppressing the INK4b-ARF-INK4a locus (Gil et al., 2004). 
Oncogene-induced senescence results in reversal of PcG-mediated repression 
of p16INK4A. Senescence induced by oncogenic RAS coincides with the loss of PcG 
protein binding at the INK4b-ARF-INK4a locus, transcriptional repression of EZH2, 
and coincident transcriptional activation and recruitment of the H3K27me3 histone 
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demethylase, jumonji domain-containing 3 (JMJD3). There is a loss of the repressive 
H3K27me3 mark, RNA polymerase II is recruited and p16INK4A expression is induced, 
culminating in senescence (Agger et al., 2009; Barradas et al., 2009) (Figure 1.6B).  
 
 
 
 
 
 
 
Figure 1.6. Epigenetic activation of the INK4b-ARF-INK4a locus due to oncogenic stress. (A) 
Composition of PRC2 (left) and PRC1 (right) PcG protein complexes. PRC2 complex contains 
enhancer of zeste homologue 2 (EZH2), embryonic ectoderm development (EED), suppressor of zeste 
homologue 12 (SUZ12) and retinoblastoma-binding protein 4 (RBBP4) or RBBP7. PRC1 is constituted 
by: a polycomb component containing a chromo domain (PC)(CBX2, 4, 6, 7 or 8), a polyhomeotic 
component (PH) (PH 1, 2, or 3) a posterior sex combs element (PSC) (BMI or MEL18) and a RING 
protein (RING1A or B) (B) In proliferating cells the INK4b-ARF-INK4a locus (here referred as CDKN2A-
CDKN2B) is repressed (OFF) by PCR2 and PRC1 complexes that establish and maintain the repressed 
state characterized by the acquisition of the silent mark, tri-methylation of lysine 27 in histone 3 (H3K27-
Me3). Expression of activated Ras results in recruitment of jumonji domain-containing 3 (JMJD3) 
leading to demethylation of H3K27-Me3 and consequent eviction of PRC proteins. The inactive mark is 
substituted by the active mark H3K4-Me3 and RNA polymerase II (RNA Pol II) is recruited resulting in 
transcriptional activation of the locus (ON). (Adapted from (Mills, 2010).  
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1.2. Developmental potential and cell reprogramming 
 
 
Mammalian organisms rely on a range of specialized cells to fulfil the diverse 
functions required for their maintenance and survival. However this extensive array 
of specialized cells arises from a single cell after fertilisation: the zygote. During 
development, cells gradually lose developmental potential and became progressively 
differentiated in order to fulfil their function in somatic tissues. Therefore cells can be 
classified on the basis of their developmental potential. The zygote is “totipotent” 
because it retains the potential to give rise to all embryonic and extra-embryonic 
tissues. Embryonic stem (ES) cells, which are derived from the inner cell mass of the 
blastocyst, can originate all embryonic but not all extra-embryonic tissues and are 
therefore classified as “pluripotent”. Further down the line are the “multipotent” adult 
tissue stem cells, such as hematopoietic stem cells, that can only give rise to cell 
types within their lineage (Figure 1.7). 
 
1.2.1. Nuclear equivalence and the beginning of cell reprogramming  
The notion that differentiation is an unidirectional process that progressively 
limits the cells developmental potential soon intrigued biologists. In 1892 Weismann 
suggested that cell specialization was due to the uneven distribution of heritable 
determinants present in the nucleus. In this way only germ cells would carry a 
complete set of determinants and could therefore evolve into a whole organism  
(reviewed in Lensch, 2009). Although several researchers tried to clarify this matter, 
it was the work by Briggs and King, 60 years later that provided the irrefutable 
answer. Working with Xenopus laevis they establishing the technique of somatic cell 
nuclear transfer (SCNT), which consisted of isolating the nucleus of somatic cells  
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Figure 1.7. Stem-cell hierarchy. The totipotent zygote formed by the fusion of egg and sperm divides 
to form the inner cell mass (ICM) and the extra-embryonic (EE) tissue of the blastocyst. When isolated 
from the blastocyst in vitro, the cells of the ICM can be maintained in culture as pluripotent embryonic 
stem cell (ESC) lines. During development cells become increasingly restricted in their lineage potential 
and generate tissue-specific, multipotent stem cells. Adult multipotent stem cells are present in different 
organs and several niches, and are important for tissue maintenance. (Adapted from (Eckfeldt et al., 
2005). 
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from late-stage embryos and transferring them into enucleated oocytes (Briggs and 
King, 1952). In this way they were able to evaluate the developmental potential of 
the somatic nucleus and demonstrate that differentiated cells retain the genetic 
information necessary to generate the whole organism. John Gurdon carried these 
results further by demonstrating that terminally differentiated cells such as those 
from the tadpole intestine were likewise capable of being reprogrammed by the 
cytoplasmatic factors present in the oocyte (Gurdon, 1962).  Dolly the sheep was the 
first mammal to be generated by SCNT using nucleus of a fully specialized 
mammary gland cell (Wilmut et al., 1997).  Importantly, this work not only 
demonstrated the nuclear equivalence theory, that somatic cells possess the same 
gene pool as the totipotent zygote, but also implies that differentiation imposes 
reversible epigenetic, rather than genetic changes. Therefore, the somatic nucleus 
can be reprogrammed by the cytoplasmatic factors present in the oocyte to establish 
a different expression programme.  
 
1.2.2. Pluripotency and self-renewal  
Many questions remained unanswered following the demonstration of the 
nuclear equivalence theory. How are the differentiation programs established and 
maintained? Which factors are able to reprogram the somatic nucleus to reverse 
differentiation? An important step towards dissecting these mechanisms was the 
establishment of pluripotent cell lines. 
 
 1.2.3.1. Derivation of pluripotent cells lines  
 Pluripotency describes the functional capacity to generate all cell types by 
differentiation into any of the three germ layers: endoderm, mesoderm and 
ectoderm. However, pluripotent cells cannot develop into an adult animal because 
they lack the potential to contribute to extra-embryonic tissue such as the placenta. 
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Pluripotency can be found transiently in vivo in the inner cell mass (ICM) of the 
mammalian blastocyst and in some regions of the epiblast. However, it can also be 
maintained in vitro under defined conditions that promote growth while inhibiting 
cellular differentiation. In this way pluripotent cells lines are also characterized by the 
ability to self-renew: the capacity to divide continually and give rise to identical 
undifferentiated cells. 
  Embryonic carcinoma (EC) cells were the first pluripotent cells to be 
propagated in vitro. These cells are derived from teratocarcinomas, which are 
malignant germ cell tumours that are comprised of both undifferentiated and 
differentiated cells belonging to the three germ layers (Kleinsmith and Pierce, 1964; 
Stevens and Little, 1954).  
The derivation of mouse embryonic stem (mES) cells from the inner cell mass 
(ICM) of mouse blastocysts was first described in 1981 (Evans and Kaufman, 1981; 
Martin, 1981), while human embryonic stem (hES) cells were derived more than 
fifteen years later (Shamblott et al., 1998; Thomson et al., 1998). Embryonic stem 
cells from mouse and human, have both the properties of self-renewal and 
pluripotency; and can therefore be maintained in culture indefinitely in an 
undifferentiated state or differentiate in vitro into derivates of the three germ layers 
and give rise to teratomas when transplanted into nude mice. In the case of mouse 
ES cells the test of pluripotency can be taken even further. By re-introducing ES cells 
into developing blastocysts one can verify their contribution to all somatic tissues 
including the germ line, in a process that originates chimeras (animals that have two 
different populations of genetically distinct cells).  
Besides ES cells, other pluripotent stem cell lines have been successively 
derived: epiblast-derived stem (EpiS) cells from post-implantation embryos (Brons et 
al., 2007; Tesar et al., 2007); embryonic germ (EG) cells from primordial germ cells 
(Matsui et al., 1992; Resnick et al., 1992); and multipotent germ stem (mGS) cells 
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from explanted neonatal or adult mouse testicular cells (Guan et al., 2006; Kanatsu-
Shinohara et al., 2004b; Seandel et al., 2007).  
Induced pluripotent stem (iPS) cells constitute another pluripotent cell line that 
is obtained from somatic cells by expression of defined factors.  The assays used to 
demonstrate pluripotency of ES cells also demonstrate pluripotency of iPS cells. But 
complete equivalence between iPS cells and their biological counterpart, ES cells, is 
still a matter of debate.  
 
 
1.2.3.2. Core transcriptional regulators of pluripotency  
The intense study of ES cell biology has uncovered numerous and diverse 
pluripotency regulators such as transcription factors, signalling transduction 
molecules, regulatory RNAs and chromatin-modifying enzymes. Three main 
transcription factors, all highly expressed in the inner cell mass and epiblast of the 
mouse embryo and in undifferentiated ES cells, have been suggested to be central 
to the transcriptional regulatory hierarchy that specifies embryonic stem cell identity. 
These are the POU-family transcription factor Oct4, the homeodomain DNA-binding 
protein Nanog and the Sox-family transcription factor Sox2. Deletion of any of these 
genes results in early embryonic lethality due to the inability to maintain pluripotent 
cells (Avilion et al., 2003; Mitsui et al., 2003; Nichols et al., 1998). While deletion of 
Oct4 or Sox2 in mouse ES cells lead to conversion to trophectoderm (Masui et al., 
2007; Niwa et al., 2000), Nanog deficient mouse embryonic stem cells are still able 
to self-renew but have an increased propensity to differentiate and cannot give rise 
to mature germ cells (Chambers et al., 2003).  
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Co-regulatory and auto-regulatory mechanisms appear to link the three factors 
in a self-reinforcing circuit. Oct4 and Sox2 can heterodimerise and control 
expression of a number of genes including Oct4, therefore one of Sox2 functions in 
maintaining pluripotency seems to be the regulation of Oct4 levels (Masui et al., 
2007). Indeed, genome-wide analysis of the occupancy of these three transcription 
factors reveal that all bind to their own promoters as well as the promoters of the 
genes encoding the other two factors (Boyer et al., 2005), suggesting that auto-
regulatory loops mediate gene expression stability and maintenance of the 
pluripotent state. In addition, to their own promoters Oct4, Sox2 and Nanog co-
occupy hundreds of genes which seem to overlap, suggesting that these three 
factors act co-ordinately to maintain a pluripotency-associated transcriptional 
program. Together with ES cell-specific active genes, these regulators also bind 
genes that are silent in embryonic stem cells and whose expression is associated 
with lineage commitment and cellular differentiation. Consequently, a key role of 
these master regulators is probably to counteract differentiation by continuously 
suppressing expression and activity of lineage specification factors (reviewed in 
Niwa, 2007) (Figure 1.8). 
New regulators of pluripotency (such as Esrrb, Dax1, Sall4, Rex1, Stat3, among 
others) have been identified by shRNA knockdown screens (Ivanova et al., 2006), 
proteomics (Wang et al., 2006) and analysis of transcription factor binding sites and 
gene expression data (Zhou et al., 2007). The extent and complexity of the 
pluripotency transcriptional network will continue to expand as the understanding of 
ES cells improves and new tools for their study become available (Orkin et al., 
2008). 
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Figure 1.8. The core embryonic stem cell transcriptional circuit. The homeodomain 
transcription factors OCT4 (also known as POU5F1) and NANOG, as well as SRY box-containing factor 
2 (SOX2), form a transcriptional module that has a central role in maintaining ES cell identity both in 
mice and humans. The three transcription factors regulate their own and each other's expression in a 
highly coordinated manner, involving positive protein–protein and protein–DNA feedback loop 
interactions. Furthermore, they co-occupy and promote transcription of numerous self-renewal and 
pluripotency genes and repress the expression of the genes involved in lineage commitment. (Adapted 
from (Macarthur et al., 2009). 
 
 
1.2.3.3 Epigenetic control of pluripotency  
Embryonic stem cells have specific chromatin features that reflect a 
transcriptionally permissive state. Accordingly, the interaction between chromatin 
and its structural proteins, such as histone H2B, histone H3 and heterochromatin 
protein 1 (HP1) is more dynamic in ES cells and therefore their chromatin is more 
plastic (Meshorer et al., 2006). Additionally, it was shown that chromatin-remodelling 
proteins are overexpressed in ES cells. These proteins are important to maintain 
chromatin in an open state and contribute to global transcriptional activity (Efroni et 
al., 2008).  
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An important level of gene regulation in ES cells is DNA methylation. 
Promoters of pluripotency-associated genes are usually hypomethylated in ES cells 
but hypermethylated and silent in differentiated cells (Farthing et al., 2008). Post-
translational modifications of histones can also dictate chromatin structure and 
transcriptional competence. Tri-methylation of histone H3 on lysine 4 (H3K4me3) is 
usually associated with transcriptional active chromatin, whereas the tri-mehylation 
of lysine 27 (H3K27me3) with inactive heterochromatin. Interestingly, both 
modification marks are often found together in promoters of developmental genes 
constituting domains of “bivalent chromatin” (Azuara et al., 2006; Bernstein et al., 
2006). Bivalent marks are thought to allow these genes to remain silent but primed 
for rapid activation in response to developmental signals.  In addition, polycomb-
group proteins (PcG) have a central role in regulating pluripotency. Members of the 
PRC2 or PRC1 bind to the promoters of many developmental genes that are 
involved in lineage-specification or in later developmental stages, many of them co-
bound with Oct4, Sox2 and Nanog (Boyer et al., 2005; Boyer et al., 2006; Jorgensen 
et al., 2006; Lee et al., 2006b). 
 
1.2.3.4. Extrinsic pluripotency regulators in mouse and human ES cells 
Although many of the pluripotency pathways are conserved between mouse 
and human ES cells, the extrinsic pathways required for pluripotency differ between 
the two species.  Mouse ES cells can be maintained in an undifferentiated state in 
culture with foetal calf serum supplemented with the leukaemia inhibitory factor (LIF), 
which activates the STAT3 signalling pathway (Niwa et al., 1998). In addition, 
signalling through bone morphogenic proteins (BMPs) together with LIF is sufficient 
for culturing undifferentiated mES cells in serum-free conditions (Ying et al., 2003). 
BMPs induce the expression of Id (inhibitor of differentiation) proteins through the 
Smad pathway. However, it is now apparent that self-renewal and pluripotency of 
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mES cells can be maintained without the addition of extrinsic growth factors, by 
simply blocking differentiation-inducing signals using inhibitors of the FGF receptors, 
ERK and GSK3 pathways (Ying et al., 2008). 
The delay between the derivation of mouse ES cells in 1981 and of human ES 
cells in 1998 was primarily due to species-specific ES cell differences. The culture 
media supplemented with LIF and serum, conditions that allow the derivation of 
mouse ES cells, resulted only in differentiation of human pluripotent cell lines. It was 
later shown that hES cells do not require active LIF/STAT3 signalling (Daheron et al., 
2004; Humphrey et al., 2004) or BMPs, which in this case promote trophectoderm 
differentiation (Gerami-Naini et al., 2004; Pera et al., 2004). Instead, FGF and 
TGFβ/Activin/Nodal signalling are of central importance. Therefore, it now appears 
largely to be a lucky coincidence that fibroblast feeder layers support both mouse 
and human ES cells, as the specific factors used to sustain mES cells do not support 
hES cells.  
Basic FGF (bFGF) allows the clonal growth of hES cells on fibroblasts in the 
presence of a commercially available serum replacement (Amit et al., 2000). The 
mechanism by which bFGF exert its functions is incompletely known, although one 
of the effects is suppression of BMP signalling that would otherwise induce 
differentiation (Xu et al., 2005). Another study demonstrates that FGF is required for 
maintenance of human-ES-cell-derived fibroblast-like cells (hdFs), which in turn act 
as a supportive niche for hES cells via IGF-II production. Importantly, the authors 
show that IGF-II has a direct role in the survival and self-renewal of pluripotent 
human ES cells. (Bendall et al., 2007). hES cells can also be propagated in feeder-
free conditions, conditioned media or serum replacement if a combination of Activin 
plus FGF2 is used (Beattie et al., 2005; Vallier et al., 2005). It has been argued that 
human ES cells resemble more closely mEpiS cells than other pluripotent mouse-
derived cell types because they also require nodal or activin signals to maintain 
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pluripotency, whereas mES cells do not (Tesar et al., 2007). In this regard, it has 
been suggested that the pluripotent state can be classified in two different ways: 
ICM-like or “naïve” state, and epiblast-like or “primed” state (Hanna et al., 2010; 
Nichols and Smith, 2009). The first is characteristic of mouse ES cells, and EG cells 
while the second is typical of the pluripotent cells derived from the mouse epiblast 
(mEpiS cells) to which hES cells resemble.   
Apart from the different extrinsic requirements for maintenance of pluripotency, 
human and mouse ES cells differ phenotipically. Human ES cells colonies are flatter 
and display sharper borders when compared with the rounded 3-D shaped mouse 
ES cells colonies (Pera et al., 2000).  In addition, the stage-specific embryonic 
antigens (SSEA) subtypes and glycolipids present in the cell membrane used as 
stem cell markers differ between the two species. Mouse ES cells express SSEA-1 
(stage-specific embryonic antigen), while human ES cells express other sub-types of 
stage-specific embryonic antigens (SSEA-3 and SSEA-4) and display other antigens 
such as the proteoglycans TRA-1–60 and TRA-1–81 (Draper et al., 2002). 
 
1.2.4 Somatic cell reprogramming  
The term “cell reprogramming” is used to describe functional and molecular 
alterations that underlie changes in cell fate. Although most often used in the context 
of reprogramming adult somatic cells to pluripotent stem cells, reprogramming also 
includes the conversion of one differentiated cell type into another in a process 
called “transdifferentiation” or “lineage conversion”.   A type of reprogramming that in 
the “Waddington landscape” can be represented as moving the marble across 
valleys (Figure 1.9). In the present work, reprogramming refers to the events that 
lead to a gain in developmental potential, such as induction of pluripotency in 
somatic cells.   
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Figure 1.9. Developmental potential illustrated by the Waddington’s epigenetic landscape. Cell 
populations with different developmental potential are represented as coloured marbles (purple, 
totipotent; blue, pluripotent; red, multipotent; green, unipotent). Developmental restrictions can be 
illustrated as marbles rolling down a landscape into one of several valleys. Reprogramming processes 
are represented as dashed lines. The marble can move uphill (dedifferentiation, gain in developmental 
potential) or across valleys (transdifferentiation). ICM/ES cells, embryonic stem cells derived from the 
inner cell mass of the blastocyst; EG cells embryonic germ cells, EC cells embryonic carcinoma cells, 
mGS cells, multipotent germ cells; iPS cells, induced pluripotent stem cells. (Adapted from 
(Hochedlinger and Plath, 2009). 
 
 
1.2.4.1 Reversing Differentiation: Why and how? 
The derivation of embryonic stem cells ignited an explosion of scientific 
interest offering unique opportunities for research and disease treatment. The goal is 
to differentiate these cells in vitro and isolate highly specialised progeny for the 
purpose of transplantation. However, since tissues or organ transplantation between 
genetically distinct individuals provoke an immune reaction that can result in graft 
rejection, the ultimate goal of regenerative medicine is to produce genetically 
equivalent material, circumventing the risk of rejection or the need for 
immunosuppressive drugs. In other words the creation of patient-specific pluripotent 
stem cell lines. In addition, having access to human pluripotent cells bearing 
mutations found in hereditary diseases would also be an important resource to 
science and medicine. Three methods have been described that are able to 
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reprogram the nucleus of a somatic cell to a pluripotent state: somatic cell nuclear 
transfer (SCNT), cell fusion and transcription factor-induced reprogramming (also 
referred to as direct cell reprogramming; Figure 1.10).  
 
Somatic Nuclear Transfer (SCNT) 
As mentioned previously, somatic cell nuclear transfer (SCNT) was developed 
to assess whether the nuclei of differentiated cells remain equivalent to the nucleus 
of pluripotent cells and was later used for cloning of several mammalian species 
(Eggan et al., 2004; Gurdon and Byrne, 2003; Hochedlinger and Jaenisch, 2002; 
Inoue et al., 2005; Wilmut et al., 1997). However the procedure is technically 
challenging, inefficient and dependent on the donation of a large number of 
unfertilized oocytes. Besides, although Byrne and colleagues have successfully 
derived nuclear-transfer ES cells from primates by improving the SCNT protocol 
(Byrne et al., 2007), the same was never achieved with human cells. Importantly, 
even if these technical barriers are one day overcome, this technique faces strong 
ethical concerns in relation to generation of human embryos exclusively for ES cells 
production.  
 
Cell Fusion  
Another method primarily used for the study of the developmental capacity of 
pluripotent cell lines is cell fusion. Fusion of embryonic carcinoma (EC) cells with 
somatic cells generates hybrid cells that acquire a stem cell molecular signature and 
are able to form teratomas in nude mice (Miller and Ruddle, 1976). Similar results 
can be obtained by fusion with mES cells (Tada et al., 2001) and hES cells (Cowan 
et al., 2005; Yu et al., 2006). However these hybrid cells are tetraploid, and therefore 
genetically unstable and still immunologically incompatible. Nevertheless this method 
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has remained useful as a tool for investigating the mechanisms of cell plasticity and 
nuclear reprogramming. Importantly, this method has limited applications if DNA 
replication and cell division are required for complete reprogramming.  
 
 
 
 
 
Figure 1.10. Three strategies for induction of nuclear reprogramming of somatic cells. Nuclear 
transfer involves the injection of a somatic nucleus into an enucleated oocyte. From this oocyte a 
blastocyst is generated from which ES cells can be derived or if development is allowed, give rise to a 
cloned organism. Cell fusion of somatic cells with ES cells results in the generation of tetraploid 
multinucleated heterokaryons that quickly acquire features of ES cells. If the fused cells proliferate they 
will become hybrids that can be euploid (balanced set of chromosomes, 4n) or aneuploid  
(chromosomes are lost and rearranged) if cells belong to different species. Transcription-factor 
transduction refers to the generation of induced pluripotent stem (iPS) cells by the ectopic expression of 
four reprogramming factors (Oct4, Sox2, Klf4 and c-Myc). iPS cells are similar to ES cells in 
morphology and expression patterns, can self-renew and have pluripotent potential. (Adapted from 
(Yamanaka and Blau, 2010). 
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Transcription factor-induced reprogramming 
The fact that somatic cells can be reprogrammed by nuclear transfer and cell 
fusion, highlights the presence of factors in the unfertilised oocyte and in the ES cells 
that are able to induce pluripotency. Based on this, Yamanaka and colleagues 
selected a group of 24 candidates because they have been implicated in the 
maintenance of pluripotency (Oct4, Sox2, Nanog) or because they were genes 
implicated in maintenance and rapid proliferation of mES cells in culture (Stat3, Klf4, 
β-catenin, E-Ras, c-Myc). To test their ability to induce pluripotency, they expressed 
these factors by retroviral transduction in mouse embryonic fibroblasts (MEFs) 
carrying a fusion of the genes encoding β-galactosidase and neomycin resistance 
expressed from the Fbx15 locus (specifically expressed is ES cells but not required 
for pluripotency). When MEFs were infected with all 24 factors and cultured on 
feeders in ES cells media neomycin-resistant, colonies emerged. In a process of 
step-wise elimination, four transcription factors, Oct4, Sox2, Klf4 and c-Myc, were 
identified as sufficient to give rise to ES-like colonies that were termed induced 
pluripotent stem (iPS) cells (Takahashi and Yamanaka, 2006).  These first iPS cells 
were not identical to ES cells since they had different gene expression and DNA 
methylation patterns, and generated abnormal chimeric embryos. However it was 
later proven by Yamanaka’s group, as well as by others, that iPS cells capable of 
germline transmission could be generated (Maherali et al., 2007; Meissner et al., 
2007; Okita et al., 2007; Wernig et al., 2007). The reprogramming by defined factors 
or “direct reprogramming” and its end product, the induced pluripotent stem (iPS) 
cells soon captivated the attention of the scientific community. Not only would direct 
reprogramming enable the relatively easy generation of patient-specific pluripotent 
stem cells, but also it would circumvent the ethical issues associated with the use of 
human embryos as source for derivation of hES cell lines.  In addition, it would be a 
useful tool to dissect the mechanisms underlying pluripotency.  
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The generation of iPS cells from human cells was achieved a year later by two 
research groups (Takahashi et al., 2007; Yu et al., 2007). While Yamanaka’s group 
used the same combination of 4 factors, Thomson’s group substitute Klf4 and c-Myc 
with Nanog and Lin-28. This suggested that the pluripotency network could be 
induced using different protocols. In the same line cells types other than fibroblasts, 
were successively reprogrammed to human iPS cells. These included skin 
keratinocytes (Aasen et al., 2008) neural stem cells (Kim et al., 2008) and umbilical 
cord blood cells (Giorgetti et al., 2009; Haase et al., 2009). One important 
achievement was the generation of iPS cells from peripheral blood cells (Loh et al., 
2009; Seki et al., 2010; Staerk et al., 2010). This will enable generation of patient-
specific iPS cells without the need for invasive skin biopsy, and subsequent time 
required for fibroblast expansion, bringing iPS cells a step closer to the clinic. 
  
1.2.4.2. Mechanisms underlying reprogramming to iPS cells 
Besides their therapeutic implications, iPS cells have been used as tool to 
understand the pluripotent state and to identify their regulators. However, direct 
reprogramming is a complex process that remains largely elusive. For example, the 
individual role of each reprogramming factor is not completely understood. In 
addition, reprogramming efficiencies are very low varying between 0.01% and 0.5% 
when using retroviral vectors (reviewed in Amabile and Meissner, 2009). To cap it 
all, reprogramming is a slow process, taking 2-3 weeks by retroviral delivery, and 10-
12 weeks using recombinant proteins. In contrast, somatic nuclear transfer, in which 
45-50% of somatic nuclei consistently undergo reprogramming, occurs in 
approximately 3.5 days (Markoulaki et al., 2008). Fusion of somatic cells with 
pluripotent cells is the fastest method, with pluripotency markers being detected 
within 24-48h (Han et al., 2008).  
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 The fact that direct reprogramming to pluripotency is such an inefficient 
process suggests that several barriers hinder the process; one of the obstacles 
might involve technical problems such as efficient delivery and optimal stoichiometry 
of reprogramming factors. This issue was addressed by studies in which “secondary 
iPS” cells were created. Secondary iPS cells are generated from iPS cell-derived 
differentiated cells (fibroblast-like cells obtained by in vitro differentiation or in the 
case of mouse cells by the generation of chimeric mice) that harbour doxycyclin 
inducible transgenes. (Maherali et al., 2008; Wernig et al., 2008). Despite the fact 
that viral transgenes are reactivated in most of these iPS cell-derived differentiated 
cells, and that there is a 50 to 100-fold increase in the reprogramming efficiency, the 
frequency of reprogramming remains quite low  (1% to 3%) (Maherali et al., 2008). 
This suggests that several biological roadblocks exist and that only a small 
percentage of cells can slowly overcome them. Two models were proposed to 
explain these observations. 
 
1.2.4.2.1. Elite versus stochastic model  
 In the “elite” or deterministic model only some cells in the whole population of 
somatic cells have the potential to be reprogrammed. This could be due to the 
existence of somatic stem or progenitor cells in the explanted cell population that 
would be susceptible to reprogram. In the “stochastic” model all cells in the 
population are equally amenable to be reprogrammed. However, they have to go 
through a series of stochastic events to acquire pluripotency (Yamanaka, 2009). 
Several studies have proved that a deterministic scenario is unlikely. For 
example, iPS cells have been derived from different somatic cells types including 
terminally differentiated somatic cells such as B and T lymphocytes (Hanna et al., 
2008). In addition, in one study the monitoring of clonal populations of B cells and 
monocytes expressing the reprogramming factors, has shown that practically all 
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somatic cells can give rise to iPS cells, although some may require long times in 
culture (Hanna et al., 2009). 
 Importantly, different cell types are reprogrammed with different efficiencies. 
Somatic stem cells such as haematopoietic stem cells can be reprogrammed quicker 
and with higher efficiency than cells from them derived such as lymphocytes (10-
40% compared with 0.01-1%) (Eminli et al., 2009). Therefore, a combination, of both 
models most accurately explains the reprogramming kinetics. A series of stochastic 
events are necessary and sufficient to reprogram any cell type, however some cells, 
such as adult progenitor and stem cells require fewer of these random events than 
terminally differentiated cells.  
 
 1.2.4.2.2.  Sequential events during reprogramming to pluripotency  
 To understand the impediments and mechanisms of direct reprogramming 
we have to understand how reprogramming works. Studies in mouse fibroblasts 
revealed that it begins with the downregulation of somatic markers followed by 
activation of early pluripotency markers such as SSEA-1 and alkaline phosphatase. 
A mesenchymal-to-epithelial transition (MET) takes place early during 
reprogramming of mouse or human fibroblasts to iPS, and TGF-β inhibition promotes 
this transition (Li et al., 2010; Samavarchi-Tehrani et al., 2010). Endogenous Nanog 
and Oct4 activation occur later in the process and are usually associated with a fully 
reprogrammed state (Brambrink et al., 2008; Stadtfeld et al., 2008a) (Figure 1.11.). 
Underlying this sequence of events, is a genome-wide remodelling of the chromatin 
to an ES-like state. In differentiated cells many developmental and differentiation-
associated genes are active, showing low DNA methylation and enrichment for 
H3K4me3. During reprogramming chromatin remodelling is necessary for silencing 
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Figure 1.11.  Landmark events during reprogramming to pluripotency. When transduced with the 
reprogramming factors, fibroblasts begin to show alterations in their expression pattern. One of the first 
events is down-regulation of fibroblast-specific genes. Another early event is the down-regulation of 
mesenchymal genes, followed by up-regulation of epithelial genes (as a more epithelial nature is 
essential for successful reprogramming to pluripotency). To acquire a cell cycle profile characteristic of 
stem cells, down-regulation of tumour suppressor pathways such as the ones involving p16INK4a/RB and 
p53/p21Cip1 has to take place. Expression of ESC-specific genes such as the one responsible alkaline 
phosphatase activity, and several membrane markers like SSEA1, are the first to be activated. 
Pluripotency genes such as Nanog and Oct4, are activated later in the process and are associated with 
a fully reprogrammed state.    
 
 
 of lineage-associated genes by establishing repressive epigenetic marks such as 
H3K27me3, and for some genes the bivalent chromatin structure characteristic of ES 
cells (Mikkelsen et al., 2008). On the other hand, in differentiated cells early 
developmental genes are silence by Polycomb-mediated H3K27me3 and all 
pluripotency-associated genes are hypermethylated. Therefore re-establishment of 
H3K4me3 active marks and loss of DNA methylation in ES-associated genes has to 
occur to allow the establishment of an ES-like expression program.  
Besides changes in chromatin structure and alteration gene expression, 
reprogramming involves the acquisition of an ES-like cell cycle regulation and 
immortality (see section 1.3). Although the timing of these changes is not clear, the 
fact that partially reprogrammed cells cease proliferation upon doxycyclin redrawal 
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during secondary iPS reprogramming, suggests that this is a late event (Figure 
1.11). 
 
1.2.4.3. Challenges and advances in the generation of iPS cells 
Although extremely promising, there are still several obstacles to overcome 
before direct reprogramming to pluripotency can be applied for clinical use. Several 
research groups have been working in improving the process, centred in two main 
objectives: the production of safer iPS cells free of viral integrations, and the 
improvement of reprogramming efficiency. 
 
1.2.4.3.1. Choice and delivery of reprogramming factors 
Although the four factor reprogramming is effective in different cells types and 
in different species, the endogenous expression of certain reprogramming factors 
has permitted their exclusion from the four factors cocktail. For example, c-Myc is not 
necessary to reprogram mouse and human fibroblasts. However, in the absence of 
c-Myc it takes longer to obtain reprogrammed colonies and the efficiency of the 
process is much lower (Nakagawa et al., 2008; Wernig et al., 2007). Neural 
progenitors cells, which express high levels of Sox2 and c-Myc, can be 
reprogrammed using only Oct4 and Klf4 or Oct4 and c-Myc (Kim et al., 2008). 
Indeed, Oct4 alone is sufficient to directly reprogram mouse neural stem cells to 
pluripotency (Kim et al., 2009).  
The presence of multiple retroviral integration sites in individual iPS cell clones 
prohibits their clinical use due to the risk of oncogenic mutations. In addition, while 
retroviral transgenes are usually silenced by DNA and histone methyltransferases  
towards the end of the reprogramming process (Lei et al., 1996; Matsui et al., 2010; 
Stadtfeld et al., 2008a), incomplete silencing can lead to partially reprogrammed 
cells that fail to activate endogenous expression of pluripotency factors and 
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depended on the expression of exogenous factors (Mikkelsen et al., 2008; 
Takahashi and Yamanaka, 2006). Moreover, residual activity or reactivation of viral 
transgenes in somatic cells derived from iPS cell lines, can lead to defective 
developmental potential and formation of tumours in chimeric animals (Takahashi 
and Yamanaka, 2006) (Okita et al., 2007).  
Although retroviral vectors are still widely used for factor delivery, if iPS cells 
are to be use in a therapeutic setting, the creation of integration-free iPS cells will be 
imperative. Several approaches have been devised to avoid the use of vectors that 
require integration; unfortunately they are usually associated with low 
reprogramming efficiencies. The first integration-free iPS cells were generated from 
mouse hepatocytes using adenoviral vectors (Stadtfeld et al., 2008b), and from 
MEFs by plasmid transfection (Okita et al., 2008). Importantly transient expression of 
the four reprogramming factors was sufficient to generate iPS cells supporting the 
notion that insertional mutagenesis does not play a role in iPS cell generation. 
Human integration-free iPS cells were later generated by adenoviral infection (Zhou 
and Freed, 2009), transfection with self-replicating episomal vectors (Yu et al., 2009) 
or with polycistronic minicircle vectors (Jia et al., 2010). 
Due to the low reprogramming efficiency when using non-integrating vectors, 
some research groups have developed retroviral vectors with loxP sites to allow viral 
excision from the host genome by transient expression of Cre Recombinase (Kaji et 
al., 2009; Soldner et al., 2009). This enables the expression of reprogramming 
factors for longer lengths of time, until reprogramming is complete. In a similar way, 
two laboratories used piggyBac transposons that can be shuttled in and out of the 
host genome by transient expression of transposase (Woltjen et al., 2009; Yusa et 
al., 2009). An alternative for generation of integration-free iPS cells is the delivery of 
the reprogramming factors as purified proteins (Zhou et al., 2009). Although this is a 
very attractive approach, the reprogramming efficiency obtained by this method is 
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particularly low. More recently it was described that iPS could be obtained by 
administration of synthetic mRNA modified to overcome innate antiviral responses. 
Importantly the efficiency of this protocol greatly surpasses previously established 
methods (Warren et al., 2010). 
 
1.2.4.3.2. Increasing reprogramming efficiency: bypassing biological 
roadblocks 
The low efficiency of reprogramming imposes limitations to mechanistic studies 
and iPS cell potential clinical translation. Therefore great effort has been put into 
finding candidate genes or molecules that could replace one of the reprogramming 
factors or interfere with specific pathways or biological processes. Interestingly the 
quest for enhancing reprogramming has also provided clues on how reprogramming 
works. 
Functional screens will continue to yield new reprogramming factors that can 
enhance four factors reprogramming or substitute some of the reprogramming 
factors. One example is the nuclear receptor Nr5a2, which was shown to enhance 
reprogramming of mouse fibroblasts and to replace Oct4 (Heng et al., 2010). 
Schöler’s laboratory have devised a functional and quantitative proteomics screen to 
identify proteins and complexes that contribute to reprogramming, by identifying 
proteins that are enriched in reprogramming-competent fractions of pluripotent cell 
extracts. In this way they found that the pluripotent-enriched components of the 
SWI/SNF complex (or BAF complex) such as Brg1 and BAF155 could significantly 
increase reprogramming efficiency when used together with the four factors or three 
factors (excluding c-Myc). A mechanistic insight into BAF complex function revealed 
that it contributes to a euchromatic chromatin state and enhance binding of 
reprogramming factors onto promoters of key pluripotency genes, thereby enhancing 
reprogramming (Singhal et al., 2010).   
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All these studies, and many other which are not mention here due to space 
restrictions, have provided useful insights into the mechanisms underlying 
reprogramming to pluripotency. However the ideal scenario would be to generate 
iPS cells using fewer factors or without disturbing the host genome.  Understanding 
the events involved in reprogramming will allow us to find which pathways can be 
modulated using small molecules to increase the efficiency of methods in which 
integration – free iPS cells are created. In fact, some chemicals have been reported 
to either enhance reprogramming efficiency or to substitute for some reprogramming 
factors. Some of these compounds affect chromatin modifications such as the 
inhibitors of DNA methyltransferases or the histone deacethylase inhibitors while 
others influence signal transduction pathways.  
Proper epigenetic remodelling has proved to be a main roadblock to successful 
reprogramming. Indeed, during iPS reprogramming a population of cells gets trapped 
in partially reprogrammed state due to the existence of reprogramming barriers such 
as epigenetic remodelling. Meissner and colleagues compared the expression 
patterns of fully reprogrammed and partially reprogrammed cells and discovered that 
partially reprogrammed cell lines reactivate a distinctive subset of stem-cell-related 
genes but show incomplete repression of lineage-specifying transcription factors, 
and DNA hypermethylation at pluripotency-related loci. To overcome the inefficient 
step of DNA de-methylation, they treated partially reprogrammed cells with 5-aza-
cytidine (AZA) and were able to promote their complete reprogramming. Accordingly, 
addition of this DNMT inhibitor enhances the reprogramming efficiency of mouse 
fibroblasts by 4-fold (Mikkelsen et al., 2008).  
In addition to inhibitors of DNA methylation, several inhibitors of histone post-
translational alterations have been identified such as histone deacetylase (HDAC) 
inhibitors, especially valproic acid (VPA), which have been shown to noticeably 
increase reprogramming efficiency in MEFs (100-fold for OSK and 50-fold for OSKM) 
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and in human fibroblasts (20-fold) (Huangfu et al., 2008). Valproic acid is thought to 
promote a genome wide acetylation that permit somatic cells to adopt a relaxed 
chromatin structure (Huangfu et al., 2008). In a chemical compound screen, an 
inhibitor of G9a histone methyltransferase BIX-01294 was found to improve 
reprogramming of mouse neural progenitor cells transduced with Oct4 and Klf4 (8-
fold)(Shi et al., 2008b). BIX-01294 enhances reprogramming of MEFs but only in 
combination with, a DNA methyltransferase inhibitor (RG108) and a L-calcium 
channel agonist BayK8644 (Shi et al., 2008a). 
Modulation of signalling pathways have also provided ways of improving 
reprogramming. Inhibition of MEK and GSK3 can bypass the requirement of LIF and 
BMP signalling in the maintenance of mouse ES cells. This is important to block 
lineage commitment induced by ERK signalling thereby maintaining the ground state 
of pluripotency (Burdon et al., 1999; Ying et al., 2008). Inhibition of GSK3, on the 
other hand, promotes mESCs propagation (Sato et al., 2004). Smith and colleagues 
used mouse neural stem cells with Oct4 driven GFP and observed that although a 
considerable percentage of cells acquired stem cell morphology early in the process, 
only 2% were GFP positive. These pre-iPS colonies presented ES cell-like 
morphology, showed down-regulation of somatic markers but incomplete activation 
of pluripotency genes. The use of MEK and GSK3 inhibitors together with LIF (2i/LIF) 
promoted the transition from pre-iPS cells to fully reprogrammed iPS cells (Silva et 
al., 2008). Another way to modulate signalling pathways is the addition of 
recombinant proteins, when Jaenisch and colleagues activated Wnt signaling by 
addition of recombinant Wnt3a, they observed an improvement in reprogramming to 
iPS cells. Additionally, they were able to reprogram human cells in the absence of c-
Myc or with only two factors, Oct4 and Klf4 (Marson et al., 2008).  
Several research groups have performed screenings to find signalling 
pathways modulators that can replace some of the reprogramming factors. In a high-
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content chemical screening to identify small molecules that can replace Sox2 in 
reprogramming, Eggan and colleagues identified a molecule that functions in 
reprogramming by inhibiting TGF-β signalling and promotes the complete 
reprogramming of mouse partially reprogrammed cells by inducing Nanog (Ichida et 
al., 2009). The same was observed in human cells however in this case in 
conjunction with inhibition of mitotic activated protein kinase (MAPK) pathway (Lin et 
al., 2009). Although inhibition of TGF-β signalling improves reprogramming by 
inducing Nanog in mouse cells, it may also promote the mesenchymal-to-epithelial 
transition, which is required in the early stages of reprogramming of mouse and 
human fibroblasts to iPS cells (Li et al., 2010; Samavarchi-Tehrani et al., 2010).  
Given the fact that one of the sequential events during reprogramming is the 
acquisition of immortality, some groups have interfered with senescence and 
apoptosis pathways to promote reprogramming. Indeed, one of the first studies 
describing reprogramming of human fibroblasts (usually more difficult to reprogram 
than mouse cells) required addition of SV40 large T (SV40 LT) and/or the catalytic 
subunit of telomerase (hTERT) (Park et al., 2008b). In another study siRNAs against 
p53 and Utf1 was shown to increase reprogramming efficiency of human cells by 
100-fold (Zhao et al. 2008). Although there was the notion that interfering with the 
p53 pathway could improve reprogramming by promoting cell survival and inducing 
rapid proliferation the exact mechanism by which p53 limits reprogramming was 
unclear. 
Recent work has highlighted the relation between tumour suppressor 
pathways inactivation and reprogramming to iPS cells, which will be discussed in this 
work. 
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1.3. The unlimited lifespan of embryonic stem cells 
 
1.3.1.  ES cells do not undergo replicative senescence 
 
One of the more remarkable features of ES cells is that they can self-renew in 
culture indefinitely, and do not undergo senescence like immortalized cells and 
transformed cells, yet they are not transformed. For example, hES cells have been 
shown to continuously grow in culture for two years, which is equivalent to about 500 
doubling times (Carpenter et al., 2004; Rosler et al., 2004). Importantly the absence 
of replicative senescence is not due to acquisition of genotypic abnormalities in 
culture as hES cells grown continuously in culture show a normal karyotype and 
have stable genomes (Maitra et al., 2005).  
This implies that the pathways responsible for senescence onset are regulated 
differently in ES cells. Indeed, gene expression profiling identified key differences in 
cell cycle regulation, regulation of telomeric proteins expression and DNA repair in 
hES cells (Miura et al., 2004) and in mES cells (Ginis et al., 2004).  
 
1.3.1.1. Embryonic stem cells exhibit telomerase activity 
 
As mentioned before most human cancers contain high levels of telomerase 
activity underscoring the importance of telomere maintenance in cellular immortality 
(Blasco, 2005). Introduction of the catalytic sub-unit of telomerase (hTERT) into 
normal, pre-crisis fibroblasts results in telomerase activity, telomere maintenance, 
and cell immortalization (Bodnar et al., 1998) but does not by itself result in 
transformation (Jiang et al., 1999).  
In contrast to most somatic cells, stem, germ and tumor cells have high 
telomerase activity through TERT transcriptional up-regulation (Thomson et al., 
1998) and several telomeric proteins such as telomere-associated protein Rif 
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homologue (RIF) (Brandenberger et al., 2004; Miura et al., 2004). Furthermore, 
telomerase-deficient mouse ES cells cease to grow after 460–480 divisions, strongly 
suggesting that telomerase is essential for immortality of ES cells (Niida et al., 1998). 
Together these observations suggest that telomere maintenance is required for 
cellular immortality and is likely to play an important role in the immortality of hES 
cells.  
Induced pluripotent stem cells also have telomerase activity (Takahashi et al., 
2007; Takahashi and Yamanaka, 2006). Furthermore it has been shown that 
telomeres are elongated in mouse iPS cells when compared to the parental 
differentiated cells, and acquire the epigenetic marks of ES cells (such as low 
density of trimethylated histones H3K9 and H4K20) (Marion et al., 2009b).  
Human cells also display telomere elongation after reprogramming (Agarwal et 
al., 2010). Dyskeratosis congenita (DC), a disorder of telomere maintenance that 
results in tissue degeneration, is caused by mutations in the dyskerin gene (DKC1). 
This gene encodes an RNA binding protein whose inactivation destabilizes the levels 
of telomerase RNA component (TERC) (Mitchell et al., 1999). Surprisingly, 
fibroblasts from dyskeratosis congenita patients can be reprogrammed to iPS cells, 
but displayed poor reprogramming efficiency when compared to normal cells 
(Agarwal et al., 2010). These data show that reprogramming of somatic cells from 
patients with a genetic impairment in telomere elongation can overcome a critical 
limitation in telomerase RNA component (TERC) levels to restore telomere 
maintenance and self-renewal. 
 
1.3.1.2.  Cell cycle regulation in embryonic stem cells 
 
Although some differences exist in the regulation of the cell cycle between 
human and mouse ES cells both are characterized by a shortened early G1 phase 
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(Becker et al., 2006; Savatier et al., 1994). The molecular regulation of the transition 
through G1 is less well defined in hES and primate ES than it is in mouse ES cells. 
Mouse ES cells growth in culture is extraordinarily rapid due to a short cell cycle (11–
16 hours), owing to a reduction in the duration of G1 phase. While in somatic cells, 
including adult stem cells, CDK2 activity is periodic and peaks at the G1 to S 
transition, mouse ES cells have constitutive CDK2 activity independently of the cell 
cycle phase. Moreover, mouse ES cells express low levels of the D-type cyclins and 
have almost no detectable CDK4 activity (Savatier et al., 1994; White et al., 2005) 
This type of regulation may be linked to cell fate decisions. Mitogen activated 
protein kinase (MAPK) signalling is important for proliferation of somatic cells, but is 
also a potent inducer of differentiation. Consequently a short G1 in mouse ES cells 
allows them to avoid the differentiation-inducing signals mediated by certain 
mitogenic signalling pathways that are usually active during early G1 in somatic cells 
(Orford and Scadden, 2008). 
A different regulation of cell cycle checkpoints that normally operate in somatic 
cells allow for a shorter G1 phase in ES cells. Indeed, massive parallel signature 
sequencing (MPSS) analysis of hES cells showed that several cell cycle regulators 
such as p53, INK4a (encoding p16INK4a), ARF and CDKN1a (encoding p21Cip1), are 
not expressed or expressed at very low levels (Brandenberger et al., 2004; Miura et 
al., 2004). This is in contrast to what has been described in mES cells, which 
express high levels of p53. However, the p53-mediated response to cell cycle arrest 
in these cells seems to be inactive. One explanation for this observation is that 
translocation of p53 to the nucleus in mES cells is insufficient (Aladjem et al., 1998; 
Ginis et al., 2004; Prost et al., 1998). In addition, expression of MDM proteins, the 
negative regulators of p53, may also contribute to the inactivation of p53 in mES 
cells (Ginis et al., 2004). ES cells may have different mechanisms from those 
present in somatic cells to protect themselves from stress and to maintain a high 
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level of genetic stability. mES cells are highly resistant to oxidative stress, and are 
very efficient in repairing DNA damage induced by radiation (Saretzki et al., 2004). In 
addition, mES cells are much more proficient at p53-indepedent apoptosis than 
differentiated cells (Aladjem et al., 1998; Corbet et al., 1999). Overall, these 
observations indicate that the absence (hES cells) or the inactivation (mES cells) of 
the p53 pathway is required for the absence of senescence in ES cells. Further 
studies have uncovered additional roles for p53 in ES cell biology and new cell cycle 
regulators, specific of ES cells such as miRNAS, which will be discuss in the 
following sections. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.12. The cell cycle of embryonic stem cells. Mouse embryonic stem (ES) cells have a 
shorter cell cycle when compared to that of most somatic cells (11–16 hours as opposed to 24 hours). 
An abbreviated G1 phase is responsible for the difference in cell-cycle length. For differentiated cells, 
the transition through G1 phase requires the mitogen-induced accumulation of cyclin D, resulting in the 
hyperphosphorylation of the retinoblastoma tumour suppressor protein (RB) by cyclin dependent 
kinases (CDK4, CDK6 and CDK2). In ES cells CDK2-CyclinE (E/2) is constitutively active throughout 
the cell cycle, which allows the transition of ES cells from M phase directly to late G1, avoiding the 
cyclin D-dependent early G1 and shortening the G1 phase. Upon commitment of ES cells, the cell-cycle 
length is extended as CDK2-cyclinE activity comes under the control of CDK4,6-cyclinD (D/4,6) and 
phosphorylated RB. + refers to cyclin–CDK activity: +/-, negligible; +, low; ++, intermediate; +++, high. 
(Adapted from Orford and Scadden, 2008)  
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1.4 Aim of this study 
 
Upon expression of the Yamanaka factors, somatic cells undergo a number of 
changes that lead to acquisition of ES cell-like characteristics and regression to an 
undifferentiated state. The gain of embryonic stem cell properties during 
reprogramming to iPS cells involves acquisition of mechanisms to escape replicative 
senescence. Human embryonic stem cells express low levels of negative regulators 
of the cell cycle, and display telomerase activity. However, reprogramming efficiency 
is extremely low and the majority of the population does not acquire these ES cell-
like properties. The aim of this study is to characterise the response of human 
somatic cells to expression of reprogramming factors to understand why only a small 
subset of the entire population of somatic cells acquire the immortal nature, 
characteristic of ES cells. 
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Chapter 2 - Material and Methods 
 
2.1. Cell lines and tissue culture methods 
 IMR90 human foetal lung fibroblasts and BJ human foreskin fibroblasts were 
obtained from the American Type Culture Collection (ATCC). MEFs were prepared 
from 13.5-day-old embryos of CD1 mice. The head and viscera were removed and 
the remaining tissue was minced and a single cell suspension was obtained by 
trypsinization  (0.1% (v/v)) (Gibco, UK) at 37°C for 15 min.  Cells were then cultured 
until they became confluent and were then frozen in foetal bovine serum (FBS; 
Sigma) containing 10% dimethyl sulfoxide (DMSO; Sigma). MEFs knockout for p53 
and Cdkn1a were a gift from Scott Lowe (Cold Spring Harbor Laboratory - CSHL). 
MEFs Oct4-GFP were kindly provided by Jose Silva (Wellcome Centre for Stem Cell 
Research, Cambridge). HEK293T packaging cells were purchased from the 
American Type Culture Collection (ATCC) and Takara BIO INC. All tissue culture 
reagents used were purchased from Invitrogen (Invitrogen Ltd, Paisley, UK), unless 
otherwise stated. IMR90, BJ, MEFs and packaging cells were cultured in Dulbecco’s 
Modified Eagle Medium (DMEM, Gibco) supplemented with 10% (v/v) FBS and 1% 
(v/v) antibiotic-antimycotic (Gibco) and grown in humidity at 37ºC with 5% CO2. H7 
hES cell line and hiPS cells were maintained in an undifferentiated state in mitotically 
inactivated MEFs (γ-irradiated; 40Gy) and plated onto 0.1% (w/v) gelatine-coated 
surfaces (Sigma). hES and iPS cells were maintained in KRS media: KnockoutTM 
Dulbecco's Modified Eagle Medium (DMEM) medium supplemented with 20% (v/v) 
KnockoutTM Serum Replacement (KSR), 1 mM L-glutamine, non-essential amino 
acids (NEAA), 0.1 mM β-mercaptoethanol and antibiotics (50 U/ml 
Penicillin/Streptomycin) supplemented with 4 ng/ml basic fibroblast growth factor 
(FGF2, PeproTech EC Ltd.). 
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2.2. Retrovirus production and transduction of target cells 
Packaging cells were seeded the previous day to reach a confluence of 70-
80% the day of transfection. For each 10 cm plate, 1 ml of serum-free DMEM 
containing 20µg of expression plasmid and 10µg of helper plasmid was prepared. 
Ecotropic helper was used for infection of MEFs, amphotropic helper plasmid or a 
combination of gag-pol and VSV-g plasmids (8µg and 2µg respectively) was used for 
infection of human fibroblasts. As transfection reagent, 75 µL of linear 25kDa linear 
polyethylenimine (PEI 1mg/ml (w/v), Polysciences) was used. The mixture was 
incubated at room temperature for approximately 30 minutes and added drop-wise to 
each plate. Transfection efficiency was monitored the next day by the presence of 
GFP (GFP; green fluorescent protein) or Cherry fluorescent protein expressed from 
a reporter plasmid. The day after transfection, the media of the transduced 
packaging cells was replaced with fresh media (6ml/plate).  In parallel, the target 
cells, MEFs or IMR90, were plated at a density of 1x106 cells per 10cm plate.    
After 48hrs, the virus-containing supernatants were collected from packaging 
cells plates, filtered through 0.45µm pore-sized acetate filters (Anachem) and 
supplemented with 4µg/ml of polybrene (Sigma). The culture media of the target 
cells was then removed and replaced by the virus-containing supernatant. Infection 
took place in 1, 2 or 3 rounds to maximize the efficiency and a period of 2.5-3 hours 
was left between each round for virus production.  Following overnight incubation, 
the medium was replaced (10ml/plate). The percentage of GFP-positive or Cherry-
positive cells was determined by flow cytometry, using as a negative control 
uninfected cells. 
Approximately three days after infection, cells were split and grown for 5-7 
days in the presence of puromycin (0.5 µg/ml; Invitrogen) in order to select for 
transduced cells. 
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2. 3. Growth assays  
2.3.1. Growth curves and colony formation assays 
For growth curves 7 × 103 cells were seeded in triplicate in 24-well plates. 
Cells were fixed on day 0 (day after plating), and after that every two days during a 
time course of 12 days. For fixation, cells were washed with PBS and fixed with 0.5% 
glutaraldehyde (w/v) (Sigma-Aldrich), in PBS for 20-30 minutes. All plates were 
stained simultaneously with 0.2% crystal violet (w/v). Crystal violet was extracted 
with 10% acetic acid (v/v) and the absorbance at 595 nm (A595) was measured using 
the Bio-Rad 680XR microplate reader. To determine the growth curves absorbance 
values at different time points, relative to absorbance of Day 0 were plotted. For 
colony formation assays, cells were plated at a density of 1 x 105 and 5 x 104 per 10-
cm dish. After approximately 15 days, cells were fixed with glutaraldehyde and 
stained with crystal violet. 
2.3.2 BrdU (5-Bromo-2’-deoxyuridine) incorporation assay   
Cells (1-4 x103) were plated in 96-well plates in duplicate or triplicates and 
subsequently incubated with 5-Bromo-2′-deoxyuridine (BrdU, 50 μM, Sigma) for 16 
hr. After incubation, cells were washed with PBS and fixed for 20 min with 4% (w/v) 
paraformaldehyde (Sigma). For immunofluorescence staining, cells were first 
permeabilized for 10 minutes with 0.2% (v/v) Triton X-100 in PBS (Sigma) and 
incubated for 30 minutes with 1X blocking solution (0.5% (w/v) BSA, 0.2% (w/v) fish 
skin gelatin (Sigma)). Treatment with DNase I (0.5U/µL; Sigma) in presence of 1mM 
MgCl2 (Sigma) was performed simultaneously with Alexa Fluor® 488 mouse anti-
BrdU antibody (1:200, Invitrogen) incubation for 1h at room temperature. Cells were 
washed three times with PBS and incubated with DAPI (Invitrogen, 1.5 µM). Plates 
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were examined using In Cell Analyser and High Content Analysis was performed, to 
discriminate positive BrdU nuclei and total nuclei.   
 
2.3.3. Senescence-associated β-galactosidade (SA-β-gal) assay 
Cells were washed once with PBS, fixed with 0.5% glutaraldehyde (w/v), and 
washed in PBS (pH 6.0) supplemented with 1 mM MgCl2. Cells were stained in X-gal 
solution (1 mg/ml 5-bromo-4-chloro-3-indolyl-beta-D-galacto-pyranoside  
[Boehringer], 0.12 mM K3Fe[CN]6, 0.12 mM K4Fe[CN]6, 1 mM MgCl2 in PBS at pH 
6.0) overnight at 37°C. After staining, cells were washed with PBS and stored at 4 
°C, in the dark. The cell nuclei were stained with 3 µM 4',6-diamidino-2-phenylindole 
(DAPI) for 30 min at RT. Bright field (BF) and DAPI images were taken using the 
Olympus CKX41 inverted fluorescence microscope, supplied with a DP20 digital 
camera. The percentage of SA-β-Gal-positive cells was determined upon counting of 
at least 100 cells.  
 
2.3.4. DNA content analysis 
Cells were trypsinized and re-suspended in 200µl of cold PBS. Re-suspended 
cells were added drop wise to 4 ml of ice cold 70% Ethanol, under vortex for rapid 
dispersion. Fixation was performed overnight at -20°C. Cells were washed twice in 
PBS, re-suspended in PI solution (propidium iodide (PI) 40µg/ml, (Sigma); RNAse 
(100µg/ml (Invitrogen) in PBS) an incubated at 37°C for 30 min. PI stained cells were 
analysed using the Guava microcapillary flow cytometry system (Millipore), and the 
Guava Cell Cycle Software. 
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2.4. Plasmid amplification and cloning to generate retroviral vectors 
 
2.4.1. Plasmids 
OSKM polycistronic cassette was sub-cloned from FUW-TetO-OSKM (Carey 
et al., 2009) (Addgene) into the EcoRI site in pBABE puro. Full-length cDNAs 
encoding mouse transcription factors Oct4 and Sox2 and Nanog were PCR-amplified 
from PMXs plasmids (Takahashi and Yamanaka, 2006) (Addgene) with primers 
containing BamHI and SalI sites for cloning into pBABE-puro retroviral vector. 
Retroviral vectors expressing c-Myc and CBX7 (Gil et al., 2004), as well as E6, E7, 
E6/E7, plasmids; HRAS V12, and plasmid for expression of a shRNA targeting p53 
(pRS-shp53) have been described before (Acosta et al., 2008; Brummelkamp et al., 
2002). pBABE-KLF4 was kindly provided by Gordon Peters (Cancer Research, UK). 
The retroviral plasmids used for direct reprogramming of human somatic cells were 
kindly provided by Ludovic Vallier (MRC Centre for Stem Cell Biology and 
Regenerative Medicine). pRetroSuper (pRS) plasmids expressing shRNAs against 
human and mouse Cdkn1a were generated as described in 2.4.4. Plasmids for 
knockdown of mouse p53 and Ink4a/Arf have been described before (Dickins et al., 
2005). Retroviral plasmids for expression of shRNAs in pRetroSuper-Hygromycin 
(shRNAs) targeting Cdkn1a (p21Cip1), p53 and INK4a were subcloned from pRS-puro 
plasmids into EcoRI/XhoI restriction sites in pRS-Hygro. MSCV-blast hTR211 and 
MSCV-blast 302a-d were obtained from Geneservice. For a full list of retroviral 
vectors, see Table A1 and A2. 
 
2.4.2 Transformation of chemically competent E. coli. 
Chemically competent E. coli One Shot® TOP10 or DH5α™ cells (Invitrogen) 
were thawed on ice and gently mixed with 3 µL ligation product or 10–100 ng 
plasmid DNA. Following 30 min incubation on ice, cells were heat-shocked for 45 
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sec at 42 °C and returned to ice for 5 min. After adding 200 µL pre-warmed S.O.C. 
medium, cells were incubated at 37°C for one hour. The total volume or a dilution of 
each transformation was spread on a Lysogeny broth (LB) agar plate supplemented 
with the appropriate antibiotics. The plates were incubated overnight at 37 °C. Single 
colonies were picked, grown in LB medium containing the appropriate selective 
antibiotic and analysed by plasmid DNA isolation, polymerase chain reaction (PCR) 
or sequencing. 
 
2.4.3 Plasmid DNA purification 
Recombinant E. coli cultures were grown for 12–16 h at 37 °C, shaking at 150 
rpm, in 250 mL LB medium containing the appropriate selective antibiotic. The cells 
were then pelleted by centrifugation at 6000 × g for 10 min at 4 °C. Large-scale 
plasmid DNA preparation was carried out using the HiSpeed® Plasmid Purification kit 
(QIAGEN), based on a modified alkaline lysis procedure. Briefly, bacterial pellet was 
resuspended in P1 buffer (50 mM Tris-HCl, pH 8.0; 10 mM EDTA; 100 µg mL-1 
RNase A). Alkaline lysis buffer P2 (200 mM NaOH, 1% SDS (w/v)) was added to the 
cells and gently mixed. Buffer P3 (3.0 M KAc, pH 5.5) was added for neutralization. 
Upon gently mixing, a precipitate formed by proteins, genomic DNA, and detergent is 
generated. The soluble fraction, containing the plasmid DNA, was applied to an 
anion-exchange resin under appropriate low-salt and pH conditions. Buffer QC (1.0 
M NaCl; 50 mM MOPS, pH 7.0; 15% isopropanol (v/v)) was added to the resin to   
remove RNA, proteins, and impurities. Plasmid DNA was eluted from the column in a 
high-salt buffer QF (1.25 M NaCl; 50 mM Tris-HCl, pH 8.5; 15% isopropanol (v/v)) 
and then desalted by isopropanol precipitation. Plasmid DNA was concentrated and 
eluted with 500 µL of buffer TE (10 mM Tris-HCl, pH 8.0; 1 mM EDTA). The 
concentration was determined by measuring the absorbance at 260 nm (A260) in a 
NanoDrop® ND-1000 UV-Vis spectrophotometer.  
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2.4.4. Generation of shRNA expressing plasmids 
Retroviral plasmids for knockdown of human and mouse Cdkn1a were 
constructed by subcloning oligonucleotides in pRetroSuper (pRS), as previously 
described (Brummelkamp et al., 2002). Briefly, the BIOPREDsi (www.biopredsi.org/) 
algorithm was used to computationally predict shRNA target sequences with an 
optimal knockdown effect for human or mouse Cdkn1a. Three target sequences 
were used to design and test independent shRNA constructs. For cloning into pRS 
vectors, the forward and reverse strands of the oligonucleotides were annealed in 
100 mM NaCl and 50 mM HEPES, pH 7.4. To achieve proper annealing, the mixture 
was sequentially incubated in decreasing temperatures (4 min at 90 °C, then for 10 
min at 70 °C and slowly cooled to 10 °C or room temperature). The annealed oligos 
were cloned into BglII and HindIII sites in the pRS vector using T4 DNA ligase 
(NEB). One Shot® TOP10 competent cells were transformed and plated on LB Amp 
agar plates. Positive clones were identified by colony PCR, using primers pRS-F (5'–
ACCTCCTCGTTCGACCC) and pRS-R (5'–TGTGAGGGACAGGGGAG). The PCR 
products were resolved on a 2.5% (w/v) agarose gel (see Agarose gel 
electrophoresis) and compared with a negative (empty pRS vector) and positive 
(previously cloned shRNA) controls. A list of the sense shRNA target sequences is 
shown in Table A3. 
 
2.4.5. Agarose gel electrophoresis. 
For sub-cloning cDNAs, restriction enzyme-digested DNA and PCR products  
(for cloning primers see Table A4) were analysed by their electrophoretic mobility on 
an agarose gel. DNA loading buffer Orange G (0.2% (w/v) in 3% glycerol (v/v)) was 
added to the samples, which were then resolved on a 1–2.5% agarose (w/v) gel with 
0.5 µg mL-1 ethidium bromide. Samples were separated at 100 V in TAE buffer (40 
mM Tris and 1 mM EDTA (pH 8.0) in 0.1% HAc (v/v)). For DNA visualization, the gel 
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was exposed to ultraviolet light using the Bio-Rad Gel Doc™ 2000 system. Image 
analysis was carried out using the Quantity One® (v4.4.1) software (Bio-Rad). The 
size of the DNA fragments was estimated by using a DNA ladder as a reference. 
For extraction of digested DNA or PCR products from agarose gels, the 
QIAquick Gel Extraction kit (QIAGEN) was used. The DNA fragment was excised 
from the agarose gel and 3 volumes of buffer QG were added. The gel was 
dissolved for 10 min at 50 °C and 1 volume of isopropanol added to it next. The 
sample was then applied to a QIAquick spin column where DNA bound to the silica 
membrane and contaminants were washed away using buffer PE. DNA was eluted 
in 30–50 µL buffer EB (10 mM Tris-HCl, pH 8.5). All steps were performed by 
centrifugation of columns at 8000 × g in a microcentrifuge. 
 
2.4.6. TA cloning 
PCR products amplifed by Taq polymerase have a single deoxyadenosine (A) 
at 3’ ends due to Taq’s non-template-dependent terminal transferase activity. This 
can be used to clone the product into a plasmid vector that has a single overhanging 
3’ deoxythymidine (T). For cloning into the pCR 2.1-TOPO® vector (Invitrogen), 2µl 
of PCR product was mixed with 1µl of Salt Solution, 1µl of pCR 2.1-TOPO® vector 
and 2µl of water in a final volume of 6µl. The mixture was incubated at room 
temperature for 10-30 min. Then 2µl of this ligation mixture was transformed into 
chemically competent E. coli cells as described in 2.4.2. 
 
2.4.7. DNA sequencing. 
DNA sequencing was carried out by the MRC Clinical Sciences Centre 
Genomics Core Laboratory using an automated ABI3730xl DNA analyser (Applied 
Biosystems). Sequences were viewed using the DNA Strider (v1.4f2) application. A 
list of sequencing primers is shown in Table A5. 
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2.5. RNA expression analysis 
 
2.5.1. Total RNA purification 
Total RNA was extracted using the RNeasy minikit (QIAGEN) or Trizol reagent 
if analysis of microRNAs was required. For extraction of RNA using the RNeasy Mini 
kit (QIAGEN), up to 5 × 106 cells were harvested and pelleted by centrifugation at 
300 × g for 5 min. The supernatant was aspirated and the cells lysed with guanidine 
thiocyanate-containing buffer RLT. The lysate was homogenised by centrifuging 
through a QIAshredder spin column and then 70% ethanol (v/v) was added and 
mixed well by pipetting. The sample was then applied to an RNeasy Mini spin 
column where total RNA bound to the silica membrane and contaminants were 
washed away using buffers RW1 and RPE. In order to remove residual DNA, an on-
column DNase I digestion was carried out using the RNAse-free DNase set 
(Qiagen). RNA was eluted in 30–50 µL RNase-free water. Wash and elution steps 
were performed by centrifugation at 8000 × g in a microcentrifuge. The concentration 
was determined by measuring the absorbance at 260 nm (A260) in a NanoDrop® ND-
1000 UV-Vis spectrophotometer. The RNA was stored at –80 °C for future 
applications. 
 
2.5.2. Quantitative RT-PCR (RT-qPCR) analysis. 
Reverse transcription (RT) and PCR were carried out separately (two-step RT-
PCR). In the RT step, 1 µg RNA was reverse transcribed into cDNA. RNA, diluted in 
water up to 11 µL, and oligo (dT)18 primer (5 µM final concentration) were mixed, 
incubated at 100 °C for 3 min and then chilled on ice for 10 min. First Strand Buffer 
(FSB), deoxyribonucleotide mix (dNTP; 500 µM final concentration each), 
dithiothreitol (DTT; 10 mM final concentration) and 200 U SuperScript™ II reverse 
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transcriptase (Invitrogen) were added to each reaction. The RT was carried out at 42 
°C for 50 min, after which the enzyme was inactivated at 70 °C for 15 min.  
RT-qPCR reactions were performed using Opticon 2 (Bio-Rad) using SYBR 
Green PCR Master Mix (Applied Biosystems) (40 cycles; 95 °C for 30 s, 58 °C for 30 
s, 72 °C for 30 s). Primers for RT-qPCR were described before (Barradas et al., 
2009; Pereira et al., 2008) or were designed using Primer3 (v0.4.0) software 
(http://frodo.wi.mit.edu/primer3/) and used at 250 nM final concentration each. To 
avoid amplification of genomic DNA, the RT-qPCR primers were designed to span 
an exon-exon junction and controls without reverse transcriptase were included. The 
TaqMan® Gene Expression Assays (Applied Biosystems) consisted of two unlabelled 
primers for amplifying the sequence of interest (900 nM final concentration) and a 
TaqMan® probe, labelled with 6-carboxyfluorescein (6-FAM™), for detecting the 
sequence of interest (250 nM final concentration). TaqMan PCR was carried out in 
Opticon 2 (Bio-Rad) using TaqMan® Universal PCR Master Mix (Applied Biosystems, 
40 cycles; 95 °C for 15 s, 60 °C for 60 s). Gene expression data was normalised to 
the ribosomal protein S14 (RPS14) for RT-qPCR and glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) for TaqMan PCR. The comparative CT method (ΔΔCT) was 
used to quantify differences in the expression level of target genes between different 
samples. The messenger RNA (mRNA) level of the target gene, normalised to an 
endogenous reference (housekeeping gene) and relative to a calibrator (empty 
vector control), was calculated using the following formula: 2–ΔΔCT, where ΔCT = CT, 
target – CT, reference and ΔΔCT = ΔCT, test sample – ΔCT, calibrator sample. For a list of RT-qPCR 
primers and TaqMan® see Tables A6 and A7, respectively. 
 
2.5.3. Purification and analysis of microRNAs expression   
For extraction of microRNAs cells were lysed and total RNA was extracted 
using Trizol reagent (Invitrogen) to avoid the loss of small RNAs.  Cell pellets were 
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first homogenised in 1ml of Trizol, followed by addition of chloroform (200µl). The 
Phenol-chloroform phase and the aqueous phases were separated by centrifugation 
(12 000 × g, 4°C, 20 min). Total RNA was precipitated from the aqueous phase 
using isopropyl alcohol (0.5ml, Sigma) and washed with 75% ethanol (v/v; 1ml). After 
air-drying, the pellet was dissolved in RNase free water (Sigma). The concentration 
was determined by measuring the absorbance at 260 nm (A260) in a NanoDrop® ND-
1000 UV-Vis spectrophotometer. All RNA samples were stored at – 80C. 
For microRNAs expression analysis, qRT-PCR was performed using individual 
TaqMan MicroRNA Assays (Applied Biosystems; Table 8). In the reverse 
transcription (RT) step, cDNA is reverse transcribed from total RNA samples using 
specific miRNA stem-loop primers from the TaqMan MicroRNA Assays and reagents 
from the TaqMan® MicroRNA Reverse Transcription Kit. 10µg of total RNA in 5µL, 
was added to a master mix containing 0.15 µL dNTPs (100 mM), 1µl of reverse 
transcriptase (50U/µL), 0.19 µL RNase inhibitor (20U/µL), and 1.5 µL 10x reverse 
transcription buffer in a total of 7µL in RNase free water. Finally, 3µL of microRNAs-
specific RT primer was added per reaction. Reverse transcription was performed in a 
thermal cycler (16 °C for 30min.; 42 °C for 30 min. and 85°C for 5min). PCR 
products are amplified from cDNA samples using the TaqMan miRNA-specific 
forward and reverse PCR primers and TaqMan probe together with the TaqMan® 
Universal PCR Master Mix. (Applied Biosystems: 40 cycles; 95 °C for 15 s, 60 °C for 
60 s). MicroRNAs levels were normalised to the expression of RNU48 and were 
calculated as described in 2.5.2.  
 
2.6. Immunofluorescence and high content analysis (HCA) 
For immunofluorescence, cells were fixed with 4% PFA (w/v) for 30 min, 
washed with PBS and permeabilised with 0.2% Triton X-100 (v/v) for 10 min. To 
block unspecific binding of primary antibody, cells were incubated for 30min in 
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blocking solution (0.5% BSA (w/v) and 0.2% fish skin gelatin (v/v) in PBS). The cells 
were then incubated with the primary antibody, diluted in blocking buffer, for 1 h at 
room temperature. Three washes with blocking buffer for removing unbound primary 
antibody were performed. The cells were subsequently incubated with the secondary 
antibody, diluted in blocking buffer, for 1 h at room temperature. Cells were washed 
with PBS three times (5 min each wash with agitation) before adding 3µM DAPI for 
20 min for nuclear staining. Acquisition of Immunofluorescence images was 
performed using the IN Cell Analyzer 1000 automated high-throughput microscope 
(GE Healthcare) with 10x or 20x objectives. Image processing was performed using 
the IN Cell Investigator (v1.7) software (GE Healthcare). 
High Content Analysis (HCA) was used for quantification of 
immunofluorescence images. Two or three (in the case of double staining) 
fluorescence images corresponding to DAPI and primary antibody/Alexa Fluor® 488-
secondary or Alexa Fluor® 594 antibody were acquired for each condition. HCA was 
performed using the IN Cell Investigator (v1.7) software (GE Healthcare). For the 
analysis, DAPI staining of the nuclei was used to identify nuclear area and number of 
cells. The nuclei were defined by using top-hat segmentation, specifying a minimum 
nucleus area of 100 µm2. To define the cell segmentation, a collar segmentation 
routine was used with a ratio of 1 µm. To determine the cellular expression of the 
analysed protein, the average intensity of pixels in the reference channel (Alexa 
Fluor® 488 or 594) within the specified nuclear region (Object Nuclear Intensity) was 
measured. Each cell was assigned a nuclear intensity value for the specific protein 
expression and that value was used to set up a threshold filter, which determined 
high levels (positive) and low levels (negative) expressing cells. The threshold filter 
used a histogram for data visualisation (Figure 2.1A-B). In order to set the filter cut-
off, expression in the control was measured (i.e. p16INK4a expression in wells with 
empty vector-transduced cells, Figure 2.1A, left panel) to define the negative 
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population (red population on the histogram). Next, the analysis of the positive 
control (i.e. p16INK4a expression in wells with H-RASV12-transduced cells, Figure 2.1B) 
was performed to determine the high-expressing population (green population on the 
histogram). Once the cut-off was set up, the analysis of the whole experiment was 
carried out. As a result, the software classified each cell as either positive or 
negative for the expression of the analysed protein (i.e. p16INK4a positive (p16) and 
negative (neg) cells in empty vector vs. H-RASV12 infected cells, Figure 2.1C) and 
generated a percentage of both cell populations (positive and negative) per well. The 
mean of the nuclear intensity was also routinely analysed and equivalent results 
were obtained. The antibodies used for the analysis were tested with robust controls 
(shRNAs) to assess their specificity. Where possible, alternative antibodies were 
used in control experiments to confirm the results obtained. For a list of primary and 
secondary antibodies used in this study se tables A9 and A10. 
 
 
2.7. Chromatin immunoprecipitation (ChIP) 
ChIP was performed as previously described (Ananthanarayanan et al., 
2004). Briefly, proteins and DNA were cross-linked by adding 37% formaldehyde 
(v/v) drop-wise directly to the cell culture medium, to a final concentration of 1.1%, 
and incubating for 10 min at RT. The reaction was then terminated by addition of 
glycine (125 mM final concentration) to the media and incubation for 5 min at RT. 
Next, the cells were washed twice with 10 mL ice-cold PBS, scraped into 5 mL cold 
PBS and transferred to a 50 mL Falcon tube. Up to 4 × 106 cells were harvested and 
pelleted by centrifugation at 400 × g for 5 min at 4 °C. The pellet was carefully 
resuspended in 1 mL cold PBS and transferred to a 1.5 mL microcentrifuge tube. A 
centrifugation at 2000 × g for 5 min at 4 °C followed, after which the supernatant was 
aspirated and the cell pellet stored at –80 °C. 
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Figure 2.1. High Content Analysis. IMR90 cells infected with empty vector and RasV12 were 
seeded in 96-well plates at a density of 4,000 cells per well. The following day, cells were stained 
by immunofluorescence for p16INK4a and DAPI (nucleus) and subjected to High Content Analysis 
(HCA). To create a Threshold Filter to distinguish cells expressing high or low levels of p16INK4a we 
generated a cut-off based on the histograms of p16INK4a nuclear intensity (Nuc Intensity Reference 
2) for cells infected with empty vector (A), RasV12 (B). In this example the cut-off was set above a 
value of nuclear intensity of 235. (C) Representative images showing classification of positive and 
negative cells in IMR90 transduced with empty vector or RasV12 expressing plasmid. 
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Chromatin preparation and immunoprecipitation were performed using the EZ-
Magna ChIP™ G kit (Millipore), according to manufacturer’s recommendations. 
These procedures were carried out in the lab of Martin Walsh, Mount Sinai School of 
Medicine, New York, USA. Succinctly, immunoprecipitation of cross-linked chromatin 
was conducted with antibodies described in Table 11. After immunoprecipitation, 
DNA was extracted using the QIAquick PCR purification kit (QIAGEN) and an aliquot 
was amplified by RT-qPCR using oligonucleotide primers described in Table A12. To 
confirm target enrichment, each PCR product was evaluated by end-point PCR. The 
input levels of immunoprecipitated histone H3 were used for normalisation. 
 
2.8. Reprogramming to induced pluripotent stem cells 
 
The reprogramming experiments to compare efficiency of reprogramming in 
cells with INK4a, Cdkn1a and p53 knockdown and empty vectors was carried out in 
collaboration with Ludovic Vallier, MRC Centre for Stem cell Biology and 
Regenerative Medicine, Cambridge. The protocol used for direct reprogramming in 
Ludovic Vallier’s laboratory is similar to the one described before (Park et al., 2008a) 
which was adapted in our laboratory to compare reprogramming efficiencies. 
 
2.8.1 Transduction of human somatic cells 
 The plasmids encoding the human reprogramming factors, empty vector 
control, MSCV-Cbx7 and pRS-shp53 were each transfected together with VSVg 
helper plasmid into HEK 293T packaging cells expressing gag-pol viral elements 
(293T GP, Takara Bio Inc). The following day, 1.105 early passage IMR90 cells (p11-
p14) were plated per 6-well. Infection was performed as described in 2.2. Two 
rounds of infection were performed to increase transduction efficiency but avoiding 
over-stressing the cells. After transduction the media was replaced with fresh media. 
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2.8.2. Generation and identification of ES-like colonies.  
Four days after transduction with reprogramming factors and controls, 1.106 γ-
irradiated MEFs were plated on 0.1% gelatin (Millipore) coated 10cm dishes. The 
following day transduced IMR90 were detached using trypsin-EDTA (Invitrogen) and 
counted. 2.105 cells were plated on feeders in DMEM 10% FBS. At day 7 after 
transduction cells were washed and the media replaced with hES cell media (KSR 
hESCs medium: Knock out DMEM + 20% Serum Replacer + FGF2 4ng/ml). Media 
was changed every day from this point (Timeline, Figure 2.2A). The first hIPSC 
colonies appeared around day 13 after transduction (Figure 2.2B). Cells were fixed 
using 4% PFA for 2 min, to avoid inactivation of alkaline phosphatase activity at day 
20-24 after transduction and stained with alkaline phosphatase detection kit 
(Millipore). Briefly, Fast Red Violet solution (0.8g/L), Napthol AS-BI phosphate 
solution (4mg/mL), and water were mixed in a 2:1:1 proportion and added to each 
plate. Cells were incubated with staining solution in the dark, for 15min, at room 
temperature. Plates were scanned and colony quantification was performed using 
ImageJ software tool to analyse particles. 
 
2.8.3. Colony picking and expansion 
 hiPS colonies were large enough to be picked around day 18-20 (Figure 
2.2B). Colonies were picked under an inverted microscope in sterile conditions using 
a p10 micropipete. The colony was transferred into a 96-well plate with round bottom 
with 100uL of hES media (KSR media previously described), and disaggregated into 
clumps by gently pipeting. The cells were then plated in 24-well 0.1% gelatin coated 
plates containing feeders. Avoiding breaking the colony into very small pieces is 
essential, since hiPS and hES cells have very poor survival when plated as single 
cells. The colonies that survived and grew without undergoing differentiation were 
mechanically passaged to 12 well plates containing MEFs feeders. Colonies were 
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repicked if necessary to isolate hiPS cells from differentiated cells or partially 
reprogrammed cells contaminating the culture.  Successfully expanded hiPS cell 
lines were characterised for the expression of pluripotency markers by 
immunofluorescence and quantitative q-RT-PCR.  
 
2.8.4. Reprogramming of mouse embryonic fibroblasts 
Reprogramming of mouse fibroblasts was performed as described in 2.8.1. 
and 2.8.2  with some modifications. Three days following transduction with the 
mouse reprogramming factors (pMXs vectors; (Takahashi and Yamanaka, 2006)) 
3.104 MEFs Oct4-GFP were plated on feeders in 6-well plates. Next day fibroblast 
media was replaced by KSR media supplemented with LIF (1000U/ml, ESGRO, 
Millipore). GFP-positive colonies were picked and expanded as described in 2.8.3., 
however instead of mechanical disaggregation, trypsin was used. miPS cells were 
keep on feeders in KSR media +LIF.   
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Figure 2.2. Reprogramming to induced pluripotent stem cells. (A) Timeline for generation of 
induced pluripotent stem cells from human fibroblasts. (B) Bright-field microphotographs acquired with 
4x magnification showing morphology of IMR90 cells and hiPS cell colonies. 
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Chapter 3 – A senescence response is induced by 
expression of the four reprogramming factors 
 
 
3.1. Early response to reprogramming factors expression in human fibroblasts  
 
During direct reprogramming to induced pluripotent stem (iPS) cells, 
expression of a group of transcription factors initiates a sequence of events that 
ultimately result in gaining of pluripotency and immortality. The study of this 
sequence of events is not simple. This because the process is very inefficient, 
resulting in only a small portion of the whole population undergoing reprogramming, 
but also because it relies on the transduction of four different transcription factors 
that can give rise to a heterogeneous population, expressing various combinations 
and levels of each factor. 
To study the effect of simultaneous expression of the four reprogramming 
factors a polycistronic system was used (Carey et al., 2009) coupled with puromycin 
selection. Carey et al. generated polycistronic viral vectors containing the mouse 
cDNAs for Oct4, Sox2, Klf4, and c-Myc (OSKM) separated by three different 2A 
peptides to reprogram human and mouse cells (Carey et al., 2009). These peptides, 
which are 18 to 22 amino acids long have been used to express multiple proteins 
from a single transcript, by mediating “ribosomal skipping” (Doronina et al., 2008; 
Ryan and Drew, 1994; Szymczak et al., 2004). To express the four reprogramming 
factors in IMR90 fibroblasts, the OSKM reprogramming cassette was transferred to 
the retroviral vector pBABE, which allows selection of transduced cells based on 
puromycin resistance (Figure 3.1A). Expression of the four reprogramming factors in 
IMR90 cells was confirmed by immunofluorescence (Figure 3.1 B). 
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3.1.1. OSKM-transduced cells show features of cellular senescence  
IMR90 human fibroblasts were transduced with an empty vector or with the 
OSKM polycistronic vector. As a control for senescence induction a vector 
expressing oncogenic RAS (H-RASG12V), which is known to induce senescence in 
human and mouse cells (Serrano et al., 1997), was used. A short-hairpin against p53 
(shp53) was included as a control for bypass of senescence. Three days after 
transduction, cells were selected by adding puromycin for approximately 7 days 
(Figure 3.2 A). The early events after the infection of IMR90 human fibroblasts with 
the OSKM vector were monitored.  
Surprisingly, expression of the reprogramming factors caused a decrease in 
the number and growth of IMR90 cells, as evaluated by colony formation assays, 
growth curves and a decrease in the percentage of cells incorporating BrdU, at 
independent time points over the course of 12 days (Figure 3.2 B-D). Growth curves 
showed that upon expression of the reprogramming factors the observed growth 
arrest was similar to the strong effect caused by expression of oncogenic RAS 
(Figure 3.2C). The BrdU incorporation assays revealed that the percentage of cells 
entering S-phase was lower in OSKM cells when compared with empty vector cells 
(≈15% compared to ≈50%; Figure 3.2 D). To confirm that the decrease in cell 
number upon OSKM expression was due to growth arrest rather than apoptosis, 
immunofluorescence for cleaved caspase 3, an apoptosis marker was performed. 
The percentage of cells that scored positive was not significantly different between 
OSKM and control cells (Figure 3.2 E). To further characterise the growth arrest 
observed in OSKM-transduced fibroblasts, DNA content analysis was performed. 
OSKM cells presented a higher percentage of cells arrested in G1 phase and a 
reduction of S-phase cells (Figure 3.2 F). This is in agreement with the fact that in 
the experimental conditions used, expression of the four factors induces cells to 
undergo growth arrest rather than apoptosis.  
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Figure 3.1. pBABE OSKM vector for expression of the 4 factors in IMR90. (A) The polycistronic 
cassette encoding the 4 mouse cDNAs was cloned into the retroviral vector pBABE, which contains the 
gene for puromycin resistance (pBABE-puro OSKM). The four cDNAs are separated by 2A peptides 
derived from foot-and-mouth disease virus FMDV (“F2A”), insect Thosea asigna virus (TaV, “T2A”) and 
equine rhinitis A virus (ERAV, “E2A”). (B). Expression of the 4 reprogramming factors (Sox2, Oct4, Klf4 
and c-Myc) in IMR90 was confirmed by immunofluorescence staining against the four proteins after 
selection of transduced cells. Cells transduced with empty vector were used as control. Dapi staining 
(blue) and Alexa-488 (green) is shown for each sample. Wheras Oct4 and Sox2 are not expressed in 
these cells; human endogenous c-MYC and KLF4 are detected. (bp) base pairs. 
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Figure 3.2. Expression of the 4 reprogramming factors induces growth arrest. (A) Timeline of the 
experiments presented in Fig. 3.2 and 3.3 and 3.4. IMR90 human fibroblasts were infected with a 
polycistronic vector expressing the 4 factors (OSKM) and selected for 7 days. (B). Crystal violet stained 
plates of IMR90 cells infected with the indicated vectors. (105 cells were seeded per 10cm-dish after 
selection and fixed 14 days later) (C) Growth curve of IMR90 transduced cells with the indicated 
vectors. Cells were seeded in triplicate in 24-well plates; one plate was fixed every two days and 
stained with crystal violet at the end of the time course. The relative cell number corresponds to the 
absorbance at each time point relative to absorbance at day 0 (day after seeding). (D) Quantification of 
BrdU incorporation in IMR90 cells transduced with the reprogramming factors and controls (Day 0 is 
day after seeding). (E) Expression of the 4 reprogramming factors in IMR90 cells do not induce a 
significant amount of apoptosis as estimated by IF using an antibody recognizing cleaved caspase 3. 
As a positive control, IMR90 cells were treated with cyclohexamide (100 µg/ml) for 1h, followed by 
treatment with TNF α (50 ng/ml) for 18 hours. (F) Percentage of cells in different stages of the cell cycle 
as analyzed by PI staining followed by flow cytometry. Cell cycle profiles for empty vector control and 
OSKM are shown in Figure A1. Results presented in A-D correspond to one representative experiment 
(n=3). 
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OSKM transduced cells displayed a distinct morphology that resembled that of 
senescent cells, with a large cytoplasm (Figure 3.3A) and a subset of cells were 
polynucleated. To further prove that the growth arrest had characteristics of 
senescence, cells were stained for senescence-associated β-galactosidase activity 
(SA-β-Gal), a widely used marker for identification of senescent cells (Dimri et al., 
1995). A higher percentage of cells displayed SA-β-Gal activity when the four 
reprogramming factors were expressed (around 50% compared with 10% of the cells 
transduced with empty vector control; Figure 3.3 B). Additionally, the expression of 
the four factors led to an increase in the percentage of cells showing senescence-
associated heterochromatic foci (SAHF; Figure 3.3 C).  
Together these results suggest that simultaneous expression of the four 
reprogramming factors induces senescence in human diploid fibroblasts.  
 
3.1.2. Levels of senescence mediators during OSKM-induced senescence 
 
To identify the pathways responsible for senescence induced by expression of 
the OSKM cassette, the expression of different senescence effectors was analyzed 
by immunofluorescence. Expression of reprogramming factors activated a DNA 
damage response as observed by elevated levels of proteins phosphorylated by 
ATM or ATR (p(S/T)Q) (Figure 3.4A). Interestingly, OSKM expression also caused 
oxidative stress, as reflected by elevated levels of the oxidized base 8oxoG, a 
common DNA lesion that results from oxidative stress (Figure 3.4B). Consistently 
with an activation of a DNA damage response (DDR) in OSKM-transduced cells, an 
up-regulation of the tumour suppressors p53 and p21Cip1 was observed in these cells 
(Figure 3.5A-B). 
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Figure 3.3 OSKM transduced cells present characteristics of senescence. (A) Bright-field pictures 
acquired with a 10x objective, showing morphology of IMR90 transduced with empty vector control, 
OSKM, RAS V12 and shp53. Amplification of an area of the picture is shown. (B) Staining for SAβ-Gal 
activity, showing higher percentage of positive cells in OSKM-transduced cells and in the RASV 12 
control. More then 100 cells were counted; error bars correspond to two independent experiments. 
Pictures were acquired with 20x objective with and without phase contrast, to better identify blue 
perinuclear staining. (C) Senescence-associated heterochromatic foci (SAHF) are present in cells 
expressing the OSKM polycistronic vector. Cells were stained with DAPI, and quantification of SAHF 
was performed using InCell Analyser and the InCell Investigator software. Areas of Dapi stained nuclei 
with high intensity were identified using a min area of 0.5µm. Nuclei containing more than 5 high 
intensity areas were scored as positive. Error bars in B and C correspond to two independent 
experiments. 
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Figure 3.4 OSKM expression induces a DNA damage response. (A) Expression of the 4 
reprogramming factors results in an increase in the cells positive for DNA damage as measured by the 
presence of proteins containing the phosphorylated residues that are ATM/ATR substrates (p(S/T)Q). 
Representative images are shown on the right hand side. (B) 8-oxo-Guanine (a common DNA lesion 
resulting from oxidative stress) levels increase in response to expression of the 4 reprogramming 
factors. Error bars correspond to duplicates in one representative experiment (n=3).  
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Additionally up-regulation of p16INK4a, a feature that is characteristic of 
senescent cells, was observed (Figure 3.5C). To analyze the contribution of the 
senescence effectors up-regulated upon OSKM expression, the four reprogramming 
factors were expressed together with the E6 and/or E7 proteins of HPV16, which 
inactivate the p53 and the Rb networks, respectively. As shown in Figure 3.5D, 
expression of either protein partially alleviates the growth arrest induced by the 
reprogramming factors, while joint expression of E6 and E7 has additive effects. To 
test specifically for the contribution of p16INK4a, p21Cip1, and p53 to the arrest, 
shRNAs targeting these factors were used. Analysis of the BrdU incorporation of 
cells infected with the OSKM vector showed that there is a partial rescue when 
shRNAs against p53, p21Cip1, and p16INK4a are co-transduced, suggesting that they 
are relevant for the arrest (Figure 3.5E). 
To understand the mechanisms underlying reprogramming to pluripotency, 
Meissner’s group have carried out a comprehensive genomic characterization of 
cells at various stages of the reprogramming process (Mikkelsen et al., 2008). To do 
so, they used mouse embryonic fibroblasts (MEFs) isolated from chimeric mice that 
had been generated from an iPS cell line carrying integrated doxycycline (Dox)-
inducible lentiviral vectors with the four reprogramming factors. Treatment of these 
MEFs with Dox allows expression of the reprogramming factors without the 
heterogeneity that usually results from multiple transduction with of the 4 factors. To 
follow the events that occur in the following days they obtained gene expression 
profiles at days 4, 8, 12 and 16, after Dox administration. On one hand they 
observed an increase in the proliferative response as noted by the upregulation of 
genes with functions such as DNA replication (Poli, Rfc4 and Mcm5) and cell cycle 
progression (Ccnd1 and Ccnd2). However, a strong increase in the expression levels 
of the anti-proliferative genes Cdkn1a (which encodes p21Cip1) and Ink4a (which  
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Figure 3.5. Molecular analysis of senescence induced by expression of reprogramming factors. 
(A-C) Expression of the 4 reprogramming factors results in an increase in the percentage of cells 
positive for p53, p21Cip1 and p16INK4a. Percentage of positive cells was determined by high content 
analysis as described in the methods. Error bars correspond to duplicates of one representative 
experiment (=3). (E, F) The ability of the 4 reprogramming factors to block proliferation of IMR90 
fibroblasts was alleviated by co-expression of Human papillomavirus (HPV) E6 and/or E7 or knockdown 
of p53, p16INK4a or p21Cip1 using shRNAs as measured by crystal violet staining (D) or BrdU 
incorporation (E). For crystal violet staining, cells co-infected with empty vector or OSKM polycistronic 
vector and vectors containing E6, E7 or both, were selected with puromycin. After selection 105 cells 
were plated per 10-cm dish and fixed 12 days later. For BrdU analysis, 4.103 cells were plated in 
duplicate per well of a 96-well plate. Next day BrdU was added and incubated for approximately 14 
hours before fixing the cells for immunofluorescence analysis. Error bars correspond to duplicates in 
one representative experiment (n=2). 
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encodes p16INK4a) was also observed (Figure 3.6A). The levels of these negative 
regulators of the cell cycle remained high during the time course and decline slightly 
at later times during the 16 days that were necessary to reprogram a small 
percentage of the population (Mikkelsen et al., 2008)(Figure 3.6A). If an early 
response to expression of reprogramming factors is up-regulation of senescence 
effectors, it is likely that intermediate stages during reprogramming still show 
elevated levels of these regulators. Partially reprogrammed cells are cells that show 
some of the stem cells features such as alkaline phosphatase activity and 
expression of some pluripotency markers; but fail to express late pluripotency 
markers, such as Nanog and endogenous Oct4 (Mikkelsen et al., 2008). Indeed, by 
re-examination of published data from two studies that characterize the expression 
of partially reprogrammed cells (Mikkelsen et al., 2008), the expression of p16INK4a 
and p21Cip1 was up-regulated in partially reprogrammed cells derived from MEFs 
when compared with iPS cells and ES cells (Figure 3.6B and C). 
To understand how the levels of these cell cycle regulators change over time 
following OSKM expression, the protein levels of p53, p21Cip1 and p16INK4a were 
measured over a course of 10 days. The percentage of cells exhibiting high levels of 
p53 or p21Cip1 decreases at later time points in IMR90 cells expressing the 
reprogramming factors (Figure 3.6A and B), while the percentage of cells with high 
p16INK4a levels remains higher throughout the time-course (Figure 3.6 C). Whether 
there is a selection for cells that express lower levels of senescence regulators or the 
levels tend to decrease with time is still not clear.  
Together, these results suggest that there is induction of senescence during 
the early stages of reprogramming, which will be referred in the following sections as 
reprogramming-induced senescence (RIS).  
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Figure 3.6 Ink4a and Cdkn1a levels during reprogramming of mouse fibroblasts and in partially 
reprogrammed cells. (A) The graphs presented were generated from data published by (Mikkelsen et 
al. 2008). These data were retrieved from the microarray data present in supplementary material (S1)of 
that paper, which refers to gene expression profile generated during doxycycline treatment (days 4, 8, 
12, and 16) of MEFs carrying integrated doxycycline-inducible lentiviral vectors expressing the four 
reprogramming factors.  Expression levels of Ink4a (encoding p16Ink4a) and Cdkn1a (encoding p21Cip1) 
upon Dox treatment are relative to the levels of expression in day 0. (B-C) Expression levels of Ink4a 
and Cdkn1a are elevated in partially reprogrammed iPS cells when compared with fully reprogrammed 
iPS cells or ES cells. Partially reprogrammed cells also referred to as Pre-IPSCs, exhibit ES cell 
morphology, but do not express all pluripotency associated genes, maintain the expression of viral 
transgenes, retain the epigenetic silencing of the X chromosome, are irresponsive to LIF and are unable 
to give rise to chimeras. (B) Values were obtained from gene expression profiling data presented in 
Supplemental Material of (Mikkelsen et al. 2008). Values of expression for Ink4a and Cdkn1a in partially 
reprogrammed cell lines (MCV6 and MCV8), IPS cell line (MCV8.1) and ES cells are relative to 
expression levels in MEFs. Partially reprogrammed cells characteristics are supplied in detail in 
(Mikkelsen et al. 2008). (C) Values presented for Ink4a and Cdkn1a correspond to the logarithm (base 
2) of the expression in partially reprogrammed (Pre-iPS) and ES and were obtained from Supplemental 
Data (Table S1) of (Sridharan et al. 2009). The values are normalized to the expression in ES cells. 
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Figure 3.7. Dynamics of the percentage of cells exhibiting high levels of senescence regulators 
in OSKM-transduced cells and empty vector control. The protein levels of senescence regulators 
p53 (a), p21Cip1 (B) and p16INK4a (C) were assessed by immunofluorescence in IMR90 cells transduced 
with the OSKM polycistronic vector or with the empty vector control over the course of 10 days. Graphs 
are correspond to one representative experiment (n=2). 
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3.3. Epigenetic regulation of the INK4a/ARF locus during RIS 
 
The INK4a/ARF locus is normally subjected to strong epigenetic repression 
mediated by H3K27 methylation and recruitment of Polycomb-repressive complexes 
(Gil and Peters, 2006). Activation of the INK4a gene by activated RAS has been 
shown to occur by reversal of PcG-mediated repression (Barradas et al., 2009). To 
evaluate the epigenetic status of the INK4a-ARF locus during RIS, chromatin 
immunoprecipitation (ChIP) assays were performed. IMR90 transduced with OSKM 
and empty vector control were treated with formaldehyde for cross-linking of DNA 
and proteins (hES cells were included as a control). Chromatin preparation 
immunoprecipitation, and quantative PCR was performed by SiDe Li in Martin 
Walsh’s laboratory (Mount Sinai School of Medicine, New York). The ratio between 
H3K27 trimethylation (H3K27me3) to total H3 was determined using primer sets 
described previously (Barradas et al., 2009) (Figure 3.8A). The repressive mark 
peaked around the INK4a promoter, and a decrease in the levels of the H3K27me3 
modification around the INK4a/ARF locus in response to the expression of 
reprogramming factors was observed (Figure 3.8B). Human ES (hES) cells were 
included for comparison, showing even higher levels of H3K27me3 than empty 
vector control IMR90 cells. In parallel, an increase in the H3K4me3 marks around 
the INK4a/ARF locus was observed, further suggesting that the locus is de-
repressed in response to the expression of the reprogramming factors (Figure 3.8C).  
Previous work has shown that expression of activated RAS reduces the extent 
of H3K27me3 at the locus by up-regulating JMJD3 and down-regulating EZH2, 
leading to a loss of PcG-mediated repression (Barradas et al., 2009). JMJD3 is an 
H3K27me3 demethylase, whereas EZH2 is a member of the PRC2 complex 
responsible for the establishment of the H3K27me3 repressive mark. To investigate 
whether the mechanisms responsible for the chromatin changes observed in the  
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Figure 3.8. The histone demethylase JMJD3 contributes to the regulation of the INK4a/ARF locus 
during reprogramming-induced senescence. (A) Schematic figure showing the organization of the 
INK4a/ARF locus and the location of the primers used. (B, C) Expression of the 4 reprogramming 
factors results in a loss of H3K27me3 marks (B) and an increase in H3K4me3 marks (C) in the 
INK4a/ARF locus as analysed by chromatin immunoprecipitation (ChIP). (D) The H3K27me3 histone 
demethylase JMJD3 is induced in response to the expression of the 4 reprogramming factors. (E) 
Quantitive RT-PCR showing upregulation of JMJD3 transcript in response to the expression of the 4 
reprogramming factors. (F) ChIP analysis showing an enrichment of JMJD3 and RNA pol II and loss of 
EZH2 at the INK4a promoter in response to expression of the 4 reprogramming factors. 
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INK4a/ARF locus were similar to those that operate during RAS-induced 
senescence, the levels of JMJD3 were analysed. An up-regulation of JMJD3 at the 
mRNA and protein level was observed (Figure 3.8D and E), In agreement with this 
result, ChIP reflected an increased recruitment of JMJD3 to the INK4a promoter 
(Figure 3.8F). Interestingly, a decrease in the binding of the H3K27me3 histone 
methyl transferase EZH2 to the locus was also observed, but only marginal effects 
on their total levels of expression (Figure 3.8F, data not shown).  
Together these results show that the INK4a-ARF locus is activated during 
reprogramming-induced senescence (RIS). Importantly, chromatin remodelling in 
this locus is critical, as in hES cells and fully reprogrammed cells, the locus is found 
in a repressed state.  
 
3.4 Dissecting the role of p53/p21Cip1 during RIS by individual expression of the 
four reprogramming factors. 
 
To understand how the p53/p21Cip1 pathway is engaged during RIS, each of 
the reprogramming factors was expressed individually in IMR90 fibroblasts. 
Surprisingly expression of any of them had a negative effect over the growth of 
IMR90 cells as shown by colony formation assays (Figure 3.9A), growth curves and 
BrdU incorporation assays (Figure 3.9B). The extent to which the individual factors 
were able to arrest growth was variable, with Sox2 and Klf4 showing the strongest 
effect. Interestingly, Nanog, an important stem cell transcription factor that can be 
omitted from the Yamanaka reprogramming cocktail, had no negative effect over the 
growth of human fibroblasts (Figure 3.9B, growth curve). Accordingly, expression of 
the four factors separately also increased the amount of SA-β-galactosidase positive 
cells, even for Oct4-transduced cells, which do not exhibit a strong growth arrest 
(Figure 3.9 C). These results suggest that the individual factors are able to induce 
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senescence, but probably some of them provoke a heterogeneous response. The 
transcription factor c-Myc for example, clearly induced senescence and p16INK4a up-
regulation, but it also gave rise to highly compact proliferative colonies (data not 
shown; Figure 3.9A).  
Next the ability of the individual reprogramming factors to regulate expression 
of senescence effectors was analysed. Sox2, Klf4, and c-Myc each up-regulated 
p21Cip1 levels. Sox2 expression resulted in a p53-independent up-regulation of 
p21Cip1, while c-Myc or Klf4 induced both p53 and p21Cip1, although only c-Myc 
provoked DNA damage (Figure 3.9 D). These results suggest that p21Cip1 is 
activated by redundant signals during reprogramming.   
Several microRNAs (miRNAs) have been identified whose expression is linked 
to pluripotency, such as the miR-290 cluster in mouse cells, (the closest homologues  
in human cells are the miRNAs that form the miR-371–373 cluster) or the miR-302 
cluster that is conserved in mouse and human (Houbaviy et al., 2003; Suh et al., 
2004). It has been suggested that these ES cell-specific miRNAs are necessary for 
the normal proliferation of ES cells, and function by targeting negative cell cycle 
regulators such as p21Cip1, the RB homolog p130, or LATS2 (Wang et al., 2008). 
The levels of miRNAs belonging to the miR-302 and miR-371-3 clusters were 
measured in IMR90 cells transduced with the OSKM polycistronic vector, and 
compared with empty vector transduced cells. Human ES cells and three different 
human iPS cell lines were included (Figure 3.10 A). While expression of miR-302 
and miR-372/3 is low or absent in IMR90 fibroblasts, in iPS cells it is reset to levels 
similar to the ones found in human ES cells. Noticeably, expression of the four 
reprogramming factors in IMR90 cells did not reset the level of the miR-302 cluster to  
the ones observed in hES cells, while expression of miR-372 or miR-373 were not 
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Figure 3.9 Dissecting the role of p53/p21Cip1 during RIS. (A) Crystal violet stained plates of IMR90 
cells infected with the indicated vectors. (105 cells were seeded per 10-cm dish after selection and fixed 
14 days later) (B) Growth curve of IMR90 transduced cells with the indicated vectors. Cells were 
seeded in triplicate in 24-well plates; one plate was fixed every two days and stained with crystal violet 
at the end of the time course. The relative cell number corresponds to the absorbance at each time 
point relative to absorbance at day 0 (day after seeding). On the right hand side a quantification of BrdU 
incorporation in IMR90 cells transduced with the reprogramming factors separately and controls is 
shown. (C) Staining for SAβ-Gal activity. More then 100 cells were counted; error bars correspond to 
two independent experiments. Pictures were acquired with 20x objective (D) Individual effect of 
reprogramming factors on the induction of DNA damage (γH2AX) and the expression of p53 and p21Cip1 
as measured by immunofluorescence. The expression of c-Myc, and Klf4 induces p53 upregulation. 
The expression of c-Myc, Klf4 or Sox2 induces the upregulation of p21Cip1. Similar results were obtained 
in 2 independent experiments. Error bars correspond to two independent experiments. 
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detected in IMR90 transduced with empty vector or OSKM vector  (Figure 3.10 A). 
This is in agreement with the fact that the miR-302 cluster is regulated by Oct4 and 
Sox2 (Barroso-del Jesus et al., 2009) however it is possible that time is required to 
reach expression of adequate levels of these ES cell-specific miRNAs during the 
reprogramming process or that expression of the cluster is not induced in all cells. 
These data suggest that uncoupling between these events; expression of the four 
reprogramming factors and expression of pluripotency-associated miRNAs may have 
a role in the p21Cip1 induction observed during RIS. To probe this hypothesis, the 
miR-302 cluster was co-expressed with the four reprogramming factors.  Ectopic 
expression of the miR-302 cluster alleviated the growth arrest induced by OSKM 
expression in IMR90, as evaluated by BrdU incorporation and colony formation 
assay (Figure 3.10 B and C). Furthermore, miR-302 prevented the up-regulation of 
p21Cip1 and p130 observed during RIS (Figure 3.10 C). Therefore, the uncoupling 
between expression of reprogramming factors and expression of ES cell-specific 
miRNAs can have a role in the senescence response of somatic cells to OSKM 
expression.  
 
3.5. Discussion and conclusions 
 
3.5.1. The senescence response to expression of reprogramming factors  
The mechanisms involved in the reprogramming of somatic cells to a 
pluripotent-like state remain largely unknown. Upon expression of the 
reprogramming factors in somatic cells, a sequence of events takes place ultimately 
originating cells that highly resemble embryonic stem cells. To understand why the 
reprogramming process is so inefficient we have to unravel the sequential events 
that result in successful reprogramming and identify the biological barriers. Most 
protocols used to  
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Figure 3.10. Expression of ESC-specific miRNAs rescues RIS. (A) Expression of microRNAs of the 
miR-302 and mir-371-3 cluster analyzed by Taqman in IMR90 cells infected with vector or 4 factors 
(OSKM), three iPS cells (iPS B6, B7, B8) and H1 hES cells (hES). miR-302a c and d expression, is 
detected at lower levels in OSKM arrested cells when compared to iPS or human ES cells. miR-372 
and miR-373 are undetected in human fibroblast as well as in OSKM arrested cells. Values are 
normalized to IMR90 infected with control vector, in the case of the miR302 cluster, and normalized to 
hES cells in the case of miR-372 an 373; u.d.l., under the detection limit. (B-C). Expression of the miR-
302 cluster (302) alleviates OSKM-induced senescence, as shown by BrdU incorporation (B) and 
colony formation assays (C). (D and E). IMR90s infected with OSKM vector were subjected to 
immunofluorescence using antibodies recognizing p21Cip1 and p130 (RBL2, retinoblastoma-like protein 
2). Expression of miR-302a-d prevents up-regulation of CDKN1a (encoding for p21Cip1) and RBL2 
(encoding for p130), which are both upregulated during reprogramming-induced senescence. (Ctrl: 
corresponds to miR-Vec-Ctrl, which contains a stuffer DNA derived from the first 211 nt of hTR 
(Voorhoeve et al., 2006). 
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 reprogram human and mouse cells rely on the fact that high viral titers and high 
transduction efficiencies result in multiple viral integration events. This is important to 
assure expression of the four different cDNAs from independent vectors, but also 
originates heterogeneous populations of cells, composed of cells transduced with 
different combinations of factors. Heterogeneous populations are difficult to study not 
only because different phenotypes can be found, but also because over time cells 
with a growth advantage will be selected. In this work, expression of the four 
reprogramming vectors from a polycistronic vector enabled the study of the early 
response of human fibroblasts to the simultaneous expression of the transcription 
factors known to induce somatic cells to regress to an undifferentiated, pluripotent 
state. Surprisingly, the first response to expression of reprogramming factors is an 
anti-proliferative response. Human fibroblasts expressing the OSKM reprogramming 
cassette show an up-regulation of negative regulators of the cell cycle, such as p53, 
p21Cip1 and p16INK4a (Figure 3.5 A-C). Accordingly, characterization of OSKM-
transduced cells, revealed that they are arrested in the G1 phase of the cell cycle, 
show lower levels of BrdU incorporation when compared with control cells, and are 
positive for the senescence associated β-galactosidase activity (SA-β-Gal activity, 
Figure 3.2 and 3.3). Whereas induction of the p53-p21Cip1 pathway seems to be due 
to an activation of the DNA damage response, as analysed by up-regulation of 
phosphorylation of ATM/ATR substrates and existence of the oxidative DNA lesion 
8-oxoG, up-regulation of p16INK4a seems to be related to an epigenetic remodelling of 
the INK4a-ARF locus (Figure 3.8). 
The systems for generation of secondary iPS cells are particularly useful to 
avoid the heterogeneity caused by viral infections from independent plasmids. 
Somatic cells that give rise to secondary iPS cells express homogeneous quantities 
of the reprogramming factors, since all cells within the population were derived from 
a single iPS clone and therefore possess the same combination of reprogramming 
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factors. In spite of this, the reprogramming efficiency of these cells, although higher 
than that obtained after primary iPS cell generation, is still extremely low.  Meissner’s 
group took advantage of this system to understand the mechanisms underlying 
reprogramming. They produced genome-wide gene expression profiles upon 
induction of the reprogramming factors during reprogramming to secondary iPS 
cells. Interestingly, they observed an upregulation of antiproliferative genes, such as 
the CDK inhibitors p21Cip1 and p16Ink4a (Mikkelsen et al., 2008). The same profiles of 
gene expression and chromatin status have been performed to compare somatic 
cells, partially reprogrammed cells, fully reprogrammed cells and ES cells. Mouse 
partially reprogrammed cells also show increased levels of p21Cip1 and p16Ink4a 
reflecting the up-regulation of these genes during reprogramming and suggesting 
that their inhibition may hinder the process (Mikkelsen et al., 2008) (Sridharan et al., 
2009). The work presented in this chapter reveals that human cells respond to 
expression of the four reprogramming factors by halting proliferation. Importantly, 
induction of p21Cip1 and p16Ink4a was also observed when using a different 
reprogramming system. Work performed by Filipe Pereira, shows that these CDK 
inhibitors are induced in human B cells during cell fusion mediated reprogramming 
(Banito et al., 2009). During the course of this work, other groups reported that the 
expression of the reprogramming factors is sufficient to directly trigger an anti-
proliferative response and showed that the expression of the four Yamanaka factors, 
or combinations of only Oct4, Sox2 and Klf4, in human or mouse fibroblasts can 
induce p53 and p21Cip1 (Hong et al., 2009; Kawamura et al., 2009).  
Therefore, induction of senescence upon reprogramming (reprogramming-
induced senescence or RIS) is observed in different cell types, using different 
reprogramming approaches and it is reflected by elevated levels of senescence 
effectors such as p21Cip1 and p16INK4a in partially reprogrammed cells. 
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3.5.2. RIS: Stress or context-dependent response?  
 
Although these observations seemed at first surprising, they probably reflect 
the stress that somatic cells undergo during reprogramming. Indeed, all of the 
reprogramming factors have been reported to have oncogenic potential. c-Myc and 
Klf4 are well-established oncogenes (Dang et al., 2005; Rowland et al., 2005). Oct4 
plays a critical role in the genesis of testicular germ cell tumours (Gidekel et al., 
2003) and has been shown to cause dysplasia in epithelial tissues (Hochedlinger et 
al., 2005). SOX2 has been implicated in breast (Chen et al., 2008), esophageal 
(Bass et al., 2009) and lung cancer (Hussenet and du Manoir, 2010). The fact that 
the reprogramming factors have oncogenic functions could explain why a 
senescence response is triggered; and in fact an obvious parallelism can be drawn 
between oncogene-induced senescence triggered by oncogenic RAS and that 
induced by expression of the reprogramming factors. Like oncogenic RAS, 
expression of the OSKM cassette leads to activation of ATM/ATR, which might 
explain p53 activation, still, the main determinants of p53 activation during 
reprogramming have not been clearly established. Differences in how p53 is 
activated during RIS might exist between cells of human and mouse origin, as 
occurs during oncogene-induced senescence (OIS). For example, a role for p19Arf in 
the activation of p53 during reprogramming in MEFs can be inferred from recent 
results (Kawamura et al., 2009), but whether p14ARF has a similar role in activating 
p53 during the reprogramming of human cells remains to be determined. 
Nevertheless it is clear that a DNA damage response (DDR) is mounted coinciding 
with the expression of the reprogramming factors (Figure 3.4) (Kawamura et al., 
2009; Marion et al., 2009a). The triggering factor for this DDR is still unclear, 
although it has been suggested that the observed pan-nuclear pattern of γH2AX 
staining is compatible with DNA damage induced by aberrant DNA replication 
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(Marion et al., 2009a).   This would be similar to what occurs during OIS. However, 
the expression of the four Yamanaka factors in human fibroblasts leads to 
accumulation of 8-oxoguanine adducts (Figure 3.4B) which are commonly the result 
of oxidative stress, and c-MYC induces DNA damage in a ROS-dependent (Vafa et 
al., 2002) rather than DNA replication-dependent manner (Egler et al., 2005). 
Therefore, the DNA damage response that occurs during reprogramming could be 
caused not only by aberrant DNA replication but also by the generation of ROS. 
Accordingly, it was later described that reprogramming is more efficient under low 
oxygen conditions (Utikal et al., 2009; Yoshida et al., 2009). Similarly is has been 
reported that vitamin C, a powerful antioxidant is also able to improve 
reprogramming efficiency (Esteban et al.).  
In addition to the activation of p53, the results presented here demonstrate that 
p16INK4a is induced early upon the expression of the four Yamanaka factors in human 
fibroblasts reminiscent of what happens in response to oncogenic RAS and other 
stress-inducing signals. Although the mechanism behind upregulation of p16INK4a 
needs to be explored further, it involves chromatin remodelling, including the loss of 
H3K27met3 marks around the INK4b/ARF/INK4a locus. The up-regulation of the 
histone demethylase JMJD3 observed in reprogramming could be partly responsible 
for this phenotype, which markedly resembles the one observed during RAS-induced 
senescence (Agger et al., 2009; Barradas et al., 2009). The INK4b/ARF/INK4a locus 
is repressed epigenetically by Polycomb group proteins in both iPS cells and ESCs 
(Figure 3.8B)(Li et al., 2009). The fact that a derepression of the INK4b/ARF/INK4a 
locus is observed when the 4 factors are expressed, suggests that a proper 
epigenetic reprogramming of this locus could be an important barrier during 
reprogramming.  
The view that somatic cells such as fibroblasts undergo a stress response 
similar to the one caused by expression of oncogenes is attractive, however, one 
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should also suppose that the scenario might be more complicated. Some of the 
reprogramming factors behave in a context-dependent manner. For example Klf4 is 
a context-dependent oncogene, able to induce a growth arrest in normal cells or 
conversely to bypass senescence induced by RAS (Rowland et al., 2005). In the 
same line it was described that Sox2 is downregulated in gastric cancer and that it 
can induce growth arrest and apoptosis when expressed in gastric epithelial cell 
lines, suggesting that it also has tumour suppressive functions (Otsubo et al., 2008). 
The different outcomes of reprogramming factors expression in somatic and ES cells 
may also result from their ability to regulate distinct target genes when expressed in 
different contexts. In fact, Oct4 and Sox2 genes are known to interact with several 
partners to activate or repress the transcription of target genes. When this happens, 
activation of other stem cell-specific genes, including Nanog, takes place. However 
this is a late event in reprogramming (Silva et al., 2009). Interestingly, Sox2 is also 
able to interact with other partners, such as Pax 6 in lens cells (Kamachi et al., 2001) 
and Brn2 in neural primordium (Tanaka et al., 2004). The availability of interacting 
partners for the reprogramming factors, and how they influence their ability to 
transactivate specific genes is a possible explanation for the context-dependent 
behaviour that these proteins exhibit.  
Moreover, the regulation of cell cycle related pathways in ES cells differs 
significantly from that of differentiated somatic cells. It is most probable that the 
unique type of cell cycle-regulation of ES cells has a role is the anti-proliferative 
response observed in somatic cells during reprogramming. Inactivation of negative 
regulators of the cell cycle enables ES cells to continuously self-renew in culture, 
and this is achieved in part by the expression of ES cell-specific microRNAs that 
target Cdkn1a and Rbl2 (Wang et al., 2008). The absence of ESC-specific miRNAS 
in somatic cells can also contribute to the differential response of reprogramming 
factors in these cells. This is in agreement with the results presented here that show 
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how expression of some of these ES-specific microRNAs is able to partially bypass 
RIS  (Figure 3.10). Similarly, it was recently described that Δ40p53, a 
transactivation-deficient isoform of the tumour suppressor p53, is highly expressed in 
mouse ES cells and during the early stages of development (Ungewitter and 
Scrable, 2010). Although the same research group described previously that Δ40p53 
impairs the regenerative capacity of adult stem cells (Medrano et al., 2009), this later 
study reveals that in ES cells the Δ40p53 isoform has a role in maintaining 
pluripotency and the abbreviated cell cycle that allows for their robust proliferation 
and growth. Accordingly, Δ40p53 haploinsufficiency results in a rapid down-
regulation of proliferation and acquisition of a somatic cell cycle.  Further analysis 
demonstrate that Δ40p53 is able to block p53 from binding target promoters, 
including Nanog and Igf-1R (Ungewitter and Scrable, 2010). The uncoupling 
between the ES-specific regulation of the pathways that mediate senescence and 
expression of reprogramming factors during reprogramming, could explain the 
results presented here. Somatic cells lack the ES cells mechanisms to avoid 
senescence, therefore while the ES cell-specific transcriptional program correlates 
with high proliferation in ES cells the outcome in somatic cells may be different. It 
would be interesting to know whether expression of Δ40p53 is able to bypass RIS 
and improve reprogramming efficiency.  
 
3.5.3. Different cell fates may limit reprogramming 
In conclusion, the results presented here, and those reported by several 
research groups, reveal an unexpected activation of the anti-proliferative response 
during reprogramming. The upregulation of senescence mediators due to expression 
of 4 reprogramming factors (RIS) underlines that senescence is an active barrier that 
may hinder reprogramming (Kawamura et al., 2009; Marion et al., 2009)(Figure 
3.11). Some of the genes activated during reprogramming are common to different 
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anti-proliferative responses, such as apoptosis, senescence or other forms of cell-
cycle arrest raising the question of which anti-proliferative response(s) is triggered 
during reprogramming. The answer is probably complex. Human fibroblasts 
expressing reprogramming factors undergo a cell-cycle arrest that presents multiple 
characteristics of senescence, including p16INK4a up-regulation, an event that is 
specifically observed during senescence but not in other types of cell-cycle arrest. 
Although apoptosis was not a significant determinant in the conditions used in this 
work, it has been described that expression of the reprogramming factors can trigger 
apoptosis (Figure 3.11); for example, Bax is upregulated in response to the 
expression of Oct4, Sox2 and Klf4, and expression of its antagonist molecule Bcl2 
results in enhanced reprogramming efficiency (Kawamura et al., 2009). Other reports 
suggest that the expression of the reprogramming factors synergizes with induction 
of DNA damage to trigger apoptosis, especially in cells that have critically short 
telomeres or are sensitized by exposure to exogenous DNA-damaging agents, such 
as ultraviolet or ionizing radiation. In such a scenario, the expression of Bcl2 restores 
the ability of these cells to be reprogrammed to levels similar to control cells (Marion 
et al., 2009a). Therefore reprogramming is limited by both anti-proliferative 
responses, as happens during tumour suppression, in which both senescence and 
apoptosis are implicated. 
The fact that alternative cell fates can be an outcome when reprogramming is 
initiated might explain the low efficiency of the process. During reprogramming a cell 
has to “choose” between proliferation, growth arrest, uncontrolled cell growth or 
apoptosis. Probably only some cells undergo the stochastic sequence of events that 
allows them to avoid these alternative fates and achieve complete reprogramming to 
pluripotency. The ones that bypass the initial barrier of senescence and apoptosis 
still have to overcome additional barriers such as complete epigenetic remodelling 
and consequent activation of pluripotency genes  (Figure 3.11). Acquisition of a stem 
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cell characteristic cell-cycle regulation, or immortality, seems also to be a late event 
during reprogramming as partially reprogrammed cells still express high levels of 
anti-proliferative genes and depend on the expression of exogenous factors for 
continuous growth (Brambrink et al., 2008; Stadtfeld et al., 2008a).  
 
 
 
 
 
 
 
 
Figure 3.11. Alternative cell fates limit reprogramming efficiency. During successful 
reprogramming, the expression of reprogramming factors in somatic cells results in the generation of 
iPS cells. In some cases, the reprogramming process is not complete and partially reprogrammed 
iPSCs that have undergone incomplete chromatin remodelling are obtained. Alternatively, the 
expression of the reprogramming factors can cause senescence (RIS), apoptosis, or contribute to the 
oncogenic transformation of the resulting cells. ESC, embryonic stem cell; iPSCs, induced pluripotent 
stem cells; KLF4, Kruppel-like factor 4; OCT4, octamer 4; RIS, reprogramming-induced senescence; 
SOX2, SRY-box 2. Adapted from (Banito and Gil, 2010). 
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Chapter 4 – Modulating senescence to improve 
reprogramming efficiency 
 
4.1 Inhibition of senescence mediators improves reprogramming efficiency.  
   
The results presented in the previous chapter reveal a link between 
senescence and the reprogramming process. If senescence limits reprogramming, 
inhibiting this response should increase reprogramming efficiency. To test this idea, 
the expression of INK4a, CDKN1a, or p53 was knocked down using shRNAs in BJ 
and IMR90 human fibroblasts (Figure 4.1A). Reprogramming experiments were 
carried out by Tamir Rashid and Imbisaat Geti in Ludovic Vallier’s laboratory in the 
MRC Centre for Stem Cell Biology and Regenerative Medicine, Cambridge. Human 
fibroblasts transduced with empty vector or shRNAs targeting the three senescence 
effectors, were infected with retroviruses expressing the human reprogramming 
factors and cultured in the appropriate conditions to promote the appearance of 
human iPS (hiPS) cell colonies. After 21 d, colonies were analyzed for expression of 
NANOG and TRA-1-60 by immunofluorescence. Double-positive colonies were 
counted as fully reprogrammed iPS cell colonies, whereas morphologically distinct 
colonies negative for both markers were scored as partially reprogrammed (Figure 
4.1 B-D). The number of fully reprogrammed colonies was higher in cells expressing 
shRNAs targeting the expression of senescence effectors. (Figure 4.1 C). Similar 
experiments were performed with IMR90 cells using morphological criteria to 
determine hiPS cell colonies and partially reprogrammed colonies (Figure 4.2 B). In 
these experiments, IMR90 cells proved more difficult to reprogram than BJ cells and 
could only be reprogrammed when senescence mediators were knockdown (Figure 
4.2B). 
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Figure 4.1. Inhibition of senescence improves reprogramming efficiency of BJ human 
fibroblasts. (A) BJ human fibroblasts were infected with shRNAs targeting senescence effectors. 
Quantitative RT–PCR showing the levels of the transcripts for p53, CDKN1A (encoding for p21Cip1), and 
INK4a (encoding for p16INK4a). BJ fibroblasts were transduced with retrovirus expressing OCT-4, SOX2, 
KLF4, and c-MYC and grown in culture conditions compatible with pluripotent stem cell growth. (B) 
Bright-field microphotographs showing distinct morphology of fully reprogrammed and partially 
reprogrammed iPS cells. (C) and (D). Colonies were analyzed by immunofluorescence for NANOG and 
TRA-1-60. The number of positive colonies is shown as the mean ± SD of three independent 
experiments.  
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Figure 4.2. Inhibition of senescence improves reprogramming efficiency of IMR90 human 
fibroblasts. (A) IMR90 human fibroblasts were infected with shRNAs targeting senescence effectors. 
Quantitative RT–PCR showing the levels of the transcripts for p53, CDKN1A (encoding for p21Cip1), and 
INK4a (encoding for p16INK4a). IMR90 fibroblasts were transduced with retrovirus expressing OCT-4, 
SOX2, KLF4, and c-MYC and grown in culture conditions compatible with pluripotent stem cell growth. 
(B) and (C) Colonies were counted based on morphologic criteria to distinguish fully and partially 
reprogrammed cells. The number of positive colonies is shown as the mean ± SD of three independent 
experiments. Bright-field microphotographs showing distinct morphology of fully reprogrammed and 
partially reprogrammed iPS cells is shown on the right hand side.  
 
 
 
    111 
 In addition a to an increase in the number of fully reprogrammed cells, knockdown 
of senescence effectors resulted in an increased number of partially reprogrammed 
iPS cell colonies in both BJ and IMR-90 cells, suggesting that senescence limits the 
initial stages of reprogramming to pluripotency (Figure 4.1D and 4.2C).  
The hiPS cell colonies generated from IMR90 or BJ fibroblasts with reduced 
levels of senescent factors were individually picked and expanded. All the hiPS cell 
lines analyzed (n=8) expressed pluripotency markers including OCT4, SOX2, 
NANOG, and TRA-1-60. Representative images of hiPS derived from BJ transduced 
with empty vector, shRNA against INK4a and p53 are shown in Figure 4.3. 
Additionally, hiPS generated in this experiment expressed other pluripotency 
markers such as DNMT3b, REX1, CRIPTO and hTERT (Figure 4.3B). The hiPS 
lines (n = 8) could be differentiated in vitro into extraembryonic tissues and into 
derivatives of the three germ layers ectoderm, mesoderm, and endoderm. 
Representative images are shown in Figure 4.4.  
Similar experiments were performed in mouse fibroblasts. MEFs expressing 
shRNA against Ink4a/Arf, Cdkn1a or p53 were generated (Figure 4.5A) and 
subsequently reprogrammed in Ludovic Vallier’s laboratory. These experiments also 
revealed increased reprogramming efficiency upon depletion of senescence 
effectors as analysed by quantification of alkaline phosphatase positive colonies 
(Figure 4.5B). Reprogramming of MEFs knockout for Cdkn1a or p53 also revealed a 
higher number of alkaline phosphatase colonies when compared with wild type 
MEFs (Figure 4.5C).  
Taken together, these data demonstrate that inhibition of senescence 
improves the efficiency of reprogramming of somatic cells, supporting the idea that 
senescence imposes a barrier to successful reprogramming to pluripotency. 
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Figure 4.3. hiPS cell lines generated upon knockdown of p53 or p16INK4a express pluripotency 
markers (A) hiPS cell lines generated from BJs transduced with vector control and shRNAs against p53 
or p16 express pluripotency markers.  (B) Q-RT-PCR for pluripotency markers showing expression in 
IPS and hES cells. Expression of DNMT3B, Rex1, and Cripto is relative to levels in BJ fibroblasts. 
Expression of hTERT is relative to levels in hES (H1) cells. 
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Figure 4.4. hIPS cells generated upon knockdown of p53 or p16INK4a  can differentiate into extra-
embryonic tissues and into derivatives of the three germ layers. (A) hiPS cell lines generated from 
BJ cells transduced with vector control and shRNAs against p53 or INK4a were cultured in growth 
conditions to promote differentiation. Representative images of immunofluorescence for extra-
embryonic markers (CDX2 and GATA6), mesendoderm (BRACHYURY and SOX17) and 
neuroendoderm (SOX2, PAX6 and SOX1) are shown. Protocols for differentiation are described in 
(Vallier et al., 2009). 
 
 
 
 
 
    114 
 
 
 
 
Figure 4.5. Enhanced efficiency of reprogramming in MEFs knockout or knockdown for 
senescence effectors. (A) MEFs were infected with the indicated vectors and selected. Q-RT-PCR 
showing the levels of the transcripts for Tp53, Cdkn1a (encoding for p21Cip1) and Ink4a (encoding for 
p16Ink4a) in the cells used for the reprogramming experiments showed in (B). (B). MEFS expressing 
shRNAs targeting Ink4a/Arf, Cdkn1a or p53 were transduced with retrovirus expressing Oct-4, Sox2, 
Klf4 and c-Myc and grown in culture conditions compatible with pluripotent stem cells growth. The 
number of alkaline phosphatase (AP) positive colonies was quantified. (C) MEFs knockout for p53 or 
Cdkn1a (p53-/-, p21-/-) and wild type MEFs (WT) were transduced with retrovirus expressing Oct-4, 
Sox2, Klf4 and c-Myc, and and grown in culture conditions compatible with pluripotent stem cells growth 
The number of alkaline phosphatase (AP) positive colonies was quantified. The number of positive 
colonies is shown as the mean ± SD of three representative experiments. 
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4.2 CBX7 expression improves reprogramming efficiency 
 
 To further study the link between senescence and reprogramming the 
reprogramming protocol was set up in the laboratory. The Polycomb group protein 
CBX7 is able to bypass replicative senescence by repressing the INK4a/ARF locus 
(Gil et al., 2004). Interestingly, CBX7 expression was found to be upregulated in 
miPS cells and mES cells when compared with differentiated cells (Mikkelsen et al., 
2008). To test the ability of CBX7 to increase reprogramming efficiency, early 
passage IMR90 cells were transduced with the four factors (from independent 
plasmids), either with empty vector, a vector expressing mouse CBX7 or shp53 as a 
positive control for improvement of reprogramming efficiency. Infection conditions 
were maximized to assure high infection rates (above 75%). IMR90 infected with 
empty vector only, were kept in parallel throughout the experiment as a negative 
control for reprogramming. Transduced IMR90 cells were plated on feeders five days 
following transduction, and maintained in conditions that support hES cells growth for 
approximately fifteen days. ES-like colonies appeared approximately 13 days post-
infection (after 8 days of changing to ES-cell growing conditions), but additional 
colonies, with varied morphology appeared at different stages previously. Addition of 
CBX7 to the reprogramming cocktail resulted in an increase in the number of alkaline 
phosphatase positive colonies (Figure 4.6 A and B). Reprogramming efficiency, 
expressed as number of AP-positive colonies per 100 cells transduced, was similar 
to the ones reported in the literature (0.01%-0.1% (Stadtfeld and Hochedlinger, 
2010)(Figure 4.6C), although this depends on several factors such as transduction 
efficiency and type and passage number of somatic cells to reprogram. In parallel to 
plating cells on feeders to promote generation of ES-cells like colonies, cells were 
plated five days after transduction for immunofluorescence analysis. The percentage 
of cells with high levels of p16INK4a was higher in cells infected with the 4 factors, 
    116 
however in cells infected with CBX7, the amount of cells showing high expression of 
p16INK4a was lower (Figure 4.6D). Immunofluorescence for p53 protein was also 
performed. The percentage of cells showing high p53 levels was greater in cells set 
to reprogram in the presence of empty vector or CBX7 expression plasmid. 
However, addition of an shRNA targeting p53 clearly avoided its up-regulation during 
reprogramming (Figure 4.6E). 
To assure that successful reprogramming was achieved in these experiments, 
colonies were picked and expanded for characterization. Two hiPS cells lines were 
successfully isolated. Their morphology was strikingly similar to the one of hES cells 
(Figure 4.7). During picking and expansion, some cell lines fail to attach or grow in 
undifferentiated state, since hES cells and iPS cells cannot survive as single cells 
and tend to differentiate when grown in low density conditions. Additionally, the carry 
over of partially reprogrammed cells, represent a problem, since these cells tend to 
grow faster and take over the cell culture (Figure 4.7 bottom panel, pre-iPS).  The 
two hiPS isolated were positive for pluripotency markers, such as OCT4, TRA-1-60 
and TRA-1-81, as determined by immunofluorescence (Figure 4.8A). IMR90 
fibroblasts and hES cells were included as controls. Quantitative PCR for 
endogenous expression of the pluripotency factors OCT4 and SOX2 (Figure 4.8B) 
revealed that these genes were expressed at levels comparable with those of hES 
cells. Similar results were obtained for NANOG, DNMT3B, REX1 and hTERT (Figure 
4.8B). The partially reprogrammed cell line shown in Figure 4.7 (pre-iPS) was also 
included, and as expected it shows incomplete activation of pluripotency markers 
(Figure 4.8B). Finally hiPS cells were analyzed for expression of exogenous factors. 
Partially reprogrammed cells are characterized by dependence on exogenous 
factors expression. The mRNA levels of exogenous factors were much lower in hiPS 
cells lines when compared with partially reprogrammed cells, suggesting that the 
transgenes are silenced in these cells (Figure 4.8). 
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Figure 4.6. Cbx7 enhances reprogramming efficiency of human fibroblasts. (A) IMR90 fibroblasts 
passage 12, were transduced with the 4 factors, together with empty vector control, a vector expressing 
mCbx7 and a vector expressing a small hairpin targeting p53. Five days after transduction 2. 105 cells 
were plated on feeders. From day 7, cells were maintained in media that supports growth of hES cells, 
and fixed on day 20-24. Alkaline phosphatase  (AP) staining was performed to visualized ES-like 
colonies. Cells infected only with empty vector were kept in the same conditions throughout the 
experiment and used as a negative control for AP staining. (B) AP positive colonies were counted using 
Image J software. Error bars correspond to the standard deviation from three independent experiments. 
(C) Reprogramming efficiency is presented as number of AP positive colonies per 100 cells infected. 
The total number of AP positive colonies in each plate was counted. The efficiency of retroviral 
transduction was measured in parallel using a red fluorescent protein (cherry) retroviral plasmid, 
followed by FACS analysis on day 5. (D) and (E) Immunofluorescence analysis of p16INK4a (D) and p53 
(E) proteins.  Cells were plated in duplicate in 96-well plates, five days after transduction, and 
correspond to the same cells plated for the reprogramming experiment presented in (A). ★★ p<0.005 
(two-tailed t-test). 
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Figure 4.7. Morphology of hiPS cell lines generated in this study. Bright-field microphotographs 
acquired at three different magnification (4x, 10x and 20x) showing morphology of IMR90 (passage 15), 
two iPS cells lines (picked and expanded from a 4F+Vector plate), hES cells H7 and one pre-iPS cell 
line. The morphology of iPS cells is strikingly similar to the morphology of hES cells, which have large 
nuclei and a low cytoplasm to nucleus ratio. Pre-iPS, or partially reprogrammed cell lines clearly differ in 
morphology when compared to hES cells. 
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Figure 4.8. iPS cell lines generated in 4.6 express pluripotency markers. (A) Expression of the 
pluripotency markers OCT4, TRA-1-60 and TRA-1-81 was analyzed by immunofluorescence in the two 
iPS cell lines successfully picked and expanded together with controls (IMR90 cells and hES H7 cells). 
Pictures were aquired with 10x magnification. (B) qPCR for pluripotency markers showing expression in 
IPS, partially reprogrammed cells (pre-iPS) and hES cells. Expression is relative to levels in IMR90 
fibroblasts.  
    120 
 
 
 
  
 
 
Figure 4.9. hiPS cell lines have silenced the expression of exogenous reprogramming factors. 
The exogenous expression of reprogramming factors was measured by Q-RT-PCR in the .  Values are 
relative to the levels in the partially reprogrammed cell line (pre-iPS). 
 
 
 
Together these results show that a protocol for hiPS cell generation and 
comparison of reprogramming efficiencies was successfully developed in the 
laboratory. Importantly, CBX7 was found to enhance reprogramming efficiency, 
further highlighting the importance of bypassing the senescence roadblock to 
achieve successful reprogramming to pluripotency.   
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In addition to human fibroblasts, mouse embryonic fibroblasts were also 
reprogrammed. Reprogramming of mouse fibroblasts has several advantages when 
compared with reprogramming of human cells. Reprogramming efficiencies are 
higher for mouse than for human cells (around 0.1% versus 0.01%), ES-like colonies 
emerge sooner and the use of reporter genes can facilitate the identification of fully 
reprogrammed colonies (reviewed in Stadtfeld and Hochedlinger, 2010). Additionally, 
MEFs are easier to transduced with retroviral vectors (transduction efficiency is 
usually above 90%). 
MEFs Oct4-GFP were transduced with the four reprogramming factors (4F) or 
with Oct4, Sox2 and Klf4 (3F).  After 4 days, the cells were plated on feeders and 
grown in conditions that support mES cells growth. ES-like colonies emerged early in 
the process (10 days after transduction) in 4F-transduced MEFs but not all exhibited 
GFP expression. Fourteen days following transduction several alkaline phosphatase 
colonies exhibiting ES-like morphology were detected using 4F reprogramming. 
MEFs transduced with 3F gave rise to ES-like colonies later (16 days after 
transduction), but most colonies exhibited ES-like morphology and expressed GFP 
(Figure 4.10.A). Fifteen GFP-positive colonies were picked and expanded from 3F-
transduced MEFs. After expansion these cells retained alkaline phosphatase activity,    
(Figure 4.10.B), GFP-expression and stained positive for Nanog (Figure 4.10.C), 
suggesting that they were fully reprogrammed miPS cells. However further 
characterization, such as expression of other pluripotency markers and silencing of 
exogenous factors need to be performed in the future.  
 As discussed previously, reprogramming of mouse cells has advantages over 
reprogramming of human cells, which makes it a good system for routine 
assessment of elements modulating reprogramming efficiencies. It will be interesting 
to test the ability of CBX7 to improve reprogramming of mouse cells both with four or 
three reprogramming factors.  
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Figure 4.10. Reprogramming of MEFs Oct4-GFP. (A) MEFs Oct4-GFP were infected with retroviral 
vectors encoding the mouse reprogramming factors (pMXs vectors from (Takahashi and Yamanaka, 
2006)) and grown in conditions that  support mES cells growth. Plates were fixed and stained for 
alkaline phosphatase activity at day 14 and 20 post-infection. After 14 days numerous colonies were 
identified in cells infected with the 4F whereas with colonies appeared later in cells transduced with 3F 
(around day 16). On the right hand side bright field picture with 20x magnification of a colony generated 
with 3F is shown. The colony is GFP-positive showing reactivation of the Oct4 locus. (B and C) Three 
miPS cell lines were successfully picked and expanded from colonies generated with 3F. The three 
miPS cell lines are AP positive (B), Oct4-positive and express Nanog (C). mES cells were included as 
control.   
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4.3. Discussion and conclusions 
 
 
4.3.1. Senescence represents a roadblock for successful reprogramming 
In the previous chapter a senescence response to the expression of the four 
reprogramming factors was characterized. A corollary to the fact that senescence 
and apoptosis are triggered during reprogramming is that the inhibition of those 
responses could increase the efficiency of pluripotency induction. The results 
presented in this chapter demonstrate that inhibition of senescence mediators, p53, 
INK4a and CDKN1a improves reprogramming efficiency of human and mouse 
fibroblasts. Indeed, Park and colleagues were among the first groups to describe the 
reprogramming of human adult somatic cells to ESC-like pluripotent cells by using 
the four Yamanaka factors in combination with the SV40 large T antigen (SV40 LT) 
and/or hTERT (Park et al., 2008b). Interestingly, these two factors are involved in 
senescence control. Later, Zhao and colleagues reported that knocking down p53 
and Utf1 could greatly increase reprogramming efficiency, but the mechanism behind 
it was still unclear (Zhao et al., 2008). At the same time that the work present here 
was published, several groups showed that knocking down p53 or its transcriptional 
target CDKN1a in human or mouse cells can significantly increase the efficiency of 
reprogramming (Hong et al., 2009; Kawamura et al., 2009; Marion et al., 2009a; 
Utikal et al., 2009). The expression of MDM2 or a dominant-negative mutant of p53 
also results in enhanced reprogramming, whereas the activation of p53 through 
different strategies reduced the reprogramming efficiency (Kawamura et al., 2009; 
Marion et al., 2009a; Sarig et al., 2010), emphasizing the importance of controlling 
p53 activity to modulate reprogramming.  
The low efficiency of reprogramming has been attributed to different biological 
roadblocks. The transition to a pluripotent state is accompanied by genome-wide 
remodelling of chromatin modifications such as DNA and histone methylation 
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patterns from a somatic to a pluripotent state (Maherali et al., 2007; Mikkelsen et al., 
2008). The promoters of pluripotency genes such as Oct4 and Nanog are silenced in 
somatic cells by DNA methylation (Gidekel and Bergman, 2002), therefore one of the 
reprogramming roadblocks is the proper demethylation of key pluripotency genes. 
Different reports have characterized cells that failed to fully reprogram (partially 
reprogrammed or Pre-iPS cells) and suggest that they are trapped in a late step of 
reprogramming. Inhibition of DNA methylation, knockdown of lineage-specific genes, 
or treatment with MEK and GSK3 inhibitors (Mikkelsen et al., 2008; Silva et al., 
2008) can either convert some of these pre-iPS to iPS or increase the proportion of 
fully reprogrammed iPS versus pre-iPS (Figure 4.10).  This work demonstrates that 
inhibiting or alleviating senescence leads to an increase in the number of fully and 
partially reprogrammed colonies (Figure 4.1 and 4.2). By inhibiting senescence 
mediators, the number of cells able to surpass the early barrier imposed by RIS is 
higher, resulting in higher numbers of both pre-iPS and fully reprogrammed iPS 
(Figure 4.10, right panel). A combination of both strategies could be used to enhance 
reprogramming efficiency synergistically. These results highlight an interesting link 
between reprogramming and tumour suppressors and emphasise how stressful the 
process of reprogramming must be for the cell. Additionally, senescence and 
reprogramming are deeply intertwined processes: a direct comparison of the ability 
of young and old cells to be reprogrammed shows that the closer cells are to the 
onset of senescence and therefore the higher the levels of INK4a and CDKN1a they 
express, the more difficult it is to reprogram them. Fibroblasts from older mice, which 
express high levels of the Ink4b/Arf/Ink4a locus products, are less efficient in 
generating iPS cells (Li et al., 2009), further linking ageing with decreased 
reprogramming efficiency. Similar experiments performed in late generation Terc–/– 
MEFs, which have critically short telomeres, emphasize the difficulty of 
reprogramming cells that are already aged or stressed (Marion et al, 2009b). 
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Therefore senescence seems to limit reprogramming in two slightly different ways, 
by functioning as an anti-proliferative/stress response as well as by limiting the 
number of cells in a population that are refractory to be reprogrammed due to pre-
existent high levels of senescence regulators.  
 
 
 
 
 
 
 
Figure 4.11. Senescence as an early barrier during reprogramming. Partially reprogrammed (Pre-
iPS) cells are trapped in a late state in the reprogramming process due to incomplete epigenetic 
resetting. Strategies including inhibition of DNA methylation, knockdown of lineage specific genes 
(Mikkelsen et al., 2008) or treatment with 2 inhibitors (Silva et al., 2008) can convert Pre-iPS cells to 
fully reprogrammed iPS cells or increase the proportion of fully vs. partially reprogrammed cells (middle 
panel). Knocking down critical senescence effectors results in increased numbers of both partially and 
fully reprogrammed cells, presumably by reducing the proportion of cells that succumb to the first 
barrier (right panel). 
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Although the efficiency of reprogramming can be improved by interfering with 
crucial anti-proliferative genes, the consequence of dismantling cell-intrinsic tumour 
suppressive mechanisms is too detrimental to consider, as it would affect the safety 
of the resulting iPS cells. Indeed, iPS cells derived from p53–/– MEFs have 
increased chromosomal instability (Marion et al., 2009a). Additionally, single-cell 
imaging during reprogramming of mouse fibroblasts in the presence of a hairpin 
against p53 revealed that although p53 inhibition expand the global population 
responsive to reprogramming, there is a higher number of aberrantly reprogrammed 
cells compared with control cells (Smith et al., 2010). It is obvious that 
reprogramming methods that include inactivation or deletion of p53 are too unsafe, 
as, even cells that have been heavily burdened with DNA damage are still able to 
acquire pluripotent properties. However this approach may help to establish useful 
cellular models for a variety of diseases in which the target somatic cells are 
particularly difficult to reprogram. 
  Sensible alternatives may also exist to benefit from disabling senescence to 
enhance reprogramming efficiency without compromising the integrity and safety of 
the resulting iPS cells. This may be achieved by identifying the mediators of 
senescence induction during reprogramming, as well as by having a complete 
understanding of ES cell-specific mechanisms of cell-cycle regulation. For example, 
Rem2 GTPase, a suppressor of the p53 pathway implicated in maintenance of hES 
self-renewal and pluripotency, has been shown to improve reprogramming efficiency 
(Edel et al., 2010). Rem2 enhances the process by accelerating the cell cycle and 
protects cells from apoptosis by suppressing p53 and regulating cyclin D1 
expression and localization. In this way the authors suggest that imposing cell-cycle 
features that are specific of hES cells might safely improve reprogramming (Edel et 
al., 2010). Although this is an interesting idea, the oncogenic potential of Rem2 
needs to be further studied.  
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A possible strategy is to transiently inhibit senescence, by using either small 
interfering RNAs or chemical compounds. In this regard, two additional studies have 
provided safer methodologies for improving reprogramming by modulating 
senescence pathways. Reprogramming cells in low oxygen conditions (Utikal et al., 
2009; Yoshida et al., 2009) or in the presence of antioxidants such as vitamin C 
(Esteban et al., 2010) has been shown to enhance the generation of iPS cells. 
Consistent with the results presented in this work, Pei's group report that one of the 
important metabolic activities that occur during the early stages of the 
reprogramming process is a significant increase in the level of reactive oxygen 
species (ROS). Addition of the natural compound vitamin C, results in an increase in 
cell proliferation and extension of cell lifespan, suggesting that vitamin C is able to 
overcome the senescence roadblock during the reprogramming process. 
Furthermore, vitamin C alleviates senescence by reducing but not abolishing p53 
and p21 expression levels (Esteban et al., 2010). Therefore this study provides a 
good example of how senescence can be modulated to improve reprogramming 
efficiency in a safer way. Understanding of the senescence roadblock during 
reprogramming will hopefully provide similar additional strategies. 
  
4.3.2. The role of the Polycomb protein CBX7 in reprogramming  
 
CBX7, a polycomb group protein that is part of the PRC1 complex, is 
involved in suppression of the INK4a/ARF locus (Bernard et al., 2005; Gil et al., 
2004) is also able to enhance the generation of partially and fully reprogrammed 
colonies. Analysis of p16INK4a after transduction with the 4 reprogramming factors 
together with CBX7 showed that the percentage of cells with high p16INK4a levels was 
lower when compared with reprogramming in the presence of empty vector control. 
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These results suggest that CBX7 can improve reprogramming by avoiding p16INK4a 
up-regulation and repressing the INK4a/ARF locus.  However it is possible that the 
ability of CBX7 to enhance reprogramming is due to additional factors. Indeed, it has 
been described that Polycomb group proteins have a critical role in the chromatin-
remodelling events required for the direct conversion of differentiated cells toward 
pluripotency (Pereira et al., 2010). In ES cells, pluripotency is maintained by 
expression of ES cell-specific factors but also by suppression of developmental 
pathways by recruitment of repressive chromatin remodelling complexes (Boyer et 
al., 2006). Pereira et al. showed that members of the PRC2 and PRC1 complex have 
a role, not only in the maintenance of the pluripotent state, but also in the 
reprogramming abilities of ES cells during cell fusion reprogramming. Interestingly, 
the inability of PRC2 mutant ES cells to reprogram is dominant suggesting that 
mutant ES cells may express factors that block the efficient reprogramming of 
differentiated cells. As stated before, the INK4b/ARF/INK4a locus is repressed 
epigenetically by Polycomb group proteins in both iPS cells and ESCs (Figure 
3.8B)(Li et al., 2009). However the authors show that human INK4a levels are not 
changed when comparing fusion of wild type or PRC2-deficient ESCs. Although this 
suggests that senescence induction is unlikely to be the cause of PRC2-null 
reprogramming defects, it is important to note that in this reprogramming system the 
ability to induce a pluripotency transcriptional program is dissociated from the 
acquisition of the type of cell cycle regulation characteristic of ES cells. Therefore, 
although senescence regulators are induced in this scenario, their down-regulation is 
not fundamental in these settings because interspecies heterokaryons cease 
proliferation and cannot divide further (Bhutani et al., 2010). It will be interesting to 
understand what is the exact role of CBX7 in improving reprogramming. The fact that 
there is an increase in both partially and fully reprogrammed colonies suggests that 
CBX7 is acting in part by alleviating senescence and increasing the number of cells 
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that bypass the initial senescence barrier. However, to understand whether CBX7 
improves reprogramming by repressing the INK4a/ARF locus, an interesting 
experiment would be to compare the ability of CBX7 to enhance the reprogramming 
efficiency using MEFs wt and MEFs that are knockout for Inka4/Arf.  
 
4.3.3. Comparing reprogramming efficiencies 
 
Identification of RIS mediators will be one of the focuses of future research 
(see chapter 5, future work).  Therefore, establishing an in house reprogramming 
protocol was also crucial for future work taking place in the laboratory. Genes that 
may have a role in mediating RIS will be tested for the ability to modulate 
reprogramming efficiency. Alkaline phosphatase staining can be used to score total, 
partially and fully reprogrammed colonies. Since RIS imposes an early barrier to 
reprogramming, the main purpose will be comparing total number of alkaline positive 
colonies. However, characterisation of fully reprogrammed cells was also important 
to assure that proper reprogramming was achieved in these experiments. There is a 
considerable degree of heterogeneity in the colonies arising during reprogramming 
with a high proportion being partially reprogrammed or simply transformed colonies. 
In the case of mouse cells drug selection cassettes linked to the pluripotency genes 
Oct4 and Nanog, which are activated in fully reprogrammed colonies have been 
used. However this approach requires genetic engineering of mice, so it cannot be 
applied in the case of human cells. Importantly, several studies report the isolation of 
high quality iPS cells without drug selection, but by simply using morphological 
criteria (Blelloch et al., 2007; Meissner et al., 2007). This is more easily applicable to 
hiPS cells, which display a distinct morphology (Figure 4.7). Indeed, several studies 
that report generation of hiPS cells rely on morphologic criteria (Takahashi et al., 
2007; Yu et al., 2007). Live cell imaging of human fibroblasts during reprogramming 
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revealed that, similar to mouse fibroblasts, it begins with down-regulation of 
fibroblasts markers, such as CD13. Early pluripotency markers such as SSEA4 and 
TRA-1-60 appear later, however not all of these cells are set to reach a fully 
reprogrammed state (Chan et al., 2009). Additionally, Chan et al. report that 
pluripotency markers such as Nanog may be present in partially reprogrammed cells 
and that the fully reprogrammed state in hiPS is associated with additional activation 
of the pluripotency markers REX1 and DNMT3B (Chan et al., 2009). Interestingly the 
two hiPS cells lines generated in the lab are positive for those markers, whereas the 
partially reprogrammed cell line express lower levels of NANOG when compared 
with hES and hiPS and no REX1 or DNMT3B (Figure 4.8B). These results suggests 
that successful reprogramming to iPS cells was achieved and that the protocol used 
is suitable to compare reprogramming efficiencies. However if the quantification of 
fully reprogrammed versus partially reprogrammed colonies is required, double 
staining with pluripotency markers and/or morphology features will also be used in 
addition to quantification of alkaline positive colonies.  
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Chapter 5 – Discussion and future work 
 
 
The generation of induced pluripotent stem cells, not only opened a vast 
range of possibilities for stem cell therapy but also provided a new tool to investigate 
pluripotency and to study specific diseases. iPS cells can be produced from adult 
cells from any individual, thus they could solve the ethical issues associated with ES-
cell use and circumvent the need for immunologically matched cell donors for 
transplantation. Still, despite their potential, it is not known whether iPS cells will be 
an effective treatment for human diseases. In fact, it is important to bear in mind that 
even embryo-derived ES cells have only been tested in a few settings, and that their 
effectiveness and safety are not well established. Importantly, if iPS cells are to be 
used in a clinical setting, several issues have to be addressed. Previous work has 
paved the way to develop methods for the generation of integration-free iPS cells, 
but probably the most worrying topic is the relationship between reprogramming and 
tumorigenesis. The idea that inhibiting tumour suppressive pathways enhances 
reprogramming highlights this concern. In this work a link between these senescence 
effectors and the expression of the 4 reprogramming factors is demonstrated. 
Similarly, several research groups have described how inhibition of the two main 
senescence mediators pathways, p53-p21Cip1 and p16INK4a-RB, improves 
reprogramming efficiency. 
 
5.1. The tumour suppressor p53 limits de-differentiation 
The p53 tumour suppressor was first linked to reprogramming when mouse 
germ cells deficient for p53, were shown to be able to give rise to ES-like cells 
(Kanatsu-Shinohara et al., 2004a). Later, another research group reported that 
knocking down p53 and Utf1 could greatly increase reprogramming efficiency, but 
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the mechanism behind it was still unclear (Zhao et al., 2008). In this work the 
activation of p53, and its downstream target p21Cip1 in response to expression of 
reprogramming factors is described.  Two research groups have reported similar 
observations upon expression of the OSKM, OSK or SO (Hong et al., 2009) 
(Kawamura et al., 2009).  
The link between reprogramming and p53 is somehow intuitive. Indeed, 
reprogramming highlights the ability of somatic cells to revert their fate towards a 
state of pluripotency, a de-differentiation process that resembles tumorigenesis. 
Sarig et al. have also reported that a mutant form of p53 could increase 
reprogramming efficiency to higher levels than the ones obtained with p53 knockout 
MEFs (Sarig et al., 2010). This further supports the link between tumorigenesis and 
the de-differentiation of somatic cells into an embryonic state.    
Undoubtedly, loss of p53 plays an important role in gain of pluripotency, but to 
completely understand why p53 is induced during reprogramming a better 
comprehension of its role in stem cell biology is necessary. Several studies have 
implicated p53 in regulating pluripotency, for example p53 has been shown to 
directly suppress the expression of Nanog (Lin et al., 2005). Similarly, p53 activation 
has been related with differentiation; soon after differentiation the phosphorylation of 
p53 in specific residues is increased (Lin et al., 2005). This suggests that p53 may 
also have a role in preventing dedifferentiation, an idea supported by the fact that 
germ cells can be reprogrammed to pluripotent stem cells when p53 is absent 
(Kanatsu-Shinohara et al., 2004a). On the other hand it is intriguing that DNA 
damage in ES cells does not lead to a p53-dependent cell cycle arrest or apoptosis 
like in somatic cells (Aladjem et al., 1998). In fact it has been shown that although 
present at high levels in mouse ES cells the p53 protein is in the cytoplasm and 
translocated inefficiently to the nucleus upon stress conditions (Aladjem et al., 1998) 
whereas in human ES cells is not present at all, or at very low levels. It has also 
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been shown that p53 is important for self-renewal of mouse ES cells because ES 
cells knockout for p53 have reduced self-renewing capability. Hu et al. showed that 
p53 up-regulates LIF expression and in this way self-renewal of cells with impaired 
p53 is avoided (Hu et al., 2007). Recently, it was reported that Δ40p53, an isoform of 
p53 which is specifically expressed is ES cells, is essential to maintain pluripotency. 
The authors suggest that this isoform regulates pluripotency by regulating the full-
length p53 and promoting IGF signalling (Ungewitter and Scrable, 2010).  
In light of the role of p53 in inhibiting dedifferentiation, the fact that p53 is 
activated during reprogramming and that its inactivation leads to enhanced 
reprogramming efficiency is logical. However, the several layers of p53 regulation 
make difficult to understand its role in stem cell biology. As these mechanisms 
become clearer, the easier will be to understand p53 dynamics during 
reprogramming. 
 
5.2. Reprogramming the INK4a/ARF locus  
In addition to p53, inhibition of the p16INK4a and p19Arf genes has been also 
shown to improve reprogramming efficiency. Li et al showed that the Ink4a/Arf locus 
is silenced during iPS reprogramming. They argue that this silencing occurs early in 
reprogramming, implying a direct effect of the reprogramming factors on this locus. 
There is, however, no consensus about the timing of downregulation of Ink4a/Arf 
expression during reprogramming (Li et al., 2009; Utikal et al., 2009). The fact that 
the Polycomb protein CBX7 improves reprogramming supports the view that 
repression of the INK4a/ARF locus is important for cells to bypass an early barrier 
during the process. In the reprogramming experiments performed in the laboratory, 
the percentage of cells positive for p16INK4a was higher than in control cells 10 days 
after infection. These results imply that epigenetic remodeling of the locus is not one 
of the first events during reprogramming of human cells. This is also supported by 
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the fact that partially reprogrammed cells express high levels of INK4a when 
compared to fully reprogrammed cells (Mikkelsen et al., 2008; Sridharan et al., 
2009). 
During reprogramming the epigenetic memory of differentiated cells is reset. 
However differentiated cells can accumulate abnormal epigenetic changes that can 
contribute to pathological conditions. The INK4a/ARF locus is frequently aberrantly 
silenced in cancer. A recent study showed how aberrant methylation of the INK4a 
gene in immortalized human fibroblasts could be reverted during reprogramming to 
iPS cells. These results suggest that the INK4a locus is not aberrantly silenced 
during reprogramming and that it can even be reverted to a “normal” state in iPS 
cells. (Ron-Bigger et al., 2010). The authors also suggest that the INK4a gene in 
hES cells although expressed at low levels is not completely repressed and in this 
way they differ from the results observed in mES cells (Li et al., 2009). Further work 
will clarify how the INK4a/ARF locus is regulated during reprogramming and in 
pluripotent human ES cells. 
 
5.3. Is cell division required for reprogramming? 
The results presented in this work as well as the work performed by several 
groups clearly demonstrate a link between activation of tumour suppressor pathways 
and reprogramming. By inhibiting these pathways we prevent senescence, apoptosis 
and cell cycle arrest, thereby increasing reprogramming efficiency. Interestingly, 
work by Jaenish and colleagues suggest that almost all cells are capable of being 
reprogrammed, even without inhibiting p53 or immortalizing the cells (Hanna et al., 
2009). When p53 was absent the process was accelerated due to an increase in the 
proliferation rate. Therefore the authors claim that p53 inhibition influences 
reprogramming kinetics rather than the overall efficiency of reprogramming (Hanna 
et al., 2009). It is still to determine whether this is cell-type specific, as in this case a 
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homogeneous population of B cells obtained from secondary iPS cell-generated 
mice, was used. It has been described that contrary to what happens with B cells, 
there is a refractory population of fibroblasts that cannot give rise to iPS cells even 
after prolonged time in culture (Stadtfeld and Hochedlinger, 2010). Utikal et al. have 
also addressed this issue by comparing the reprogramming efficiency of wild-type 
MEFs growing in 15% foetal bovine serum, with that of p53 knockout MEFs in 0.5% 
serum. Although the proliferation rate was lower in the MEFs deficient for p53 
growing in low serum conditions, the reprogramming efficiency was still higher when 
compared to wild-type MEFs (Utikal et al., 2009). Additionally, live imaging studies of 
fibroblasts during reprogramming, revealed that after expression of reprogramming 
factors in MEFs, several distinct cell types based on broad morphological and 
proliferative characteristics, arise. As expected, most cells failed to initiate 
reprogramming and generally resembled the initial somatic fibroblast population, 
which the authors classified as exhibiting arrested/apoptotic or slow-dividing 
phenotypes. However a subpopulation of cells (about 1% of the total population) 
characterized by high rates of proliferation and small size, appears early in the 
process. Tracing back iPS colonies to their source, showed that they arise from this 
sub-population (Smith et al., 2010). These results are in agreement with the ones 
presented in this work that suggest that an initial senescence barrier limits 
reprogramming efficiency. Whether cells maintained in culture for long periods of 
time are able to bypass RIS and reprogram is still unclear. However since, bypassing 
RIS could involve spontaneous inactivation of tumour suppressors this should be 
avoided. 
Apart from the senescence barrier, only a subset of cells from the initial 
population of fibroblasts is able to down-regulate differentiation markers and activate 
pluripotency genes. This implies that some cells are refractory to reprogramming. 
One of the limiting factors to achieve successful reprogramming is the demethylation 
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of pluripotent loci. This can be achieved by passive demethylation, due to inhibition 
of the DNA methyltransferase, DNMT1 during DNA replication, or by an active 
mechanism that is independent of DNA replication (Hanna et al., 2010). A recent 
study provided evidence suggesting that an active demethylation mechanism 
independent of DNA replication and cell division takes place during cell fusion 
mediated reprogramming. The authors show that reprogramming towards 
pluripotency in single heterokaryons is efficiently initiated without cell division or DNA 
replication and depends on activation-induced cytidine deaminase (AID), required for 
promoter demethylation and induction of OCT4 and NANOG gene expression. 
(Bhutani et al., 2010). This is a very interesting study that enables the 
characterization of early events in reprogramming to pluripotency. However it is 
important to point out that it is still not known whether demethylation of the OCT4 
gene detected in heterokaryons after cell fusion actually reflects the events that lead 
to fully reprogrammed iPS cells. Indeed, the levels of OCT4 observed after cell 
fusion are much lower (100-fold) when compared with ES cells and its promoter is 
partially demethylated (Bhutani et al., 2010). This is reminiscent of partially 
reprogrammed cells that can express low levels of OCT4 without achieving proper 
promoter demethylation (Mikkelsen et al., 2008).  
Maybe the question lies on whether we can consider that a cell that cannot 
divide but express pluripotency markers is a fully reprogrammed cell. In other words, 
we need to understand whether proliferation and pluripotency are dissociable 
identities or if the in vitro pluripotent state of ES cells implies rapid proliferation and 
immortality. Early studies performed in embryonic carcinoma  (EC) cells led to the 
idea that the length of G1 phase is directly linked to the responsiveness of 
pluripotent stem cells to differentiation signals (Jonk et al., 1992; Mummery et al., 
1987). In this way, the short G1 characteristic of ES cells, would limit the time that 
cells are exposed to differentiation cues. Indeed, there is evidence that inhibition of 
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G1 progression compromises pluripotency (Filipczyk et al., 2007). Additionally, it has 
been proposed that mitosis is essential for changes in global transcriptional 
regulation systems, as it involves displacement of transcription factors from 
condensed chromatin (Egli et al., 2008). If this is the case, inhibition of senescence 
mediators would increase reprogramming efficiency by limiting the cells that are 
trapped in a senescent state and by increasing the proliferation rate and facilitating 
the changes required to achieve pluripotency. Whether replication is necessary for 
direct reprogramming is not completely clear, and may be context-dependent, 
however understanding the unique mode of cell cycle regulation of ES cells and its 
implication in pluripotency will certainly continue to be a focus of research. 
 
5.4. Pluripotency, reprogramming and transformation 
 
Beyond the technological implications, the results presented in this work also 
emphasize the relationship between reprogramming and tumorigenesis, and 
illuminate interesting biological processes. Most tumours have defects in the p53 and 
p16INK4a/RB pathways, which were shown to enhance and accelerate 
reprogramming. It is thus tempting to speculate that this ability is necessary for 
tumour initiation or maintenance. The initial idea that cancer arises from de-
differentiation of fully committed specialized cells has been replaced in favour of the 
cancer stem cell hypothesis (Reya et al., 2001). The belief is that in many cancer 
types, tumour growth and propagation is sustained by the so-called cancer stem 
cells (CSCs), which represent a subpopulation of tumour cells with the ability to self-
renew and maintain tumour growth (Clarke and Becker, 2006). CSCs were first 
identified in leukaemias (Lapidot et al., 1994) and later shown to be crucial for certain 
solid tumours (Gupta et al., 2009), although their relevance for other tumours, such 
as melanoma, remains unclear (Quintana et al., 2008). The fact that inhibiting 
    138 
tumour suppressor pathways enhances reprogramming to a more undifferentiated 
state suggests that alterations in the p53 or the p16INK4a/RB pathways have an 
impact on tumorigenesis, not only by affecting proliferation, but also by contributing 
to reprogramming somatic cells to a more dedifferentiated state. Related 
mechanisms may exist, as shown by the fact that p53 loss increases the pool of 
CSCs by promoting the symmetrical cell divisions of cancer stem cells (Cicalese et 
al., 2009). Interestingly, deletion of the three RB family proteins triggers the 
reprogramming of MEFs to generate CSC-like cells, and cells that resemble CSCs 
can even be generated from MEFs that only lack RB1 if they are forced to grow 
beyond contact inhibition (Liu et al., 2009). Another study reported how simultaneous 
inhibition of RB and p53 pathways (by inhibiting Arf) in mice leads to extensive loss 
of differentiation of post-mitotic myocytes (Pajcini et al., 2010). These results 
implicate the Ink4a/Arf locus in the lack of regenerative potential in mammals, as the 
authors emphasise, but also highlight how inactivation of tumour suppressor 
pathways during tumorigenesis might lead to a more undifferentiated state.  
Two studies, published during the course of this work further underscore the 
link between pluripotency and tumorigenesis. Aggressive, poorly differentiated 
tumours were shown to express high levels of ES cell-associated factors (Ben-
Porath et al, 2008). Additionally, the expression of some oncogenes such as c-Myc 
in epithelial tumours is sufficient to reactivate an ES cell-like transcriptional signature 
(Wong et al., 2008). However, in a very recent study, different regulatory modules 
based on gene expression in ES cells, were defined: a core pluripotency module, a 
Myc module and a PRC module. The authors argue that the ES cell-like module 
identified before (Ben-Porath et al, 2008) (Wong et al., 2008) is composed mainly of 
Myc genes rather than core pluripotency module genes (Kim et al., 2010). Although 
some issues still need clarification, these observations suggest that reprogramming 
to a more dedifferentiated state occurs during tumour progression and might be 
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favoured by alterations in crucial tumour suppressors. If the acquisition of stem-cell-
like properties goes hand-in-hand with tumorigenesis, it is reasonable to think that 
the mechanism triggered by expression of the reprogramming factors, which 
ultimately leads to reprogramming, elicits the tumour suppressor pathways that 
protect cells against uncontrolled growth. In fact, the cellular response to the 
expression of the reprogramming factors or stem-cell-specific genes mimics the 
senescence response observed during OIS, emphasizing the parallels between RIS 
and OIS (Fig 5.1).  
 
 
 
Figure 5.1. Parallels between reprogramming and oncogenic transformation. (A) Aberrant 
oncogene expression triggers senescence (OIS) in primary cells, which limits oncogenic transformation. 
The expression of the reprogramming factors also triggers senescence (RIS), limiting the efficiency of 
reprogramming. (B) As a consequence, when senescence is disabled, cells are more susceptible to 
either oncogenic transformation or reprogramming. OIS, oncogene-induced senescence; RIS, 
reprogramming-induced senescence. 
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The fact that there is an intricate relationship between pluripotency and 
tumorigenesis suggests that some of the events that lead to reprogramming to iPS 
cells may overlap with the ones involved in tumorigenesis. ES cells are derived from 
the cells of the inner cell mass of the embryo, which are forced to grow in culture. 
Thus, they could represent a cell type that does not exist in nature; indeed, they 
share characteristics with tumour cells. ES cells, like tumour cells, grow 
independently of the presence of mitogenic stimuli, have low levels of proteins that 
are part of tumour suppressor pathways frequently inactivated in cancer and express 
telomerase. Crucially, one of the widely used pluripotency test, the ability to cause 
teratomas when cells are injected into nude mice, also reflects tumorigenic potential. 
Unfortunately this unwanted similarity might be somehow unavoidable. In fact, 
embryo-derived hES cells share with iPS cells one of the main challenges that hinder 
their use in a therapeutical setting. The ability to properly differentiate them and more 
importantly the stability of the differentiated state will dictate the safety of using hES 
or iPS cells for therapy as the presence of undifferentiated cells will give rise to 
tumours. Thus, one ongoing challenge is to learn how to achieve accurate 
differentiation of ES and iPS cells into specific cell types. Nevertheless, if 
senescence pathways that guard the genome against oncogenic mutations also 
guard cells against de-differentiation we have to be absolutely sure that they are 
intact and operating in iPS cells.  
 
 
5.5. Future work: Identification of RIS mediators 
 
 
5.5.1. Genetic screen for bypass of RIS 
 
As stated before, identification of mediators of senescence induction during 
reprogramming might provide a safer and more efficient way of improving 
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reprogramming than inhibiting key tumour suppressor pathways. To set up a screen 
assay for bypass of RIS an inducible system for expression of the four 
reprogramming factors was generated. The OSKM polycistronic cassette was cloned 
into a retroviral vector containing a tetracyclin responsive element (pBABE TRE 
puromycin). For inducible expression, IMR90 cells were transduced with the 
retroviral vectors containing the OSKM cassette, HRASV12 or Cherry fluorescent 
protein under the control of the TRE, together with a vector constitutively expressing 
the M2rtTA transactivator with hygromycin resistance. The inducibility and the 
leakiness of the system were first assessed by analysing the expression of the 
Cherry fluorescent protein (Figure 5.2A). Cherry expression was detected one day 
after treatment with doxycyclin (4µg/ml) and continued to increase until day 5 post-
treatment. In contrast, Cherry was not detected in the absence of doxycyclin or in the 
control cells (Figure 5.2A). OSKM expression led to a decrease in the percentage of 
cells incorporating BrdU over a time course of five days (from 50% to 10%). Similar 
results were observed with the RASV12 control. Furthermore, inhibition of cell 
growth by induction of OSKM expression was assessed by crystal violet staining of 
low-density plates (Figure 5.2C). 
To identify genes involved in RIS a genetic screen using an shRNA library is 
going to be performed. IMR90 containing inducible OSKM will be transduced with a 
genome-wide shRNA library and maintained in parallel in the presence and absence 
of doxycyclin. The frequency of the shRNAs in both settings will be determined by 
massive parallel sequencing using next generation sequencing.  
Hopefully, this screening will allow identification of genes, whose loss of 
function leads to bypass of OSKM-induced senescence. Therefore, enrichment of 
shRNAs will uncovered genes that may be involved in the establishment and 
maintenance of the growth arrest induced by the expression of the reprogramming 
factors. 
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Figure 5.2. OSKM-inducible system for identification of RIS mediators. (A) Cells were transduced 
with a vector containing the Cherry fluorescent protein under the control of a TET responsive element 
(CherryTRE), and a vector constitutively expressing the M2rtTA transactivator. Selection with puromycin 
and hygromycin over approximately 8 days allowed isolation of double transduced cells. In the absence 
of doxycyclin there is no cherry expression cells whereas upon doxycyclin addition (Dox) there is an 
induction of the fluorescent protein. Microphotographs were acquired with 10x magnification on day 5; a 
DAPI/Cherry merge is shown.  (B) The same system was used for inducible expression of OSKM and 
HRASV12 (OSKMTRE and RASTRE respectively). BrdU incorporation assays show how proliferation is 
arrested when these cells are grown in presence of doxycyclin. (C) Crystal violet stained plates showing 
difference in growth in the presence of Dox in OSKMTRE and RASTRE when compared with control cells 
(EVTRE). 105 cells were plated in duplicate per 10-cm dish. Next day 4µg/ml of doxycyclin was added to 
one set of plates. Plates were fixed and stained with crystal violet 14 days later. 
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In particular it will be interesting to identify mediators that are specific to the 
arrest induced by the reprogramming factors. By comparing shRNAs able to bypass 
RIS with the ones able to bypass oncogene induced-senescence, it will be possible 
to avoid inhibiting genes whose activity is required for protecting cells against 
uncontrolled growth and transformation. Modulating the activity of these candidate 
genes or the pathways in which they are involved may constitute potential strategies 
to improve reprogramming efficiency. Additionally, it will be interesting to unravel 
which pathways are activated and may contribute to RIS, to further understand the 
link between gain of pluripotency and tumorigenesis.   
 
5.5.2. SILAC analysis for identification of proteins enriched during RIS 
A complementary strategy to understand which genes and pathways may 
regulate the senescence induced during reprogramming is to generate gene or 
protein expression profiles. Stable isotope labelling with amino acids in cell culture 
(SILAC) is a simple and efficient approach for labelling proteins for mass 
spectrometry-based quantitative proteomics. Early passage IMR90 cells were grown 
for two passages in SILAC media containing ‘light’ (L-Arginine and L-Lysine) or  
‘heavy’ (H-Arginine and H-Lysine) amino acids, to allow incorporation into newly 
synthesized proteins. Each population was transduced with the OSKM retroviral 
vector and empty control vector and selected with puromycin. Seven days after 
transduction, cells were harvested and mixed. Mass spectrometry and peptide 
quantification analysis was performed by Bram Snijders in the Biomolecular Mass 
Spectrometry and Proteomics Laboratory (MRC Clinical Science Centre).  
Functional annotation using the DAVID bioinformatics resources (database for 
annotation, visualization and integrated discovery) revealed that the list of proteins 
with L/H rations lower than 0.5 (2 times down-regulation) were enriched for protein 
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involved in cell cycle progression (Benjamini, 1.5x10-22), mitosis (1.3x10-20) and DNA 
replication (9.7x10-19). Therefore these preliminary data reflect the arrest in cell cycle 
described before and validate the assay. Proteins such as Cyclin B1, DNA 
replication licensing factors (MCM2-7), BUB1B and the Antigen of KI-67 are among 
the list of down-regulated proteins. Another example is topoisomerase II alpha 
(TOP2A), which has also been identified as down regulated in RAS-induced 
senescence (Mason et al., 2004). Similarly, proteins that are up-regulated in OSKM-
transduced cells, are related to signal peptide or secreted proteins (1.1x10-6) and 
lysosome (4.7x10-4). Interestingly beta galactosidase was one of the proteins 
enriched in the OSKM sample, as well as other lysosome-related proteins. Some of 
the proteins detected and over-represented in OSKM cells have been implicated 
before in replicative and oncogene-induced senescence: tissue inhibitor of 
metalloproteinase 1 and 3 (TIMP1, TIMP3), creatine kinase type-B (CKBB) and 
insulin growth factor binding proteins 6 and 7 (IGFBP6 and 7) (Chang et al., 2002; 
Shelton et al., 1999; Trougakos et al., 2006; Wajapeyee et al., 2008).   
The similarly between the protein or genes expression profiles between RIS 
and in OIS reflects the parallelisms between these two processes, as discussed 
before. However, the aim will be also the identification of pathways which specifically 
operate during RIS, and which could be safely modulated to improve 
reprogramming. For this purpose it will be interesting to compare these protein 
profiles with the ones obtained by SILAC analysis of senescence induced by 
activated RAS (Juan Carlos Acosta, unpublished data) to identify RIS-specific 
modulators.   
 Inhibition of the aryl hydrocarbon receptor (AHR) has recently been described 
to promote of ex vivo expansion of hematopoietic stem cells (HSCs) (Boitano et al., 
2010). Interestingly, AHR was found 4-fold overrepresented in OSKM cells. AHR is 
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normally in the cytoplasm in an inactive form. Upon ligand binding to chemicals such 
as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), its dissociation from chaperones 
results in AHR translocation to the nucleus where it function as a transcription factor 
(Puga et al., 2002). Besides inhibition of AHR being implicated in HSCs expansion, it 
has been shown that knock out mice for AHR exhibit defects in hematopoiesis 
(Singh et al., 2010). Consequently, Singh et al. suggest that AHR has a role in 
maintaining proper quiescence of hematopoietic stem cells thereby restricting their 
excessive or unnecessary proliferation (Singh et al., 2010). Indeed, several studies 
suggest a role for the AHR in cell cycle control, although the precise mechanism 
remains ill defined. Some observations suggested that in the absence of an 
exogenous ligand, the AHR promotes cell cycle progression  (reviewed in Marlowe 
and Puga, 2005). In contrast, early studies have demonstrated that treatment with 
AHR ligands, such as TCDD, inhibits cell proliferation. It was described that AHR 
binds to and synergizes with RB to repress E2F-dependent transcription therefore 
inducing cell cycle arrest (Puga et al., 2000). Additionally, it has been suggested that 
AHR silencing may be associated with cancer progression and it acts as a tumour 
suppressor in hepatocellular carcinoma (Fan et al., 2010). It would be interesting to 
determine whether inhibiting AHR has an effect in reprogramming efficiency or 
whether AHR has a role in RIS. The fact that this receptor is silenced in a subset of 
tumours and that its function is necessary to maintain normal quiescence of HSCs 
suggest that its inhibition might be unsafe. However several AHR antagonist have 
been described (Boitano et al., 2010; Prud'homme et al., 2010) that would allow 
transient inactivation of the receptor without permanently compromising its activity. 
Although a total of 5710 proteins have been detected, the sensitivity of this 
technique is limited. However, a total of 225 proteins were found to be more than 2 
fold up-regulated while 242 proteins were 2-fold down-regulated. Before trying to 
understand their link with RIS, additional work is being performed to validate these 
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results. Reverse labelling will be performed and the mass spectrometry and peptide 
quantification analysis will be repeated. Additionally, analysis of the protein profiles in 
low serum conditions could enrich for proteins specific of the OSKM-induced arrest 
and discard the ones over-represented as a consequence of the difference in 
proliferation rates in the two populations.  
 
5.6. Concluding remark  
 
The study of reprogramming to pluripotency has yielded some mechanistic 
clues about how this process works, which have been used to improve the 
technology. Unexpectedly, the study of the reprogramming process is also revealing 
new information on, for example, the links between pluripotency and transformation. 
Perhaps the study of reprogramming, which has mostly been seen as a markedly 
artificial process with promising applications will also increase our understanding of 
other crucial aspects of basic biology (Ramalho-Santos, 2009).  
The fact that the same alterations that drive oncogenic progression can 
influence the reprogramming of somatic cells to iPS cells supports the view that 
tumour suppressor pathways involved in protecting cells against uncontrolled cell 
growth, can also have a role in protecting cells against dedifferentiation. In this 
regard inactivation of these pathways could be involved in the creation of CSCs, 
described to support the progression of specific cancer types. Furthermore, it 
suggests that derivation of safe iPS cells could present enormous challenges. 
Hopefully, the high pace and quality of cancer and stem cell biology research will 
soon provide answers for all these questions.  
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Table A1. Retroviral constructs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
           
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Vector cDNA Antibiotic resistance 
pBABE Empty Vect. puromycin 
pBABE OSKM puromycin 
pBABE Sox2 puromycin 
pBABE Oct4 puromycin 
pBABE Klf4 puromycin 
pBABE c-Myc puromycin 
pBABE Nanog puromycin 
pLPC Cherry puromycin 
pBABE GFP puromycin 
pBABE RAS V12 puromycin 
MSCV Cbx7 puromycin 
LXSN Empty Vect. neomycin 
LXSN E6 neomycin 
LXSN E7 neomycin 
LXSN E6/E7 neomycin 
pRS Empty Vect. puromycin 
pRS sh-hp53 puromycin 
pRS sh-hp16 puromycin 
pRS sh-hp21 puromycin 
MLP sh-mp53 puromycin 
MLP sh-mp16/Arf puromycin 
pRS sh-mp21 puromycin 
pRS sh-hp53 hygromycin 
pRS sh-hp16 hygromycin 
pRS sh-hp21 hygromycin 
MSCV hTR211 blasticidin 
MSCV 302a-d blasticidin 
MSCV M2rtTA M2rtTA hygromycin 
pBABE TRE OSKM OSKM puromycin 
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Table A2. Plasmids acquired from Addgene 
 
 
Vector cDNA 
Antibiotic 
resistance 
Addgene 
ref. 
pMXs Oct4 - 13366 
pMXs Sox2 - 13367 
pMXs Klf4 - 13370 
pMXs Myc T58A - 13372 
pMXs Nanog - 13354 
FUW Tet-OSKM zeocin 20321 
FUW M2rtTA zeocin 20342 
 
 
 
 
 
 
 
 
 
 
Table A3. shRNA target sequences. 
 
Gene Target sequence 
INK4a GAGGAGGTGCGGGCGCTGC 
CDKN1a TCCCACAATGCTGAATATACA 
 hp53 GTAGATTACCACTGGAGTC 
Cdkn1a CTCCCAGTCTCCAAACTTAAA 
mp53 CACTACAAGTACATGTGTA 
Ink4a/Arf CCGCTGGGTGCTCTTTGTGT 
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Table A4. Primers for cloning 
 
Primer Sequence (5’ to 3’) 
Sox2 BamHI GGGGATCCATGTATAACATGATGGAGACGG 
Sox2 Sal I GGGTCGACTCACATGTGCGACAGGG 
Nanog BamHI GGGGATCCATGAGTGTGGGTCTTCCTGG 
Nanog Sal I GGGTCGACTCATATTTCACCTGGTGGAGTC 
Oct4 Bgl II GGAGATCTATGGCTGGACACCTGGCTTCAG 
Oct4 Sal I GGGTCGACTCAGTTTGAATGCATGGGAGAGCC 
M2rtTA BamHI  GGGGATCCATGTCTAGACTGGACAAGAG 
M2rtTA Sal I GGGTCGACTTACCCGGGGAGCATGTCAA 
 
 
 
 
 
 
 
 
Table A5. Sequencing primers. 
 
Primer Sequence (5’ to 3’) 
M13 F (-20) GTAAAACGACGGCCAG 
M13 R CAGGAAACAGCTATGAC 
pBABE F CTTTATCCAGCCCTCAC 
pBABE R ACCCTAACTGACACACATTC 
pMSCV F CCCTTGAACCTCCTCGTTCGACC 
pMSCV R GAGACGTGCTACTTCCATTTGTC 
pRS F GCTGACGTCATCAACCCGCT 
pRS R TGTGAGGGACAGGGGAG 
TOPO II F CGAGCTCGGATCCACTAGTAA 
TOPO II R  CGGCCAGTGAATTGTAATACG  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Table A6. RT-qPCR primers. 
 
 
Target gene  Sequence (5’ to3’) 
RPS14 TCACCGCCCTACACATCAAACT CTGCGAGTGCTGTCAGAGG 
P53 CCGCAGTCAGATCCTAGCG AATCATCCATTGCTTGGGACG 
INK4 CGGTCGGAGGCCGATCCAG GCGCCGTGGAGCAGCAGCAGCT 
 
CDKN1a 
CCTGTCACTGTCTTGTACCCT 
GCGTTTGGAGTGGTAGAAATCT 
 
Rps14 
GACCAAGACCCCTGGACCT 
CCCCTTTTCTTCGAGTGCTA 
 
p53 
CACGTACTCTCCTCCCCTCAAT 
AACTGCACAGGGCACGTCTT 
 
Ink4a/Arf 
GTGTGCATGACGTGCGGG 
GCAGTTCGAATCTGCACCGTAG 
 
Cdkn1a 
CCTGGTGATGTCCGACCTG 
CCATGAGCGCATCGCAATC 
 
Endogenous OCT4 
CCTCACTTCACTGCACTGTA 
CAGGTTTTCTTTCCCTAGCT 
 
Exogenous OCT4 
CCTCACTTCACTGCACTGTA 
TCCTGTCTTTAACAAATTGGACT 
 
Endogenous SOX2 
ATGTCCCAGCACTACCAGAG 
GCACCCCTCCCATTTCCC 
 
Exogenous SOX2 
CCCAGCAGACTTCACATGT 
TCCTGTCTTTAACAAATTGGACT 
 
Exogenous-KLF4 
GATGAACTGACCAGGCACTA 
TCCTGTCTTTAACAAATTGGACT 
 
Exogenous-MYC 
AAGAGGACTTGTTGCGGAAA 
TCCTGTCTTTAACAAATTGGACT 
 
NANOG 
CATGAGTGTGGATCCAGCTTG 
CCTGAATAAGCAGATCCATGG 
DNMT3B 
GTCAAGCTACACACAGGACTTGACAG 
AGTTCGGACAGCTGGGCTTT 
hTERT 
GCCAGCATCATCAAACCCC 
CTGTCAAGGTAGAGACGTGGCTC 
 
REX1 
GCGTACGCAAATTAAAGTCCAGA 
CAGCATCCTAAACAGCTCGCAGAAT  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Table A7. TaqMan Gene Expression Assays (Applied Biosystems) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table A8. TaqMan microRNA Assays (Applied Biosystems)  
Target miRNA  Catalogue 
no. 
Mature microRNA sequence/target sequence 
RNU48  GAUGACCCCAGGUAACUCUGAGUGUGUCGCUG AUGCCAUCACCGCAGCGCUCUGACC 
hsa-miR-302a 529 UAAGUGCUUCCAUGUUUUGGUGA 
hsa-miR-302b 531              UAAGUGCUUCCAUGUUUUAGUAG  
hsa-miR-302c 533 UAAGUGCUUCCAUGUUUCAGUGG 
hsa-miR-302d 535 UAAGUGCUUCCAUGUUUGAGUGU 
has-mir-372 560 AAAGUGCUGCGACAUUUGAGCGU 
has-mir-373 561 GAAGUGCUUCGAUUUUGGGGUGU    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Target gene  Catalogue n. 
GAPDH 4333764F 
JMJD3 Hs 00389749-m1 
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Table A9. Primary antibodies. 
 
Target Clone Company Catalogue no. Source 
8-Oxoguanine 483.15 Millipore MAB3560 mouse 
γH2AX JBW301 Millipore 05-636 mouse 
BrdU – Invitrogen A21303 mouse 
H3K27me3 poly Millipore 07-449 rabbit 
p16INK4a JC-8 CRUK – mouse 
p21Cip1 CP74 Sigma P 1484 mouse 
p21Cip1 poly Abcam ab18209 rabbit 
p53 DO-1 Santa Cruz sc-126 mouse 
P-(Ser/Thr)Q poly Cell Signaling 2851 rabbit 
Cleaved caspase3 5A1E Cell Signaling 9664 rabbit 
JMJD3 poly Aviva Systems Biology ARP40102 rabbit 
c-MYC poly Santa Cruz sc-764 rabbit 
Nanog  poly Abcam ab80892 rabbit 
Oct4 C-10 Santa Cruz sc-5279 mouse 
Klf4 poly Abcam ab34814 rabbit 
Sox2 poly Abcam ab15830 rabbit 
Gata 6  Abcam ab22600  
Sox1 poly R&D Systems AF3369 goat 
Brachyury poly R&D Systems AF2085 goat 
Sox17 poly R&D Systems AF1924 goat 
Cdx2 CDX2-88 BioGenex MU392A-UC mouse 
Pax6 poly Covance PRB-278P rabbit 
TRA-1-60 - Santa Cruz sc-21705 mouse 
TRA-1-81 - BD Pharmingen 560072 mouse 
 
 
 
 
 
Table A10. Secondary antibodies. 
 
Target Label Company Catalogue no. Source 
mouse Alexa Fluor 488 Invitrogen A11029 goat 
mouse Alexa Fluor 594 Invitrogen A11032 goat 
rabbit Alexa Fluor 488 Invitrogen A11034 goat 
rabbit Alexa Fluor 594 Invitrogen A11037 goat 
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Table A11. Antibodies for ChIP. 
 
Target Clone Company Catalogue no. Source 
EZH2/KMT6 poly Abcam ab3748 rabbit 
H3K27me3 poly Diagenode CS-069-100 rabbit 
H3K4me3 poly Diagenode pAb-003-050 rabbit 
Histone H3 poly Abcam ab1791 rabbit 
RNA Pol II 4H8 Abcam ab5408 mouse 
    
Table A12. Primers for ChIP. 
 
Position Sequence Location 
PS2 F-GTGGGTCCCAGTCTGCAGTTA 
R-CCTTTGGCACCAGAGGTGAG 
p14ARF, exon 1 
PS3 F-GGAGCGATGTGATCCGTTATC 
R-TGAAATCCCAATCGTCTTCCAC 
4.5 kb downstream of p14ARF start site 
 
PS4 F-GCACTTGCCCTTCCAGGTATA 
R-TGATAGTTCAAGGCCCTATGCC 
15 kb downstream of p14ARF start site 
 
PS5 F-CTCAAAGCGGATAATTCAAGAGC 
R-AAGCCTTAAGAACAGTGCCACAC 
1 kb upstream of p16INK4a promoter 
PS6 F-ACCCCGATTCAATTTGGCAG 
R-AAAAAGAAATCCGCCCCCG 
0.2 kb upstream of p16INK4a promoter 
PS8 F-GCCAAGGAAGAGGAATGAGGAG 
R-CCTTCAGATCTTCTCAGCATTCG 
0.2 kb downstream of p16INK4a, exon 1 
PS11 F-TAGGAGGCCCCATTAAGCATAC 
R-TGTAGTTGCCAGGAGTTGGAGG 
0.8 kb downstream of p16INK4a, exon 3 
 
CCND1 F-CACGGACTACAGGGGAGTTTTG 
R-TTTCCACTTCGCAGCACAGGAG 
0.1 kb downstream of CCND1 promoter  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Figure A1. Cell cycle profiles. For cell cycle analysis, cells were fixed and stained with 
propidium iodide as described in 2.3.4. Cells were analysed using Guava microcapillary flow cytometry 
system (Millipore), and the Guava Cell Cycle Software. Cell cycle profiles for empty vector control 
(pBABE) annd OSKM are presented. 
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